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SYNTHESIS, CHARACTERIZATION, AND INVESTIGATION OF NITRIC OXIDE 
DONORS FOR BACTERIAL DETECTION AND ANTIBACTERIAL ACTIVITY  
 
 
Antibiotic resistance is a critical problem, especially with the emergence of “superbugs,” 
which are bacteria species that have become immune to most common antibiotics. To address 
this alarming issue, it is necessary to both prevent the overuse of current antimicrobial 
therapeutics, and to develop new, effective antibacterial treatments. By detecting when the 
source of a patient’s infection is bacterial, and which species is causing the infection, antibiotics 
can be prescribed only when they are needed, and the most effective antibiotic can be chosen. 
The development of new antibiotics with new mechanisms of action are also a productive path to 
help solve the problem of antibiotic resistance. Bacteria that encounter antibiotics with novel 
mechanisms of action have not yet evolved pathways to resistance against the therapeutic, so 
these innovative compounds will be highly successful at eradicating infections.  
Nitric oxide is a small molecule with potent antibacterial activity due to its reactivity and 
ability to form reactive nitrogen species, which induces nitrosative stress in bacteria cells and 
cell death. The development of a new antibiotic incorporating nitric oxide could lead to a very 
powerful antibacterial agent. Combining the ideas of detecting bacterial infections with the 
antibiotic potential of nitric oxide into a multifunctional molecule would give the benefits of both 
detection of a bacterial infection, and potent antimicrobial action. The focus of this work is to 
develop a small molecule to both sense and kill bacteria. This goal is accomplished through the 
development of a dual-function small molecule to detect and kill bacteria through a colorimetric 
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change and release of nitric oxide to kill bacteria. Another approach to achieve this goal is the 
synthesis of a molecule that bacteria can sense, an inactive drug until bacterial enzymes cause the 
release of nitric oxide to kill the bacteria. Nitric oxide release is localized to bacteria causing an 
infection, which can help prevent bacteria from developing resistance by avoiding unnecessary 
exposure. 
Toward the goal of addressing the problem of antibiotic resistance, a nitric oxide donor 
attached to a fluorescent compound is synthesized, creating a compound that can both detect and 
kill the deadly multi-drug resistant bacteria strain, Pseudomonas aeruginosa. Detection occurs 
through a bacterial enzyme-activated color change, showing a visible color change from blue to 
yellow under UV light. The synthesized compound spontaneously releases 853 µmol of nitric 
oxide/g at a 10 mM initial concentration of the compound. Antibacterial efficacy studies after 
exposing Pseudomonas aeruginosa to a 10 mM dose of the synthesized compound show a 65% 
reduction in bacteria after 24 hours. This work is the first instance of a small molecule dual-
function material that can both detect and kill bacteria.  
To address the goal of developing a bacteria-specific nitric oxide releasing compound, 
novel nitroaromatic-protected piperazine diazeniumdiolate (nitric oxide donor) prodrugs are 
synthesized to release nitric oxide upon enzyme activation to kill bacteria. These prodrugs are 
activated by an enzyme in the nitroreductase family, which are found almost exclusively in 
bacteria, and reduces the nitroaromatic-protecting group of the synthesized compounds, 
catalyzing the release of nitric oxide. Experiments show that nitric oxide release from the 
synthesized compounds only occurs in the presence of a bacteria-derived nitroreductase enzyme, 
demonstrating the possibility of site-specific delivery of an antibacterial therapeutic. The amount 
of nitric oxide release is measured at concentrations of 0.01, 0.1, and 1 mM, and is well within 
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known antibacterial levels at concentrations of 0.1 and 1 mM, reaching nitric oxide 
concentrations of up to 4.8 µM. The antibacterial activity of the compounds is demonstrated after 
exposure of the compounds to Escherichia coli, a nitroreductase-producing bacterial species and 
common infection forming species, leading to up to a 94% reduction in the number of viable 
bacteria after 24 hours at 1 mM concentrations of the prodrug. This study is the first example of 
an antibacterial diazeniumdiolate prodrug activated by a nitroreductase enzyme, and further 
demonstrates the possibilities of antibacterial prodrugs. 
Medical devices are a site where bacterial infections can develop, and these infections are 
often incredibly difficult to treat, sometimes requiring the removal of the device. Medical 
devices could be coated with an antibacterial material that releases antibiotics to prevent 
infections. To investigate the application of the nitroreductase enzyme-activated nitric oxide 
releasing prodrugs for antibacterial medical device coatings, the prodrugs are incorporated into 
polyvinyl chloride and polyurethane films to create antibacterial prodrug polymer composite 
materials. Characterization of nitric oxide release from the surface of the composite films is 
observed only after metabolism by a bacterial nitroreductase enzyme, demonstrating the prodrug 
nature of the polymer composite. Excitingly, antibacterial efficacy experiments resulted in a 66% 
reduction in Escherichia coli after exposure to the diazeniumdiolate-composite films. This work 
details the first example of an antibacterial enzyme-activated NO-releasing polymer. 
The development of these novel compounds and materials represents significant advances 






The road to earning my PhD has been a long one, and I would not have made it to this 
point without the support of many amazing people. I would like to thank my advisor, Melissa, 
for giving me the opportunity to direct a project independently, allowing me to develop as an 
independent scientist, and believing that I could get it done. Thanks to all of the members of the 
Reynolds group, both past and present, who helped me become a better scientist. Thanks 
especially to Dr. Heather Rubin for providing her synthetic advice and ideas whenever I needed 
them. Thanks to Dr. Jesus Tapia for running MS samples for me. Thanks to Dr. Bella Neufeld, 
Jenna Gordon, and Yanyi Zang for their help and advice on running cell culture experiments. 
Thanks to Alyssa Galvin for maintaining the NOAs and being my go-to person when I had a 
problem with them. 
I would also like to express my thanks to my friends and family. Thanks to my parents 
for inspiring me to get a PhD in the first place. Thanks to my sisters for supporting me and 
always being just a phone call away. Thanks to Aaron for being my stress support system and 
supporting me during even the most difficult times. I will be forever grateful for all of the 
amazing friends I’ve made in grad school. Thanks to Alix for being a great friend and confidant 
during the longest days. Thanks to Eve, Jen, Annaliese, Kim, Angela, Chris, Leslie, Lily, and Jaz 









ABSTRACT .................................................................................................................................... ii 
ACKNOWLEDGMENTS ...............................................................................................................v  
CHAPTER 1 – INTRODUCTION  
1.1 Addressing the Problem of Antibiotic Resistance .........................................................1 
1.2 Physiological and Therapeutic Role of Nitric Oxide .....................................................2 
1.3 Categories of Nitric Oxide Donors ................................................................................4 
1.4 Synthesis, Characterization, and Properties of Diazeniumdiolates ...............................6 
1.5 Enzyme-Activated Nitric Oxide Prodrugs ...................................................................10 
1.6 Antibacterial Diazeniumdiolates ..................................................................................14 
1.7 Dissertation Overview .................................................................................................16 
1.8 References ....................................................................................................................19 
CHAPTER 2 – L-ALANYL AMINOPEPTIDASE-ACTIVATED BACTERIAL INDICATOR 
 2.1 Introduction ..................................................................................................................30 
2.2 Experimental Methods .................................................................................................36 
2.3 Synthetic Routes to L-alanyl Aminopeptidase Indicator .............................................39 
2.4 Chemical Approach to Functionalization of Indicator with Nitric Oxide Donor ........50 
2.5 Conclusion ...................................................................................................................60 
2.6 References ....................................................................................................................63 
CHAPTER 3 – SYNTHESIS, CHARACTERIZATION, AND APPLICATION OF 
PRO/FLUORO/NO 
 3.1 Background ..................................................................................................................68 
3.2 Introduction ..................................................................................................................69 
vii 
 
3.3 Experimental Methods .................................................................................................72 
3.4 Development of Synthetic Route to Pro/Fluoro/NO ....................................................79 
3.5 Pro/Fluoro/NO as a Bacterial Indicator .......................................................................81 
3.6 Synthesis and Characterization of Properties of Pro/Fluoro/NO .................................83 
3.7 Antibacterial Activity of Pro/Fluoro/NO with Pseudomonas aeruginosa ...................90 
3.8 Conclusion ...................................................................................................................93 
3.9 Nuclear Magnetic Resonance Spectra .........................................................................95 
3.10 References ................................................................................................................101 
CHAPTER 4 – NITROREDUCTASE-ACTIVATED PIPERAZINE DIAZENIUMDIOLATES 
 4.1 Background ................................................................................................................107 
4.2 Introduction ................................................................................................................107 
4.3 Experimental Methods ...............................................................................................110 
4.4 Synthesis of Nitroaromatic-Protected Diazeniumdiolates .........................................116 
4.5 Nitric Oxide Release Properties of Nitroreductase-Activated Diazeniumdiolates ....119 
4.6 Antibacterial Activity of Piperazine Diazeniumdiolates ...........................................124 
4.7 Conclusion .................................................................................................................128 
4.8 Nuclear Magnetic Resonance Spectra .......................................................................130 
4.9 References ..................................................................................................................136 
CHAPTER 5 – POLYMER BLENDS OF NITROREDUCTASE-ACTIVATED PIPERAZINE 
DIAZENIUMDIOLATES 
 5.1 Background ................................................................................................................142 
5.2 Introduction ................................................................................................................142 
5.3 Experimental Methods ...............................................................................................145 
viii 
 
5.4 Synthesis of PVC/PU Blends with Piperazine Diazeniumdiolates ............................151 
5.5 Characterization of PVC/PU Blends with Piperazine Diazeniumdiolates .................152 
5.6 Antibacterial Activity of Polymer Blends with Escherichia coli ..............................157 
5.7 Conclusion .................................................................................................................159 
5.8 Representative SEM Images ......................................................................................160 
5.9 Experimental NO Release Plots .................................................................................164 
5.10 References ................................................................................................................165 
CHAPTER 6 – CONCLUSIONS AND FUTURE DIRECTIONS 
6.1 Conclusions ................................................................................................................169 
6.2 Future Directions .......................................................................................................170 









1.1 Addressing the Problem of Antibiotic Resistance 
 Bacteria are microscopic single-cell organisms ubiquitous in our environment. They can 
play beneficial roles in our environment and in our bodies, but if a certain species grows out of 
control, there can be severe detrimental effects. Since Paul Erlich discovered an antibiotic to treat 
syphilis in 1911 and Alexander Fleming discovered penicillin in 1928, leading to the mass 
production of antibiotics in the 1940s, health care providers have had a “miracle cure” for 
bacterial infections.1 However, with the discovery of antibiotics, antibiotic resistance has 
followed not far behind.2 Antibiotic resistance has high costs to hospitals and society at a whole.3 
Resistance to antibiotics is due the development and spread of resistance genes in bacteria and 
the overuse of antibiotics.4 If bacteria develop resistance genes to antibiotics, which allow them 
to produce proteins that neutralize the antibiotic’s effects, these genes can spread among the 
community of bacteria and sometimes even between bacterial species. This developed resistance 
then renders a specific antibiotic or class of antibiotics inert for that type of bacterial infection. 
Resistance is a natural development for bacteria in their fight for survival, so it cannot be 
completely prevented, but there are ways to slow its spread.5,6  
One way to limit the development of resistance development in bacteria is to limit use of 
antibiotics except in times where it is strictly necessary. If antibiotics are used unnecessarily or 
incorrectly, bacteria with resistance genes can avoid eradication, then multiply and spread, 
creating “superbugs,” bacterial strains that are resistant to many or all of current common 
antibitotics.7 To prevent the overuse of antibiotics, it is important to only use antibiotics when it 
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is certain that an infection or illness is caused by bacteria, and which species is responsible. To 
do this, it is important to have reliable methods to detect bacterial infections and identify which 
species is causing the infection. Many methods have been developed to detect bacteria, including 
colorimetric, electrochemical, and biological detection. By detecting that an infection is in fact 
caused by bacteria, and which bacterial species is the cause, a patient can be treated effectively 
while limiting the spread of resistance. 
Another way to address resistance development is to circumvent bacterial resistance 
mechanisms by developing new antibiotics with new mechanisms of action. While the 
development of resistance is inevitable, new antibiotics can buy more time. As more bacterial 
species become resistant to all known antibiotics, it becomes more critical than ever to create 
new antibiotics.7 Often, pharmaceutical companies will make derivatives of known antibiotics, 
such as β-lactam antibiotics like penicillin and amoxycillin. However, these antibiotics usually 
have the same or similar mechanisms of action, such as targeting the same protein in bacteria to 
kill or disable them. This means that bacteria often quickly develop resistance to these 
derivatives, as their resistance genes quickly develop mutations that render the new antibiotic 
ineffective. For this reason, it is important to develop new antibiotics with new mechanisms of 
action, although is a difficult task. 
1.2 Physiological and Therapeutic Role of Nitric Oxide 
 For many decades, nitric oxide was known only as one of the nitrogen oxide (NOx) air 
pollutants. In the past few decades, however, researchers have discovered that nitric oxide also 
has beneficial effects, first as an important cardiovascular cell signaling molecule in the body.8 In 
1998, Robert Furchgott, Louis Ignarro, and Ferid Murad were awarded the Nobel Prize for their 
work in the 1980s demonstrating the role of NO as a cardiovascular signaling molecule.9 In 
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1992, Science named NO the “Molecule of the Year,” demonstrating the impact that the 
discovery of the role of NO has had on the field.10  
In addition to cell signaling, NO also plays many other roles in the body. NO is 
synthesized in the body from the amino acid L-arginine, converted to citrulline and NO via 
various NO synthase (NOS) enzymes.11,12 NO has been shown to improve wound healing by 
increasing the rate of cell proliferation.13 NO can act as a vasodilator to increase blood flow, a 
role exploited by the administration of nitroglycerin to treat various conditions such as heart 
attacks and acute hypertension.14–16 In addition to these functions, NO is produced as part of the 
immune response to infectious agents invading the body.17,18 When applied exogenously, NO has 
been used to treat certain types of cancers, promote wound healing, and kill bacterial infections 
and disperse biofilms.18–20  
 The antimicrobial activity of NO is particularly important in stemming the spread of 
antibiotic-resistant bacteria due to its multiple mechanisms of action. NO can react under 
physiological conditions, forming nitrites (NO2
-) and nitrates (NO3
-), as well as reactive nitrogen 
species (RNS) like peroxynitrite (ONO2
-) that have additional toxic effects.21,22 The effects of 
NO and RNS produced from NO are referred to as nitrosative stress, which can cause a myriad 
of negative effects against bacteria.23,24 NO or the RNS it forms kill or harm bacteria by mutating 
its DNA structure, inhibiting DNA repair and synthesis, or increasing alkylating agents and 
hydrogen peroxide that can react with DNA.25,26 It can also inhibit protein synthesis, alter 
proteins by S-nitrosylation, inactivate enzymes, and peroxidate cell membranes. For bacteria to 
develop resistance to all of the mechanisms of action of NO, multiple mutations must happen 
simultaneously, which is unlikely. Studies by the Schoenfisch group showed that bacteria are 
unable to develop resistance to exogenously applied NO, even after 20 days.27 In addition, NO is 
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able to virtually eradicate NO, achieving up to a log-8 reduction (99.999999%) in a number of 
different bacterial species,28 as well as successfully dispersing biofilms using NO as a 
therapeutic.29,30 Neufeld showed that the concentration of NO needed to achieve a 90% reduction 
in Pseudomonas aeruginosa biofilm viability was 2.73 mM of NO from S-nitrosoglutathione.29 
 The inherent properties of NO give it the potential to be a very effective therapeutic. NO 
is nonpolar, uncharged, and hydrophobic.31,32 NO has a very small radius compared to other 
gaseous molecules, even oxygen or carbon dioxide.33 It can easily cross cell membranes due to it 
small radius, and its hydrophobic nature increases its ability to enter cells.34 These properties 
make NO a leading target for development into a therapeutic, but its inherent nature as a gas 
makes its delivery as a drug difficult. 
1.3 Categories of Nitric Oxide Donors 
As NO has been shown to have many therapeutic benefits, it is of high interest to develop 
NO-releasing drugs. NO is naturally in a gaseous state, and gaseous NO is an approved treatment 
for pulmonary hypertension.35 However, it is difficult to deliver NO otherwise due to its gaseous 
nature, short half-life, and near-instantaneous reaction with oxygen to form nitrogen dioxide, a 
toxic gas. For these reasons, many NO donors have been developed to store and deliver NO in a 
stable, controlled way, with a multitude of release rates and mechanisms.36 Broadly, the most 
common NO donors fall into the categories of organic nitrites/nitrates, metal nitrosyls, S-
nitrosothiols, and diazeniumdiolates.36–40  
Organic nitrites and nitrates are compounds with structures made up of organic R groups 
attached to nitrite (NO2
-) or nitrate (NO3
-) groups (Figure 1.1a-b). These compounds are typically 
known to release NO via specific NO-generating enzymes.41 Examples of organic nitrites and 
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nitrates used as therapeutics include amyl nitrite and nitroglycerin, which can treat hypertension 
and reduce pain in heart attacks.42 
Metal nitrosyls are complexes involving a NO ligand attached to a transition metal 
(Figure 1.1c). These compounds can release NO under physiological conditions or with a light-
trigger.43,44 One common metal nitrosyl, sodium nitroprusside, releases NO by binding to 
oxyhemoglobin, and releasing cyanide, methemoglobin, and NO.45  
S-nitrosothiols (RSNOs) are structures involving organic R groups attached to a 
nitrosated thiol group (Figure 1.1d). These compounds are produced endogenously and are found 
in the bloodstream in low concentrations, as well as bound to proteins, typically on nitrosated 
cysteine residues.46,47 RSNOs release NO through thermal, photocatalytic, or transition-metal 
catalyzed methods, releasing NO and a corresponding disulfide formed from two thiol groups.48  
Diazeniumdiolates (also called NONOates) are made up of secondary amines with the 
same or different R groups, attached to two NO groups (Figure 1.1e-f). “Diazen” refers to the 
nitrogen-nitrogen double bond, “ium” to the positive charge on nitrogen, and “diolate” to the two 
negatively charged oxygen atoms.49 It is standard in the field to refer to the two oxygen atoms as 
1 and 2 (Figure 1.1e),49 and they are usually named with an abbreviation of the secondary amine 
and forward slash NO in uppercase letters, such as PROLI/NO, a diazeniumdiolate formed from 
proline.50 These types of donors will be discussed more in depth in the next section.  
Fig. 1.1 Examples of NO donor structures a) organic nitrite b) organic nitrate c) metal 
nitrosyl d) S-nitrosothiol e) unprotected diazeniumdiolate f) O2-protected diazeniumdiolate 
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1.4 Synthesis, Characterization, and Properties of Diazeniumdiolates  
Diazeniumdiolates are of special interest as NO donors due to their ability to be protected 
and prevent spontaneous NO release prior to enzyme activation.51 Instead of the typical 
spontaneous NO release characteristics of most other NO donors or release by specific native 
enzymes, diazeniumdiolates are unique in that they can be protected by a variety of different 
organic groups to allow activation by a chosen enzyme to meet the requirements for the intended 
application.  
Diazeniumdiolates are typically synthesized by reacting secondary amines with NO gas 
under high pressure, commonly under basic conditions.38,49 Solvents used in these reactions can 
range from polar protic (methanol), polar aprotic (acetonitrile), to non-polar (diethyl ether).50,52,53 
There are two main proposed mechanisms for diazeniumdiolate formation (Figure 1.2). At low 
pressures (0-30 psi), there is first order dependence in NO.54 In a stepwise reaction, the amine  
performs a nucleophilic attack on one molecule of NO, forming a nitrosamine radical anion.54–56 
Next, the nitrogen of the nitrosamine anion forms a radical bond with a second molecule of NO.  
 
Fig. 1.2 Two proposed mechanisms for the formation of diazeniumdiolates. Mechanism 1 
(left, blue arrows) is proposed for reactions at 0-30 psi, and has a first order dependence on 
NO. Mechanism 2 (right, green arrows) is proposed for reactions at ≥50 psi, and has a second 
order dependence on NO. 
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The base (usually sodium methoxide, NaOMe, or a second amine molecule) deprotonates the 
amine, and the molecule tautomerizes to the diazeniumdiolate structure. At high pressures (50 
psi and higher), Bohle and coworkers proposes a second order dependence in NO, where NO 
forms an electrophilic dimer (N2O2), then the lone pair of the amine attacks one nitrogen of the 
NO dimer (Figure 1.2).54 The mechanism from that point is the same as at low pressures. 
Secondary amines form diazeniumdiolates much more readily as they are better nucleophiles 
than primary amines.55 X-ray crystal structures of diazeniumdiolates have shown that the cis 
form of diazeniumdiolates with both oxygens on the same side (Figure 1.1e) is the most stable 
structure.49 
As NO gas is a strongly oxidizing chemical, safety precautions must be undertaken when 
using it as a reagent. A reactor system to run these types of reactions should be built completely 
with stainless steel parts, which are inert to NO gas. These reactions are run at high pressure, so 
the reactor system should be equipped to handle the necessary pressure and not be pressurized 
past the maximum rating of the parts of the reactor system. NO forms nitrogen dioxide (NO2) 
upon contact with oxygen, which is a toxic environmental pollutant gas, so when NO is released 
from the reaction vessel, it must be bubbled through an appropriate solution to neutralize the NO 
gas waste. To address some of the hazards associated with these types of reactions, to scale up 
these reactions for their potential use in pharmaceuticals, Zhong and coworkers as part of the 
process chemistry team at Merck have developed an alternative synthesis.57 They found that 
during the course of diazeniumdiolate-forming reactions, sodium methoxide can react with NO 
to form dangerously high levels of nitrous oxide (N2O) in a side reaction, which was previously 
noted by DeRosa, et. al.58 Zhong and coworkers even noted “two unexpected explosions were 
reported in a 500 mL autoclave reactor (during venting), because of the rapid depressurization of 
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high-pressure nitric oxide (NO) from the headspace through Teflon-lined steel-braided tubing to 
atmospheric pressure.”57 To avoid potential explosion risk upon scale-up, the Merck team 
developed an alternative synthetic procedure involving Ca(OH)2 as the base and water as the 
solvent in the presence of NO at pressures ranging from 15-350 psi. They were able to show that 
the reaction conditions were successful across a broad range of amine starting materials in high 
yield. This novel procedure could offer greater risk mitigation for future syntheses of 
diazeniumdiolates.  
The success of diazeniumdiolate-forming reactions can usually be monitored visually by 
the formation of a precipitate in the reaction, as the product is highly ionic and does not dissolve 
well in the organic solvents typically used to run the reaction. The precipitate is filtered and 
rinsed once the reaction is complete, isolating a free flowing white solid. Diazeniumdiolates have 
an overall negative charge, balanced by the base counter ion (usually sodium, Figure 1.1e).  
The most direct way to analyze the product of diazeniumdiolate reactions is by UV-vis. 
Diazeniumdiolates typically have an absorbance peak at 250 nm, with a molar extinction 
coefficient between 7.2-9.4 M-1cm-1.49 This peak can be shifted to ~235 nm by protecting groups 
on the diazeniumdiolate (Figure 1.1f).49 Analysis of the reactions can also be based on NMR 
spectra, which can be taken in a mixture of deuterated sodium hydroxide and deuterated water to 
stabilize the compound. Diazeniumdiolates are typically stable as solids stored at -20 °C, or in 
basic solutions (pH 12). They dissolve easily in water and aqueous solutions due to their charged 
nature and display low solubility in most organic solvents. Diazeniumdiolates release two moles 
of NO per mole of diazeniumdiolate spontaneously in neutral or acidic solutions or when heated. 
The half-life of NO release from diazeniumdiolates can range from seconds to hours depending 
on the identity of the amine the diazeniumdiolate functional group is formed on.38,51 They 
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display first order kinetics in NO release.49 The release properties of diazeniumdiolates can be 
tuned by the identity of the amine and the surrounding conditions.  
Diazeniumdiolates are proposed to release NO via a hydrolysis mechanism (Figure 
1.3).59,60 The amine is protonated, giving it a positive charge. The negative charge on O2 pushes 
onto the adjacent nitrogen, forming a double bond, and the double bond between the two 
nitrogens breaks, pushing the electrons to form a double bond between the other nitrogen and O1 
of the diazeniumdiolate functional group. The secondary amine is released and homolytic 
cleavage of the bond between the two nitrogens in the remaining NO dimer releases two 
molecules of NO. This proposed mechanism explains why a protecting group on O2 prevents NO 
release, as the negative charge is not there to push onto the adjacent nitrogen, causing the 
compound to break apart.51 The amine can be protonated, but no further reaction occurs. 
 
One challenge with diazeniumdiolates is that they can form N-nitrosamines as a side 
product or decompose to form N-nitrosamines (Figure 1.4a).38,61 Most nitrosamines have been 
shown to be activated to form carcinogenic species.62,63 However, PROLI/NO is a common 
diazeniumdiolate which can decompose to form N-nitrosoproline, but nitrosoproline has been 
shown to be non-carcinogenic (Figure 1.4b-c).50,64 Nitrosamines are typically yellow in color and 
display UV-vis peaks at 230-240 and 330-350 nm, which can help distinguish this decomposition 
product from diazeniumdiolate product formation.36 When working with diazeniumdiolates, it is 
important to make sure they are under stable conditions to avoid decomposition to a carcinogenic 
Fig. 1.3 Proposed mechanism for NO release from a diazeniumdiolate. Two moles of NO are 
released per one mole of diazeniumdiolate. 
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species, and to test these decomposition products to determine their toxicity. In the case of using 
these compounds as therapeutics, it is especially important to investigate decomposition products 
that could potentially form under physiological conditions.   
 
1.5 Enzyme-Activated Nitric Oxide Prodrugs  
Because NO plays many roles in the body and is highly reactive, it is important to deliver 
it site specifically to avoid side effects. NO is cell permeable, and has a very short half-life in 
blood, making it an excellent candidate for site-specific delivery. A wide variety of O2-protected 
diazeniumdiolates have been synthesized, the general structure of which are shown in Figure 
1.1f, with a variety of triggers for NO release.51 These protected diazeniumdiolates are often 
prodrugs, inactive until they encounter a trigger such as an enzyme to release NO as the active 
therapeutic. 
Ionic (unprotected, Figure 1.1e) diazeniumdiolates release NO spontaneously and can be 
unstable, which can be problematic for their application as therapeutics. To address these 
problems, diazeniumdiolates can be protected by covalently binding an R group at the O2 
position (Figure 1.1f). As O2 is nucleophilic in nature, these protection reactions are typically 
selective and relatively simple.65 Protected diazeniumdiolates are synthesized by first 
synthesizing the ionic diazeniumdiolate, then functionalizing with a protecting group, usually 
from an electrophilic source such as an alkyl halide, sulfate ester, or epoxide.49 Protected 
Fig. 1.4 Structures of (a) general nitrosamine, which can form after decomposition of 
diazeniumdiolates and are typically carcinogenic (b) N-nitrosamine, a non-carcinogenic 
nitrosamine (c) PROLI/NO, a common diazeniumdiolate formed from the amino acid proline 
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diazeniumdiolates release NO more slowly or only in the presence of a specific trigger, such as 
an enzyme.51  
MOM-PIPERAZI/NO is an example of a protected diazeniumdiolate that is not enzyme-
activated. It is a piperazine-based diazeniumdiolate protected by a methoxymethyl ether (MOM) 
group at the O2 position (Figure 1.5). The MOM protecting group slows NO release 
considerably, from a half-life of 5 minutes for unprotected PIPERAZI/NO to 17 days with a 
MOM protecting group.66 For MOM-PIPERAZI/NO, NO release is still spontaneous as the 
MOM protecting group is naturally hydrolyzed over time, but it is significantly slowed. 
However, for most protected diazeniumdiolates, the protecting group is not hydrolyzable, and 
NO release is only activated with a specific enzyme or other compound.  
 
Fig. 1.5 Selected examples of enzyme-activated diazeniumdiolates and trigger, typically an 
enzyme, that leads to the release of NO 
12 
 
There are many other examples of diazeniumdiolates that are enzyme-activated by a 
variety of enzymes. Diazeniumdiolates can be protected by carbohydrates and NO release is 
activated by a carbohydrate-cleaving enzyme. A diazeniumdiolate is reacted with a halogenated 
glycoside, forming a glycosidic bond with the diazeniumdiolate. NO release is then caused by 
the corresponding glycosidase. For example, the Wang group developed a series of glycoside-
protected diazeniumdiolates, including D-galactose cleaved by a β-D-galactosidase, D-glucose 
cleaved by β-D-glucosidase (Figure 1.5), and D-mannose cleaved by α-D-mannosidase, for 
potential application as sugar transporters into cells.67 Valdez and coworkers demonstrated that 
these glycosylated diazeniumdiolates are pH sensitive, and synthesized a N-acetylglucosamine 
protected structure activated by a N-acetylglucosaminidase enzyme for antileishmanial 
applications (Figure 1.5).68 Nandurdikar, et. al. synthesized N-acetylglucosamine protected 
PROLI/NO with potentially biocompatible byproducts.69 Showalter and coworkers investigated 
glycosylated diazeniumdiolates as a protection-deprotection system.70 The Wang group also 
synthesized a novel sialated diazeniumdiolate, activated by a neuraminidase enzyme to target 
influenza viruses (Figure 1.5).71 
Another class of enzyme-activated diazeniumdiolates are protected by esters or related 
functional groups and are cleaved by esterases. Several examples from Saavedra, et. al. are 
acetoxymethylated diazeniumdiolates formed by reacting bromomethyl acetate with an ionic 
diazeniumdiolate, such as AcOM-DEA/NO (Figure 1.5). The resulting ester-protected 
diazeniumdiolates are activated to release NO by a porcine liver esterase, and are shown to 
induce apoptosis in leukemia cells.72  
Cytochrome P450 enzymes have also been used to trigger liver-specific NO release from 
enzyme-activated diazeniumdiolates. Saavedra and coworkers synthesized V-PYRRO/NO 
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(Figure 1.5) by attaching a vinyl group to a pyrrolidine-based diazeniumdiolate, and 
demonstrated that this compound can protect liver cells from apoptosis, which could potentially 
prevent liver toxicity and failure.53 Chakrapani et. al. synthesized an alternative to V-
PYRRO/NO, V-PROLI/NO, a proline-based diazeniumdiolate, to increase water solubility, and 
showed that NO release is still activated by cytochrome P450 enzymes from the liver.73 
Glutathione-S-transferases (GSTs) are a family of enzymes that work to detoxify and 
remove foreign compounds from the body.74 These enzymes are often over-expressed in cancer 
cells, so they have been a target for enzyme-activated diazeniumdiolates for anticancer 
applications. Several of these diazeniumdiolates have been synthesized, including JS-K, a 2,4-
dinitroaryl GST-activated diazeniumdiolate (Figure 1.5).74,75 This compound displays potent 
anti-proliferative effects and other mechanisms of anticancer activity against a variety of cancer 
cell lines.76,77 Another GST-activated diazeniumdiolate, PABA/NO (Figure 1.5), was synthesized 
by Findlay and others, and also displays anticancer activity in a human ovarian cancer model.78 
Chakrapani and coworkers synthesized PABA/NO analogues to further investigate the anticancer 
therapeutic potential.79 Saavedra and coworkers also investigated these 2,4-dinitroaryl-protected 
compounds for their use as HIV antiviral therapeutics.80 
Other enzyme-activated diazeniumdiolates have been synthesized for specific 
applications. One example is a DT-diaphorase enzyme-activated diazeniumdiolate, INDQ/NO, 
protected by an indolequinone (Figure 1.5).74 DT-diaphorase is an over-expressed enzyme in 
cancer cells, and Sharma and coworkers demonstrated that the INDQ/NO therapeutic inhibits 
cancer cell proliferation.81 Tang and coworkers coupled diazeniumdiolates to small peptide 
chains to make α-chymotrypsin-activated NO-releasing therapeutics to treat prostate cancer.82 
Nitroreductase enzymes are found in bacteria, and have been used in gene-directed enzyme 
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prodrug therapy to treat cancer. Sharma et. al. synthesized several nitroreductase activated 
diazeniumdiolates and demonstrated their anti-proliferative effects in cancer cells (Figure 1.5).83 
Hibbard, et. al also synthesized novel nitroreductase-activated diazeniumdiolates for applications 
to treat bacterial infections, as nitroreductase enzymes are found almost exclusively in bacteria.84 
1.6 Antibacterial Diazeniumdiolates 
 NO is known to be a potent antimicrobial agent, and several groups have used 
diazeniumdiolates to make antibacterial materials due to their stability and controlled, 
predictable release.85 Clinical studies with DETA/NO (Figure 1.6), a diethylenetriamine based 
diazeniumdiolate, showed that it had potent activity against both Candida and other fungal 
species.86 Chen, et. al. showed that Escherichia coli transformed with a lacZ gene were able to 
hydrolyze a β-galactosidase-activated diazeniumdiolate, β-Gal-NONOate (Figure 1.6), and kill 
the galactosidase-producing E. coli cells up to 87.6%.87 The Chakrapani group synthesized novel 
boronic acid-protected diazeniumdiolates (BORO/NO, Figure 1.6) that are activated by hydrogen 
peroxide (H2O2).88 They showed that cotreatment of various bacteria species such as E. coli, 
MRSA, and Pseudomonas aeruginosa, with BORO/NO and H2O2 increased the amount of 
 
Fig. 1.6 Selected examples of antibacterial diazeniumdiolates 
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intercellular NO, which would likely correlate to increased antibacterial activity. Collins, Allan, 
and coworkers developed PYRRO-C3D (Figure 1.6), a cephalosporin-3-diazeniumdiolate 
prodrug, activated to release NO with transpeptidases or β-lactamases.89,90 They showed that 
PYRRO-C3D has anti-biofilm activity against Haemophilus influenzae biofilms with 
coadministration of the antibiotic azithromycin, and against Streptococcus pneumoniae bacteria 
in both planktonic and biofilm form.89,90 
While some examples of small molecule diazeniumdiolates have been used to induce 
antibacterial activity, often they are incorporated into polymers or macromolecules to make 
antibacterial materials. A variety of polymeric and macromolecular platforms have been 
investigated, from nanoparticles, synthetic polymers like polyurethane (PU) or polyamidoamines 
(PAMAMs), to natural polymers like chitosan.91 These materials have been investigated to kill 
planktonic bacteria,92,93 biofilms,94 or both.93,95 Xu and Siedlecki wrote a review detailing 
antibacterial polyurethanes, including NO-releasing PUs with antibacterial properties.96 The 
Schoenfisch group developed composite PU electrospun fibers doped with diazeniumdiolate 
groups and PAMAM dendrimers and demonstrated their broad spectrum antibacterial activity.97 
Yang and coworkers synthesized hyperbranched PAMAM polymer chains, modified the 
polymers with propylene oxide, and functionalized the polymers with diazeniumdiolate groups, 
then showed that the material is able to eradicate oral bacteria.98 Backlund, et. al. derivatized 
PAMAMs functionalized with diazeniumdiolates to create scaffolds with bactericidal activity 
against Streptococcus mutans biofilms, a bacteria species causing dental cavities.99 Shim, et. al. 
showed that a branched, diazeniumdiolate functionalized-polyethylenimine (PEI) displayed 
antibacterial activity against several periodontal pathogens.100 Nurhasni and coworkers 
synthesized nanoparticles made of poly(lactic-co-glycolic acid) (PLGA) and diazeniumdiolated 
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PEI, and investigated the nanoparticles antibacterial activity against MRSA and P. aeruginosa.101 
Park and coworkers made hollow polydopamine nanoparticles functionalized with 
diazeniumdiolate groups, and demonstrated the nanoparticles potent antibacterial activity against 
E. coli and P. aeruginosa.102 Other groups have functionalized the natural oligosaccharide 
chitosan with diazeniumdiolate groups for antibacterial effects. Liu, et. al. derivatized chitosan 
and functionalized the polymer with diazeniumdiolate groups, then tested its antibacterial 
efficacy against E. coli.103 The Schoenfisch group also derivatized chitosan with secondary 
amine groups, then functionalized with diazeniumdiolate groups on the chitosan oligosaccharides 
and demonstrated the 5-log reduction in P. aeruginosa biofilms after exposure to the NO-
releasing polymer.104 These examples demonstrate the wide variety of NO-releasing 
diazeniumdiolate macromolecules designed and investigated for their antibacterial activity. 
Many antibacterial diazeniumdiolates have been synthesized and analyzed, both small 
molecules and polymeric or macromolecular materials. Many enzyme-activated 
diazeniumdiolates have also been synthesized, and some tested for their antibacterial efficacy. 
However, there is a severe lack of work developing diazeniumdiolates activated by wild type 
bacterial enzymes and investigation into their antibacterial activity. 
1.7 Dissertation Overview 
 The overarching goal of this dissertation is to synthesize a new antibiotic incorporating 
nitric oxide that can both detect and kill bacteria. To do this, I aim to create a small molecule that 
can sense bacteria and kill bacteria, ideally an enzyme-activated prodrug. The research question I 
aimed to answer in my research was: can a small molecule nitric oxide-releasing prodrug be 
synthesized that functions to both sense and kill bacteria?  
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 In the first project I worked on, I synthesized a fluorescent small molecule that changed 
color in the presence of bacteria. The goal of this project was to functionalize the fluorescent 
amide with a diazeniumdiolate. Bacterial enzymes would then metabolize the fluorescent 
molecule, changing the color of the molecule and indicating the presence of bacteria. This would 
also destabilize the molecule and trigger the release of NO from the diazeniumdiolate. 
Unfortunately, I was unable to successfully functionalize the fluorescent amide moiety with a 
diazeniumdiolate group. As a new approach, I synthesized an analogue of the fluorescent 
molecule which had a secondary amine functionality, and I was able to functionalize the 
compound with a diazeniumdiolate group. In this case, however, NO is released spontaneously, 
killing P. aeruginosa, then the bacterial enzymes cause a color change to indicate bacterial 
presence. With this first project, I was able to accomplish the goal of creating a molecule that 
could both sense and kill bacteria, although only the color change is enzyme-activated.  
 With my second project, I wanted to address the problem of creating an enzyme-activated 
NO-releasing antibacterial prodrug. This molecule would ideally sense bacteria, be metabolized 
by a bacterial enzyme, then release NO as the active therapeutic to kill bacteria. To accomplish 
this, I synthesized several nitroaromatic-protected diazeniumdiolates. Many bacteria species 
have nitroreductase enzymes that can reduce nitroaromatics. These enzymes can metabolize the 
protecting group, leading to the removal of the nitroaromatic group and causing the release of 
NO. In this way, I was able to achieve the goal of creating a bacterial enzyme-activated NO-
releasing small molecule. Exposure of the therapeutic to bacteria (Escherichia coli) and 
subsequent NO release then led to significant eradication of the bacteria. While there is not a 
visible color change like the compound in my first project, bacteria could potentially be detected 
through NO release. 
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 After synthesizing these small molecules, I wanted to make a material that would have 
applications in medical device development. Antibacterial coatings for medical devices could 
help prevent infections from forming on medical devices, which are often very difficult to treat. 
Incorporation of an antibiotic, such as the nitroaromatic-protected diazeniumdiolates I 
synthesized, into a device coating could release NO to kill bacteria, preventing infections from 
forming and increasing the lifetime of medical devices. I incorporated the nitroreductase-
activated diazeniumdiolate compound into a polyvinyl chloride/polyurethane composite and 
measured NO release from the polymer composite. NO release continued to be enzyme-
activated, unchanged from the powder small molecule form. I also showed that the 
diazeniumdiolate polymer composites display antibacterial activity. My research demonstrates 
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 The CDC estimates that there were 700,000 cases of hospital-acquired infections, or 
nosocomial infections, in 2011, resulting in about 75,000 deaths.1 The most common of these 
infections are caused by antibiotic-resistant bacteria, such as Pseudomonas aeruginosa and 
Acinetobacter baumannii.2 Bacterial resistance to antibiotics is spreading at an alarming rate and 
is one of the most significant current health threats according to the World Health Organization.3 
Without the development of new antibiotics or new ways to treat bacterial infections soon, there 
will be no way to treat infections that were once easy to cure. My approach to addressing the 
antibiotic resistance problem is to design and synthesize a nitric oxide releasing compound to 
detect and kill bacteria. Nitric oxide is a small, gaseous molecule known to have potent 
antimicrobial activity.4 The project detailed in this chapter outlines progress toward the synthesis 
of a new antibiotic incorporating nitric oxide.  
2.1.2 Nitric oxide and its antimicrobial activity 
Within the past few decades, nitric oxide (NO) has become increasingly recognized as a 
biologically important molecule. The many roles NO plays in the body and its importance as a 
potential drug candidate have been discovered and studied extensively.5 NO acts as a vasodilator 
to expand blood vessels and lower blood pressure or as a cell signaling molecule in the 
cardiovascular system.6 NO is produced as part of the immune response to infectious agents 
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invading the body.7 When applied exogenously, NO has been used to treat certain types of 
cancers, promote wound healing, and as an antimicrobial.8–10  
The antimicrobial activity of NO is particularly important in stemming the spread of 
antibiotic-resistant bacteria due to its multiple mechanisms of action. NO is a highly reactive 
radical molecule that forms reactive species in the body that can kill or harm bacteria by reacting 
directly with DNA structure, inhibiting DNA repair, or increasing alkylating agents and 
hydrogen peroxide that can react with DNA.4 In order for bacteria to develop resistance to NO, 
multiple mutations must happen simultaneously, which is unlikely. Studies by the Schoenfisch 
group showed that several common species of bacteria, including methicillin-resistant 
Staphylococcus aureus (MRSA), are unable to develop resistance to exogenously applied NO, 
even after 20 days.11 
2.1.3 Prodrugs 
Because NO is involved in varied functions throughout the body, it is critical to deliver 
NO site-specifically, so as not to interfere with other functions. While NO plays several 
beneficial roles in the body, in high doses, it can also have negative effects on the body, killing 
certain cells.12 NO is also an unstable gaseous molecule, reacting quickly with oxygen and 
forming toxic derivatives.13,14 When considering NO as a therapeutic, these problems must be 
addressed. 
Targeted drug delivery can be extremely beneficial to avoid adverse side effects from 
drugs. Site-specific delivery can be achieved with prodrugs, which are inactive drug compounds 
that release the active form of a drug after being metabolized, either through an enzymatic or 
chemical transformation.15 Prodrugs can help avoid adverse or unintended side effects by 
preventing the active drug compound from being released in areas where it is not needed. 
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Prodrugs also increase chemical stability, stabilizing the active compound until it is metabolized 
and preventing unwanted side reactions. Due to all of these properties, NO-releasing prodrugs 
are ideal for addressing the issues of using NO as a therapeutic, such as instability, reactivity, 
and side effects. 
NO-releasing prodrugs have been synthesized previously, usually dependent on enzyme 
activation to release NO.16,17 In the form of a prodrug, NO is no longer free to react and form 
toxic derivatives or to interfere with other normal processes in the body. The prodrug circulates 
in the body until it encounters a specific enzyme that metabolizes the prodrug and releases NO as 
the active drug.16,18–20 If the enzyme that activates the drug is only found in a specific location, 
such as the liver, then NO will only be released when the prodrug reaches the liver.20 Enzyme-
activated prodrugs allow for a very specific, targeted release of NO as a drug, while avoiding 
adverse side effects caused by NO. 
2.1.4 N-Diazeniumdiolates 
As NO is naturally a gaseous compound, several types of NO donor compounds have 
been developed to trap NO in a stable form for delivery. N-diazeniumdiolates are the most 
commonly used NO donor functional group for enzyme-activated NO prodrugs. Their general 
structure is shown in Figure 2.1, and it is standard in the field to refer to the two oxygen atoms as 
1 and 2 as shown in Figure 2.1a.21 Diazeniumdiolates release two moles of NO per mole of 
diazeniumdiolate, with half-lives ranging from seconds to days.16 NO is released when the 
nitrogen atom with R1 and R2 substituents is protonated (Figure 2.1), so the basicity of that 
nitrogen determines the half-life, and changes depending on the nature of the R1 and R2 groups.21 
Diazeniumdiolates are typically formed by reacting a secondary amine under a high pressure NO 




To increase the stability and half-lives of diazeniumdiolates, various groups have been 
attached to O2 to protect the diazeniumdiolate (Figure 2.1b).16 These groups can simply increase 
the half-life, or they can prevent release of NO entirely until the protecting group is removed. 
Often, enzymes are used to cleave the O2-protecting group, allowing the specific release of NO.16 
Diazeniumdiolates are a logical choice to use as an NO donor functional group when developing 
an enzyme-activated NO prodrug.  
2.1.5 Project Idea 
The goal of my research project is to synthesize a small molecule prodrug that detects the 
presence of bacteria and kills bacteria. When the prodrug is in the presence of bacteria, a 
bacterial enzyme will metabolize the prodrug, releasing the active drug to kill the bacteria. By 
detecting a bacterial infection, and localizing release of the active therapeutic, this compound 
will help address the problem of antibiotic resistance. To accomplish this idea, I envisioned 
synthesizing a small molecule sensor that is functionalized with a NO donor that detects bacteria, 
and upon activation by a bacterial enzyme, releases NO as an antimicrobial agent. A publication 
by Marie Cellier and coworkers sets a precedent for enzyme-activated bacterial detection.22 They 
synthesized several small molecules that changed their fluorescent color in the presence of 
several strains of gram-negative bacteria, including P. aeruginosa and A. baumannii.22 The 
molecules consisted of a fluorescent tag attached to the amino acid L-alanine. The bacterial 
strains they investigated release a protease enzyme called L-alanyl aminopeptidase that cleaves 




the alanine group from the fluorescent tag. A protease is a protein-specific enzyme that cleaves 
peptide bonds, removing amino acids. In the molecules synthesized by Cellier, the amino 
acid/fluorescent compound fluoresces blue. When the compound was in the presence of bacteria, 
the protease L-alanyl aminopeptidase cleaved the amino acid and released the free fluorescent 
tag which appears yellow. This fluorescent color change was used to visualize the presence of 
bacteria. Colorimetric detection would be ideal for the intended application of determining 
infections on bandages. For health care workers, it is important to change bandages when 
necessary, but avoid disturbance of a patient’s wound when unnecessary. The ability to visually 
determine if a wound is becoming infected by the color of the bandage would be extremely 
helpful for indicating when bandages should be changed, and if antibiotics should be applied. 
Based on colorimetric bacterial sensing molecules, I envisioned synthesizing the bacterial 
sensing portion of the molecule and then functionalizing it with a diazeniumdiolate group that 
would only be activated once the amino acid was cleaved, represented in Figure 2.2. This figure 
shows a representation of ideal function of the final synthesized dual ability compound. The 
initial molecule would not be fluorescent or would fluoresce one color, but once the bacterial 
protease cleaves the amino acid, the remaining compound would be unstable. The 
diazeniumdiolate group and fluorescent sensor portions of the molecule would spontaneously 
break apart and release NO and the fluorescent molecule, changing color (yellow star, Figure 
2.2). The bacteria I am focused on inhibiting are two antibiotic-resistant strains that cause many 
Fig. 2.2 Representation of protease-activated NO release. An amino acid (AA) protects a 
NO donor, then is removed by a protease enzyme. NO is released spontaneously and the 




nosocomial infections, P. aeruginosa and A. baumannii.2,23 The fluorescent function of the 
molecule could be used to visualize P. aeruginosa and A. baumannii, which could be useful in 
the case of an external wound, or as a laboratory technique to determine if the bacteria are 
present. If the fluorescent portion proved unnecessary, such as if the prodrug was used internally 
where fluorescence cannot be seen, I also envisioned a simpler molecule without the fluorescent 
moiety. In this case, the sensing function would come only from detecting NO release.  
2.1.6 Project Objectives 
The rapid spread of antibiotic resistance calls for new antibiotics to be developed. The 
goal of my project is to synthesize an enzyme-activated NO-releasing antimicrobial prodrug. The 
research question the work in this chapter attempts to answer is: can a dual function small 
molecule be synthesized with a fluorescent tag that changes color in the presence of bacteria and 
leads to NO release to kill bacteria? This will be accomplished by: 
I. Synthesizing the fluorescent molecule 
II. Labeling an amino acid with the fluorescent tag 
III. Functionalizing the fluorescent tagged amino acid with a diazeniumdiolate group 
IV. Adding an O2-protecting group to prevent spontaneous release of NO 
V. Measuring NO release in the presence of and without L-alanyl aminopeptidase 
VI. Testing the compound for antimicrobial activity against P. aeruginosa and A. baumannii 
The completion of all six of these steps would complete the development of an antibacterial 
prodrug that indicates the presence of bacteria and releases NO to kill bacteria only when 
bacteria are present. This would fully address the goal of this research project, although 
unfortunately, after experimentation, this goal was not fully addressed, and I changed the 
direction of the project to better address this goal. 
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2.2 Experimental Methods 
 
2.2.1 2-nitroacridin-9(10H)-one (2). 9(10H)-Acridone (0.976 g, 5 mmol) was stirred in 36% 
acetic acid (65 mL, 0.077 M) for 5 minutes. A mixture of concentrated nitric acid (68%, 4.7 mL, 
1 M) and glacial acetic acid (10.43 mL, 0.5 M) was slowly added, and the reaction was stirred 
for 5 hours at 55 °C. The hot reaction mixture was poured over 50 g of ice, and the precipitate 
was filtered. The precipitate was heated to boiling in absolute ethanol and filtered while hot to 
remove acridone. The solid was heated in boiling glacial acetic acid, filtered while hot, and 
rinsed with water to remove the 4-isomer. A pure yellow powder was obtained (821 mg, 67%). 
1H NMR (400 MHz, d6-DMSO) δ 12.34 (s, 1H), 8.97 (d, J = 2.7 Hz, 1H), 8.45 (dd, J = 9.2, 2.7 
Hz, 1H), 8.23 (d, J = 7.9 Hz, 1H), 7.81 (t, J = 7.0 Hz, 1H), 7.66 (d, J = 9.2 Hz, 1H), 7.58 (d, J = 
8.3 Hz, 1H), 7.36 (t, J = 7.5 Hz, 1H). Spectra matched the previously reported values.24  
 
2.2.2 10-methyl-2-nitroacridin-9(10H)-one (3). A previously reported synthetic procedure was 
modified as follows.25 Safety note: DMF and NaH can pose a potential explosion risk, so it is 
important to use a blast shield when running the reaction, avoid scaling up the reaction, do not 
decrease the ratio of solvent to NaH, and ensure the reaction is cooled to 0 °C before adding 
NaH and during the reaction. To a solution of 2 (200 mg, 0.833 mmol) in DMF (6.7 mL, 0.125 
M) at 0 °C was added NaH (83.2 mg, 2.08 mmol), and the reaction was stirred 30 minutes at 0 
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°C. Iodomethane (129 µL, 2.08 mmol) was added and the reaction was heated at 60 °C for 18 
hours. The reaction was cooled to rt, quenched with 15 mL of deionized water, and then the 
precipitate was filtered. The crude precipitate was recrystallized from 25:1 DMF:H2O and rinsed 
with diethyl ether, affording the title compound as yellow crystals (145.2 mg, 69%). 1H NMR 
(400 MHz, d6-DMSO) δ 9.03 (d, J = 2.9 Hz, 1H), 8.51 (dd, J = 9.6, 2.8 Hz, 1H), 8.34 (d, J = 8.2 
Hz, 1H), 8.04 (d, J = 9.6 Hz, 1H), 7.98-7.87 (m, 2H), 7.45 (t, J = 7.3 Hz, 1H), 4.00 (s, 3H). 
Spectra matched the previously reported values.25 
 
2.2.3 2-amino-10-methylacridin-9(10H)-one (4). A previously reported synthetic procedure was 
modified as follows.26 To a solution of 3 (254.3 mg, 1 mmol) in 8 N HCl (19.2 mL, 0.052 M), a 
mixture of SnCl2∙H2O (67.7 mg, 3 mmol) in 8 N HCl (28.6 mL, 0.035 M) was added. The 
solution was heated under reflux at 120 °C for 1 hour. After cooling to rt, 4 M NaOH was added 
until the mixture reached pH 11, then the precipitate was filtered and rinsed with water. The 
crude product was purified by flash column chromatography (SiO2, 70% ethyl acetate in 
hexanes, 100% ethyl acetate gradient), affording the title compound as a bright orange solid 
(122.8 mg, 55%). 1H NMR (400 MHz, d6-DMSO) δ 8.27 (d, J = 8.1 Hz, 1H), 7.76-7.67 (m, 2H), 
7.61 (d, J = 9.2 Hz, 1H), 7.46 (d, J = 2.8 Hz, 1H), 7.25 – 7.12 (m, 2H), 5.23 (s, 2H), 3.85 (s, 3H). 





yl)carbamate (5). A previously reported synthetic procedure was modified as follows.22 N-Boc-
L-alanine (248.3 mg, 1.05 equiv) was dissolved in dry THF (12.5 mL, 0.1 M) under Argon and 
cooled to -10 ⁰C in salt ice bath. Added N-methyl morpholine (137.4 µL, 1 equiv) and isobutyl 
chloroformate (163.4 µL, 1 equiv), then added 4 (280.3 mg, 1.25 mmol) after 90 seconds. Stirred 
20 hours, added 10 mL of DCM, washed with 0.1 M citric acid (15 mL), sat. NaHCO3 (15 mL), 
deionized water (15 mL), brine (15 mL). Washed combined aqueous with 3×15 mL of DCM. 
Dried over MgSO4, filtered, concentrated.  Recrystallized crude product from isopropanol and 
diethyl ether (1:1). Product is a yellow powder (312.1 mg, 63% yield). 1H NMR (400 MHz, 
CDCl3) δ 8.53 (d, J = 7.9 Hz, 1H), 8.33 (d, J = 2.3 Hz, 1H), 7.65 (t, J = 7.5 Hz, 1H), 7.44 (dd, J 
= 23.3, 9.0 Hz, 2H), 7.31 – 7.22 (m, 2H), 3.83 (s, 3H), 1.76 (s, 1H), 1.48 (s, 9H), 1.46 (s, 3H). 
Spectra matched the previously reported values.22  
 
2.2.5 (S)-1-((10-methyl-9-oxo-9,10-dihydroacridin-2-yl)amino)-1-oxopropan-2-aminium, 
trifluoroacetic acid salt (6). Added trifluoroacetic acid (5 mL, 0.025 M) to 5, stirred 2 hours, 
concentrated in vacuo. Precipitated out with diethyl ether (7 mL), dissolved crude product in 
water (2 mL), washed with ethyl acetate (2 mL), concentrated. Collected pure product as a 
greenish-yellow powder (51.6 mg, 97% yield). 1H NMR (400 MHz, DMSO) δ 10.63 (s, 1H), 
8.59 (d, J = 2.6 Hz, 1H), 8.31 (d, J = 8.1 Hz, 1H), 8.21 (s, 3H), 8.01 (dd, J = 9.3, 2.6 Hz, 1H), 
7.90 (d, J = 9.4 Hz, 1H), 7.86 – 7.77 (m, 2H), 7.31 (t, J = 7.1 Hz, 1H), 4.02 (q, J = 7.1 Hz, 1H), 




2.2.6 Tert-butyl (S)-(1-oxo-1-(phenylamino)propan-2-yl)carbamate (7). Followed literature 
procedure.27 In brief, N-Boc-L-alanine (1.45 mmol, 1 eq) and triethylamine (2.28 mmol, 1.6 eq) 
were dissolved in anhydrous THF (7.3 mL, 0.2 M) and cooled to -15 °C under Ar. Ethyl 
chloroformate (1.74 mmol, 1.2 eq) was added dropwise over 5 minutes, then the reaction stirred 
for 20 minutes, then aniline (1.5 mmol, 1.03 eq) was added. The reaction was allowed to stir at   
-15 °C, then warmed to rt and stirred overnight (18-20 h). 5% NaHCO3 solution (2.5 mL) was 
added to the reaction and stirred for 30 minutes. Added 5 mL of water to reaction, then extracted 
with ethyl acetate (10 mL) three times, washed with 10% citric acid (15 mL), brine (15 mL), and 
dried over Na2SO4. Pure product was collected as a white powder (300 mg, 78%) after 
purification by flash column chromatography (SiO2, 100% hexanes, 50% hexanes in diethyl 
ether, 20% hexanes in diethyl ether gradient). 1H NMR (400 MHz, CDCl3) δ 8.36 (s, 1H), 7.50 
(d, J = 8.1 Hz, 2H), 7.28 (dd, J = 16.9, 8.9 Hz, 2H), 7.08 (t, J = 7.3 Hz, 1H), 4.30 (s, 1H), 1.46 (s, 
9H), 1.43 (d, J = 7.0 Hz, 3H). Spectra matched the previously reported values.27 
2.3 Synthetic Routes to L-alanyl Aminopeptidase Indicator 
I conceived of three compounds to synthesize (Figure 2.3) in the development process of 
the dual function antibacterial indicator. The first was the compound published by Cellier, with 
the fluorescent attachment, 1 in Figure 2.3.22 Compound 1 fluoresces blue with the amino acid 
attachment, but when the amino acid is cleaved, it fluoresces yellow. The alanine moiety would 
remain Boc-protected during the diazeniumdiolate reaction to prevent potential reaction with the 
alanine amine. Since this compound requires multiple steps to synthesize, I also wanted to 
synthesize a less complex model compound (2) that could be used to optimize the 
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diazeniumdiolate-forming reaction conditions. This model compound is structurally similar to 1 
but would require fewer steps to synthesize. The model compound 2 in Figure 2.3 requires only 
one step to synthesize from commercially available starting materials, versus four steps to 
synthesize the fluorescent compound 1. Compound 3 in Figure 2.3 does not include any aromatic 
or fluorescent functionality, which could be useful if visualizing the presence of bacteria through 
fluorescence proves unnecessary. The bacteria-sensing function of compound 3 could come from 
sensing NO directly. 
 
2.3.1 Development of Synthetic Procedure for Fluorescent Indicator 
I began the synthesis of 1 with nitrating acridone 4 to form 5 (Figure 2.4), then 
methylating the amine to form 6. The next step is reducing the nitro group to an amine, then 
coupling the Boc-protected amino acid to 7 to form the product 1. I attempted to follow the 
synthetic procedure published by Cellier et. al. to synthesize 1, but their experimental procedures 
often lacked necessary details and several of the reactions did not work as they reported, 
potentially due to ambiguity in their procedures.22 To overcome this challenge, I modified 
Cellier’s reported procedures or found new procedures to achieve improved yield (Figure 2.4.) 
First, I nitrated acridone (4) with nitric acid in the presence of acetic acid to form 5, 2-
nitroacridone, based on previously reported procedure by Gao and coworkers.24 Based on the 1H-
NMR spectrum of the product, this reaction forms a 4:1 ratio of the desired product with the nitro  






group in the 2-position to an undesired side product with the nitro group in the 4-position (Figure 
2.5). Gao’s experimental procedure did not mention formation of this side product, and the 
original method of purification, recrystallization from absolute ethanol, did not remove the 
undesired side product. To attempt to avoid forming the 4-isomer, I followed another synthetic 
procedure of 5 reported by Chen, but encountered the same problem of forming the undesired 
isomer, as well as being left with a small amount of unreacted starting material.28 Increasing the 
reaction time did not decrease the amount of unreacted starting material. Cellier did mention 
forming the 4-isomer as a side product and their solution was to dissolve the mixture of isomers 
in boiling acetic acid. I found that this method worked, dissolving the 4-isomer and leaving the 
2-isomer as a solid. After several attempts at this synthesis, I optimized the method to purify 
Fig. 2.4 Overall reaction scheme for synthesis of Boc-protected fluorescent L-
alanylaminopeptidase indicator 1 
  
Fig. 2.5 The 2-isomer and 4-isomer products resulting from the reaction of acridone 4 to 
nitroacridone. The 2-isomer is the desired product, which was separated from the undesired 4-
isomer in a later step. 
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product 5 by combining the procedures of Cellier and Gao and coworkers.22,24 I used the amounts 
and procedure reported by Gao and worked up the reaction following Cellier’s procedure. The 
starting material acridone (4) dissolves in hot ethanol while the product does not, so this provides 
a way to remove any leftover starting material. Boiling the crude product in glacial acetic acid 
dissolves the 4-isomer while the desired 2-isomer remains solid and filtering immediately after 
removes any 4-isomer. Recrystallization from 25:1 DMF:water further purifies the product. This 
procedure gives an average yield of 64% of a mixture of isomers. 
The next step of the synthesis, methylation of 5 to 6 in Figure 2.4, was straightforward. I 
followed a synthesis reported by Stopka and colleagues to methylate 5.25 I deprotonated the 
amine with sodium hydride (NaH) in N,N-dimethylformamide (DMF), then added methyl iodide 
(MeI) as the methyl group donor. As a safety note, although DMF is a common solvent to use in 
reactions with NaH, it can pose an explosion risk.29 To account for these risks, it is important for 
the scientist to be aware of the risk and place a blast shield in front of the reaction in case of an 
explosion. In addition, the risk can be minimized by increasing the solvent to NaH ratio (8.7% 
NaH, 3.7% mineral oil, and 87.6% DMF in the experimental methods described in this chapter), 
running the reaction at lower temperatures (0 °C in the experimental methods described in this 
chapter), running the reaction on small scale, or using a different solvent that does not pose these 
risks, such as THF.29 After completing the work-up procedure reported by Stopka, my product 
still contained impurities. I used Cellier’s purification technique of recrystallization from DMF 
and water to further purify my product. This technique gave the desired results, and NMR 
analysis showed that the product was pure. If I used starting material containing both the 2- and 
4-isomers of nitroacridone (Figure 2.5), the NMR of 6 after the methylation reaction showed no 
sign of the 4-isomer. This was an excellent observation, as it meant I did not need to purify 5 
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before carrying the product on to the next step. My procedure for this step produced an average 
yield of 70%.  
To reduce the nitro group, 6 to 7 in Figure 2.4, I tried different procedures before finding 
success. I first followed Cellier’s reported experimental procedure using tin(II) chloride 
dihydrate (SnCl2∙2H2O) in ethanol, but the reaction did not produce any product. I found a 
different synthesis reported by Manfroni and coworkers, using tin(II) chloride dihydrate and 
hydrochloric acid (HCl) that was succesful.26 The crude product showed evidence of the 
undesirable 4-isomer as well as the desired 2-isomer, similar to Figure 2.5. Fortunately, I was 
able to develop column chromatography conditions using a gradient solvent system, 70% ethyl 
acetate:30% hexanes, then 100% ethyl acetate on silica gel to separate the isomers, giving an 
isolated yield of 7 of 60%. When dissolved in ethanol, I observe that compound 7 appears yellow 
under a 365 nm UV light. 
For the reaction of 7 to form 1 in Figure 2.4, I followed the procedure reported by 
Cellier.22 I added N-methylmorpholine (NMM) and isobutyl chloroformate (iBuCF) to N-Boc-L-
alanine, then added 7. It is necessary to couple Boc-protected L-alanine to 7 because NO reacts 
readily with amines to form diazeniumdiolates. To push the diazeniumdiolate to form at the 
amide position as desired, the amine group on the amino acid needs to be protected. Cellier’s 
procedure for this reaction did not report amounts of solvents or a specific reaction time, so I 
chose reasonable values for these variables. The reaction worked, although their reported 
purification technique of recrystallizing from isopropanol and isopropyl ether did not 
successfully purify my product. Instead, I found that by pouring cold ether over the oily crude 
product, my product precipitates out. My yield for this reaction is 28% on average. 
2.3.2 Synthesis of Model Compound  
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To avoid depleting my supply of synthesized compound 1 while optimizing conditions to 
form the diazeniumdiolate, I decided to synthesize a structurally similar model compound 2 that 
could be used for optimization instead. Compound 2 is synthesized through a one-step coupling 
reaction between aniline 9, and N-Boc-L-alanine 8 (Figure 2.6), using ethylchloroformate and 
triethylamine (Et3N) in tetrahydrofuran (THF). The phenyl group on 2 is similar enough to the 
acridone group on 1 for the diazeniumdiolate reaction conditions to be applicable. To synthesize 
compound 2, I reacted aniline with Boc-L-alanine to form the amide, following a procedure 
published by Chen and colleagues.27 The reaction was successful (Figure 2.6), and after 
purification by column chromatography, I obtained compound 2 with an average yield of 85%. 
 
2.3.3 Synthesis of Non-Fluorescent Indicator 
As the visible fluorescent color change is not useful in all applications, I also decided to 
synthesize a version of the fluorescent indicator without a fluorescent attachment, 3 in Figure 
2.7. In this case, there will be no way to visualize the presence of bacteria with UV light, so by 
detecting the release of NO after functionalization with a diazeniumdiolate group, the presence 
of bacteria can be detected. To synthesize compound 3, I followed a procedure by Islam, et. al, 
starting with N-Boc-L-alanine 8 and esterifying it with trimethylsilyldiazomethane (TMSD) in 
methanol (MeOH) and benzene, forming 10 (Figure 2.7).30 From 10, I performed an amidation 
reaction with ammonium hydroxide (NH4OH) in MeOH to give 4, following a procedure by 





Singh and coworkers.31 According to literature, these reaction steps should give quantitative 
yields.30,31 However, based on the NMR data for my final product, there were major impurities 
present, which I removed with a basic work-up step. After this work-up step, the highest yield I 
achieved was 16% over both steps, which is not close to literature reports of quantitative yield. I 
hypothesized that water might be reacting with the reagents and decreasing the yield, so I tried 
running the reaction under an inert atmosphere with distilled solvents, but this did not improve 
the yield. My distilled solvents most likely still contained small amounts of water even after 
storage over activated molecular sieves, so I purchased anhydrous solvents under inert gas. 
However, using anhydrous solvents did not improve my yields either. It is possible that the TMS 
group was not removed, forming product 11 (Figure 2.8) instead of the methyl ester, proposed as 
a potential issue in a paper by Kühnel et. al.32 It proved to be less expensive and less time 
consuming to purchase compound 4 instead of continuing in my attempts to improve my yield. 
2.3.4 Experiments Investigating Bacterial Indicator Properties of Synthesized Compounds 
With compound 1 synthesized, I wanted to replicate the bacterial studies published by 
Cellier et. al. as a proof of concept.22 These cell studies were performed by Bella Neufeld of the 
Reynolds group. Because the bacteria produce the protease L-alanyl aminopeptidase, which  
Fig. 2.7 Reaction scheme for synthesis of non-fluorescent indicator 3 




recognizes only the unprotected form of L-alanine, I removed the Boc group in 1 by stirring it 
with trifluoroacetic acid to give 12 in Figure 2.9. Using Cellier’s procedure as a guide, Bella 
dissolved the compounds I synthesized, 1 and 12, in dimethyl sulfoxide (DMSO) and added 
them to Colombia agar. She then inoculated the plates of agar with P. aeruginosa at 37˚C for 18 
hours. After incubation, the plates were illuminated under 365 nm UV light to determine 
fluorescence, shown in Figure 2.10. Yellow fluorescence indicates that enzymatic cleavage 
occurred, releasing the free amino acid 8 and aminoacridone 7 to fluoresce yellow. Blue 
fluorescence indicates that no enzymatic cleavage occurred; it is the color of the background 
fluorescence. All the columns of cell culture plates in Figure 2.10 are identical replicates; they 
differ across the rows. On the left is the positive control, which was inoculated with P. 
Fig. 2.9 Deprotected fluorescent indicator 12 
Fig. 2.10 Cell culture plates of bacterial studies under UV light. Left column: positive control 
(PC, P. aeruginosa only); middle column: compound 1, Boc-protected fluorescent compound; 
right column: compound 12, Boc deprotected fluorescent compound in both images A and B. 
A B 





aeruginosa, but did not contain any of the compounds I synthesized. The positive control in 
image A (Figure 2.10) has weak blue fluorescence, which is due to the inherent ability of P. 
aeruginosa to fluoresce on its own.33 In the middle column of plates is compound 1 in the 
presence of P. aeruginosa, a control to show that the enzyme cleaves only the unprotected amino 
acid. In image A in Figure 2.10, strong blue fluorescence is observed for the middle plates, 
which matches my expectations, as the compound should not be metabolized and change color. 
The bacterial enzyme should not recognize the Boc-protected amino acid, so no cleavage occurs 
and 1 fluoresces blue. On the right plates is compound 12, and image B in Figure 2.10 clearly 
shows yellow fluorescence. This indicates that the L-alanyl aminopeptidase in P. aeruginosa 
cleaved the compound as expected, and that the indicator produces a visible color change in the 
presence of bacteria. These bacterial studies with P. aeruginosa showed that blue fluorescence 
occurred with the Boc-protected compound, as expected for the background color. Yellow 
fluorescence was observed only with the deprotected compound, providing a proof of concept 
that my compounds act as a bacterial indicator as Cellier’s paper showed they should.22 
2.3.5 Boc Group Deprotection 
Removing the Boc group from my compound once the diazeniumdiolate reaction is 
complete will be one of the last steps before the synthesis is finished, so I started testing reaction 
conditions to remove the Boc group on the model compound 2. Boc groups are typically 
removed under acidic conditions, but diazeniumdiolates are acid sensitive, so I searched the 
literature for basic conditions to remove the Boc group. Tom, et. al. used sodium tert-butoxide 
(NaOtBu), sodium ethoxide (NaOEt), or sodium methoxide (NaOMe) in refluxing THF to 
remove primary Boc groups.34 El Kazzouli and coworkers removed the Boc group with sodium 
carbonate in refluxing dimethoxyethane (DME) and water.35 Yin and Zhang tested several 
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conditions based on the paper published by El Kazzouli et. al., and found that for their system, 
sodium hydroxide (NaOH) in THF and water at room temperature removed the Boc group.36 I 
tested all of these reported conditions and many variations on these variables with the model 
compound 2 to attempt to form the deprotected product 13 (Equation 1). I investigated variables 
such as the identity and amount of the base, solvent, additives, temperature, and reaction time. 
Using stronger bases, such as NaOMe, versus a weaker base, like Na2CO3, could lead to the 
desired product or to side products. Different solvents change the solubility of the reagents, 
leading to a more homogeneous or heterogeneous solution, which affects how the reagents 
interact. Additives like water could also change the solubility of the base. Lower temperatures 
and shorter reaction times could lead to the formation of lower amounts of side products. Higher 
temperatures or longer reaction times could allow reactions that did not previously work to 
happen or lead to higher yields. The conditions tested are shown in Table 2.1, but unfortunately, 
I found limited success. 
Entries 1-8 show variations of the reaction described by Tom.34 In entries 1 and 2, I tried 
the reaction conditions as described in Tom’s paper, but I found that NaOMe afforded only a 
small amount of deprotected product. NaOEt, on the other hand, cleaved the starting material at 
the wrong location, producing aniline. To avoid this unwanted pathway, I decreased the reaction 
time, as shown in entries 3 and 4. This also produced aniline, along with unreacted starting 
material. I also tried lower temperatures (Table 2.1, entries 5-6), and fewer equivalents of NaOEt 
(Entries 7-8). While this lead to a small increase in the yield of the desired product, none of the 
conditions afforded a large amount of deprotected product, so I decided to test other conditions.  
Entry 9 shows the optimized conditions published by Yin,36 and entry 10 shows the 





Table 2.1 Optimizing Basic Boc Deprotection Conditions 
Entry Base Equiv. 
base 







1 NaOMe 4 THF H2O (10 eq) 70 18 8 
2 NaOEt 4 THF H2O (10 eq) 70 18 Aniline 
3 NaOEt 4 THF H2O (10 eq) 70 2 Aniline 
4 NaOEt 4 THF H2O (10 eq) 70 6 Aniline 
5 NaOEt 4 THF H2O (10 eq) rt 19 13 
6 NaOEt 4 THF H2O (10 eq) 40 19 Aniline 
7 NaOEt 1 THF H2O (10 eq) 40 19 13 
8 NaOEt 2 THF H2O (10 eq) 40 19 19 
9 NaOH 2.4 THF:H2O (1:1) - rt 19 13 
10 Na2CO3 1.2 DME:H2O (1:1) - 40 19 12 
11 Na2CO3 1.2 THF:H2O (1:1) - 40 19 16 
12 Na2CO3 1.2 Et2O:H2O (1:1) - 40 19 14 
13 Na2CO3 1.2 dioxane:H2O (1:1) - 40 19 16 
14 K2CO3 2.4 DME:H2O (1:1) - 80 17 13 
15 NaOH 2.4 DME:H2O (1:1) - 80 17 12 
16 Na2CO3 1.2 DME:H2O (1:1) - 80 23 13 
17 Na2CO3 1.2 DMF:H2O (1:1) - 85 20 35 
18 Na2CO3 1.2 dioxane:H2O (1:1) - 80 23 13 
19 Na2CO3 1.2 DMF:H2O (1:1) - 110 18 12 
20 Na2CO3 1.2 DMF:H2O (1:1) - 140 18 52 
21 K2CO3 1.2 DMF:H2O (1:1) - 85 18 9 
22 NaOH 1.2 DMF:H2O (1:1) - 85 18 13 
23 NaOMe 1.2 DMF:H2O (1:1) - 85 18 10 
24 NaOEt 1.2 DMF:H2O (1:1) - 85 18 8 
25 Na2CO3 1.2 DMF:H2O (1:1) - 85 18 0 
26 Na2CO3 2.4 DMF:H2O (1:1) - 85 18 3 
27 Na2CO3 5 DMF:H2O (1:1) - 85 18 5 
28 Na2CO3 1.2 DMF:H2O (1:1) - 80 20 13 
29 Na2CO3 1.2 DMF:H2O (1:1) - 85 18 16 
30 Na2CO3 1.2 DMF:H2O (1:1) - 85 18 18 
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product, so I varied the conditions to try to increase the yield. Entries 14 and 15 show different 
bases, potassium carbonate (K2CO3) and NaOH, that Yin tried in their optimization, neither of 
which provided any improvement. Entries 11-13 and 16-18 show various polar aprotic solvents, 
THF, diethyl ether (Et2O), 1,4-dioxane, DME, and DMF, some at higher temperatures. The only 
solvent that provided any significant improvement in yield was DMF.  
Based on these results, I optimized the reaction using DMF as the solvent. I increased the 
temperature, entries 19 and 20, and found that at 140 ˚C, higher amounts of deprotection were  
possible, but the reaction also produced several side products and decomposed some of the 
starting material. Furthermore, temperatures in that range will most likely decompose the 
diazeniumdiolate group. Entries 21-24 show several different bases in DMF, but none of these 
increased the amount of product. In entries 25-27, I varied the equivalents of base, but found no 
improvement. Strangely, entry 25 was run in almost identical conditions as entry 17 which 
previously showed an increased yield, but in this case, no deprotection occurred at all. I ran the 
reaction again to see if perhaps entry 17 was anomaly, and based on entries 28-30, it seems it 
must have been. None of the three identical reactions gave yields even close to what I had 
observed previously. So far, none of the basic Boc deprotection strategies that I have employed 
have been very successful, so a new strategy will be necessary to afford the final unprotected, 
product with a diazeniumdiolate group attached. 
2.4 Chemical Approach to Functionalization of Indicator with Nitric Oxide Donor 
2.4.1 Development of High-Pressure NO Reactor Set Up 
In order to synthesize diazeniumdiolates, a high-pressure gas reactor set-up is necessary, 
so I set up our NO reactor system in order to run these reactions. The NO reactor is made up 
completely of stainless-steel parts, as NO is a strongly oxidizing gas and would react with other 
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materials. The metal tubing (Figure 2.11) is connected by Swagelok fittings for a leak-proof seal. 
The reactor on the left is connected to an argon tank to purge the system (Figure 2.11a-b), and 
there are positions for five possible reactions at one time (Figure 2.11c). On the right, the system 
is connected to a high purity (>99%) NO tank (Figure 2.11c). The Swagelok connections must be 
tightened properly, but not overtightened, in order to prevent leaks in the system. Leaks can 
allow NO to be released into the atmosphere, which is dangerous, and the reaction will not hold 
pressure over the course of the reaction, which can prevent the reaction from being successful. 
To test for leaks while setting up the reaction system, I filled the system with argon gas, closed 
the valves, and checked each gauge at particular time points to determine if the system was 
leaking (indicated by decreasing gauge readings) and where the leak was occurring. Once I 
determined that there were leaks in the system, I used Snoop, a soapy solution, to help find the 
leak. The solution is sprayed on joints, and if bubbles form, that is a sign that gas is leaking at 
that point. Once the leak is found, the joint should be checked for damage and replaced if so or 
Fig. 2.11 NO reactor system set-up a) argon tank to purge the reactor system of oxygen b) tubing 
and gauge connecting argon tank to NO reactor system c) reactor set-up with high purity NO 
tank to the right of the system d) reaction vessel attached to reactor system 
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tightened slightly if there is no apparent damage. Teflon tape can also be used to prevent leaks 
for certain types of joints. The process of filling the system with argon and checking the gauges 
should be repeated until pressure is maintained at each gauge for at least 24 hours, or the longest 
potential reaction time. Once the reactor system is determined to be leak free, a reaction vessel 
and valve set up (Figure 2.11d) should be attached to the reactor system and pressurized with 
argon gas, then left for at least 24 hours to ensure that the reaction set up and valve also do not 
have leaks. If the set-up leaks, the rubber gaskets on the quick release valve should be replaced 
and retested. 
To set up a reaction, the reaction mixture is placed in a reaction vessel with a stir bar. If 
the reaction volume is small (<10 mL), a glass vial can be placed in the coated reaction vessel to 
hold the reaction solution. The vessel is sealed with a valve, and the valve is connected to the 
reactor system and stirred below on a stir plate (Figure 2.11d). The system is purged with argon, 
then filled with NO to the pressure needed for the reaction. The reactor system is only rated to be 
pressurized up to 100 psi, and reactions requiring pressures higher than that should not be run on 
our system. The reaction is then sealed off separately from the rest of the system, and the 
reaction is allowed to run until complete. The rest of the reactor system is purged with argon to 
remove any leftover NO. Once complete, the reaction is opened to the rest of the system, and the 
system is again purged with argon several times. The reaction vessel can then be removed from 
the reactor system and opened to workup the reaction and purify the product. 
There are several safety guards to ensure that the risks of using the NO reactor are 
mitigated. NO is a P-listed chemical and can be hazardous to work with. In our applications, it is 
used in a high-pressure gas reactor system, which also poses its own risks. The reaction mixture 
is placed in a polymer-coated reaction vessel (Figure 2.12a) which is sealed with a quick release 
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valve (Figure 2.12c, 2.12e). The polymer coating means that if the reaction explodes, the vessel 
and reaction will be contained within the coating. The quick release valve means that the reaction 
vessel can be immediately removed from the reactor at any time without purging the vessel, as it 
is a fully contained unit (Figure 2.12e). As NO reacts readily with oxygen, the system must be 
purged with argon gas several times before adding NO to the system, after NO is added to the 
system, and when the reaction is complete. Any waste NO that needs to be released from the 
reactor system is absorbed through the waste solution, a solution of potassium permanganate 
(KMnO4) and potassium hydroxide (KOH), which reacts with the NO to form solid manganese 
oxide (MnO), neutralizing the NO gas (Figure 2.12f).37 The solution appears bright purple in 
color when freshly prepared due to the KMnO4, but when it is no longer active and needs to be 
replaced, it is clear with a brown solid, which is the MnO. To prevent any water in the system 
Fig. 2.12 Safety features of the NO reactor set-up a) polymer coated reaction vessel to contain 
vessel in case of explosion b) tubing on reactor connecting to quick release valve c) quick release 
valve d) NaOH/CaSO4 capsule e) coated vessel attached to quick release valve f) KMnO4/KOH 
waste solution to absorb waste NO gas 
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and to help neutralize any NO leaks in the system, a capsule containing sodium hydroxide 
(NaOH) pellets and calcium sulfate (CaSO4, Drierite) is part of the system (Figure 2.12d). Cotton 
wool is placed at each end of the capsule to prevent the pellets from falling out into the tubing. 
All of these safety precautions and proper training of the reactor user helps to mitigate the risks 
of working with a high-pressure NO reactor.  
2.4.2 Analyzing Reaction Products of UNC Chapel Hill Samples 
 
While I was in the process of setting up our in-house NO reactor system, I sent samples 
of my starting materials to UNC Chapel Hill, where Lei Yang of Mark Schoenfisch’s group 
performed initial reactions with NO to attempt to form the proposed diazeniumdiolate structures 
(Figure 2.13). When the reacted samples were sent back, I used UV-Vis and NMR spectroscopy 
to confirm whether the reaction was successful or not. Diazeniumdiolates have a very distinctive 
peak around 250 nm in their UV-Vis spectrum, so this feature is an easy way to determine if the 
reaction was successful.21 Diazeniumdiolates are unstable in non-basic solutions, so I took UV- 
Vis measurements for 14-16 in 0.01 M NaOH, shown in Figure 2.14. The UV-Vis spectrum of 
14 showed peaks at 263 and 413 nm, which is not indicative of a diazeniumdiolate. To determine 
what these peaks were, I took a UV-Vis spectrum of compound 2 in EtOH, as it is too non-polar 
to dissolve in aqueous solutions. This spectrum showed peaks at 261 and 414 nm, very similar to 
14 in Figure 2.14, so these peaks are most likely due to the fluorescent compound alone. The  
Fig. 2.13 Potential diazeniumdiolate products with fluorescent, model, and non-fluorescent 
indicator starting materials 
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UV-Vis spectrum of 15 showed a peak at 258 nm, which is a higher wavelength than a normal 
diazeniumdiolate feature but could still possibly be indicative of diazeniumdiolate formation. 
The UV-Vis spectrum of 16 showed a peak at 250 nm, which is a good indication that the 
diazeniumdiolate was formed. This data indicated to me that further testing would be needed to 
determine if 15 or 16 were formed in the reaction. 
While 14 was almost certainly not formed successfully based on the UV-Vis data, further 
studies would confirm if 15 and 16 were formed or not. Because diazeniumdiolates are unstable 
in water at pH 7, their decomposition can be tracked by UV-Vis spectroscopy by observing the 
disappearance of the diazeniumdiolate peak at 250 nm when the compounds are dissolved in 
water. I dissolved compounds 15 and 16 in water and immediately collected UV-Vis spectra, 
finding a peak at 260 nm for 15 and 250 nm for 16. The absorbance was 0.347 for 15 at 0 
minutes and 0.820 for 16. As can be seen in Figure 2.15, absorbance did not decrease at all for 
Fig. 2.14 UV-vis spectra for potential diazeniumdiolate compounds 14-16 in 0.01 M NaOH, 
after reaction of NO with fluorescent, model, and non-fluorescent starting materials. 
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15 over 24 hours. For compound 16, however, absorbance steadily decreased over the first four 
hours of the experiment and decreased further after 24 hours. This water decomposition study 
indicates that the diazeniumdiolate reaction was successful for the non-fluorescent compound 
and 16 was formed, but 15 was not successfully formed.  
I also attempted to use NMR studies to confirm whether the reaction with NO was 
successful in forming compounds 14-16. Because diazeniumdiolates are unstable in non-basic 
solutions, an NMR spectrum of a diazeniumdiolate is typically collected in a solution of 
deuterated sodium hydroxide (NaOD) and deuterated water (D2O). I first collected NMR data 
with the samples dissolved in 10% NaOD in D2O (Figure 2.16). The NMR spectra of all three 
compounds showed none of the expected peaks. All of the spectra displayed solvent peaks and 
some unknown impurities with three singlets between 1.5-3 ppm. The NMR of compound 15 
also had some small peaks in the aromatic region, but the spectrum was noisy and the peaks were 
difficult to interpret. 
Fig. 2.15 Tracking decomposition of potential diazeniumdiolate compounds 15 and 16 in 
water over 24 hours by measuring peak absorbance at 260 or 250 nm 
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Because the NMR spectra in NaOD were inconclusive, I attempted a similar water 
decomposition experiment to corroborate the UV-Vis data. I dissolved the three compounds in 
water and let them sit for at least one hour to decompose the diazeniumdiolate group if present. I 
then removed the water under vacuum and dissolved the remaining solids in deuterated 
chloroform and deuterated methanol. However, the NMR spectra for all three compounds 
showed the same unknown impurity as in NaOD, and none of the peaks for the starting materials 
were observed (Figure 2.16). After collecting this NMR data, the results are inconclusive. I 
believe that my compounds are unstable in the NMR solvents I have used and are decomposing 







Fig. 2.16 a) NMR spectrum of pure model compound 2. b) NMR spectrum of reaction product of 
potential diazeniumdiolate 15 formation in 10% NaOD/D2O solvent. c) NMR spectrum of 
reaction product of model compound potential diazeniumdiolate formation 15 after 
decomposition in water to attempt to return to starting material in CDCl3/MeOD solvent. 
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data. Solely based on UV-Vis data, compounds 14 and 15 were not successfully synthesized, but 
compound 16 was synthesized. 
2.4.3 In-House Process to Synthesize Diazeniumdiolates 
Once our in-house NO reactor system was set up and ready to use, to ensure that the 
reactor was functioning properly, I synthesized the common diazeniumdiolates PROLI/NO19 and 
MAHMA/NO38 (Figure 2.17) based on previously reported procedures. These reactions were 
successful based on UV-vis peaks at 251 nm for PROLI/NO and 249 nm for MAHMA/NO. 
After establishing the proper reactor function, I began testing reaction conditions to form the 
diazeniumdiolates 15 and 16 with the model compound 2 and the non-fluorescent compound 3. 
Diazeniumdiolates are usually formed by reacting amines with NO, but I will be adding NO at  
the amide position to form the diazeniumdiolate group on my compounds. I tried conditions 
based on a report from Holland where they successfully formed a diazeniumdiolate on 
nicotinamide.39 They used a mixture of methanol and ether as solvents, NaOMe in methanol as 
the base, and pressurized NO to 50 psi, allowing the reaction to run for 72 hours (Figure 2.18). I 
tried these reaction conditions, shown in Table 2.2, entries 1 and 8. Unfortunately, these 
reactions seemed to form the nitrosamine product (Figure 2.18) based on the UV-vis analysis 
(Figure 2.19). Nitrosamines typically have UV-vis peaks around 230 nm and 340 nm,40 which 
can be observed in the UV-vis spectra of the products of these conditions in Figure 2.19. The 
product of the model compound reaction had UV-vis peaks at 239 and 351 nm, and the product 
MAHMA/NO PROLI/NO 
Fig. 2.17 Structures of common diazeniumdiolates PROLI/NO and MAHMA/NO synthesized to 
test function of NO reactor set-up 
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of the non-fluorescent compound reaction had peaks at 231 and 342 nm, which are indicative of 
nitrosamines. I tried changing reaction variables such as solvent ratio (Table 2.2, entries 2-3, 9-
10), which could improve solubility of the starting materials. I tried changing NO pressure 
(Table 2.2, entries 3, 10), as higher NO pressures can promote diazeniumdiolate formation, but 
the desired product still was not formed. Changing reaction time (Table 2.2, entries 3, 5, 7, 12) 
also did not change product formation. One hypothesis was that the diazeniumdiolate was 
Table 2.2 Reaction conditions attempted to functionalize model and non-fluorescent 






Solvent ratio Time (h) 
1 Model 21 50 MeOH:ether (3:2) 72 
2 Model 21 50 MeOH:ether (2:3) 72 
3 Model 21 80 MeOH:ether (1:9) 72 
4 Model -20 80 MeOH:ether (1:9) 48 
5 Model 21 80 MeOH:ether (1:9) 24 
6 Model -15 80 MeOH:ether (1:9) 24 
7 Model -15 80 MeOH:ether (1:9) 5.5 
8 Non-fluorescent 21 50 MeOH:ether (3:2) 72 
9 Non-fluorescent 21 50 MeOH:ether (1:4) 72 
10 Non-fluorescent 21 80 MeOH:ether (1:9) 72 
11 Non-fluorescent -20 80 MeOH:ether (1:9) 48 
12 Non-fluorescent 21 80 MeOH:ether (1:9) 24 
Fig. 2.18 Attempted diazeniumdiolate reactions and conditions and potential nitrosamine 
products on right a) model compound reaction b) non-fluorescent compound reaction 
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 unstable at room temperature and was decomposing to the nitrosamine before the reaction could 
be analyzed, so I ran the reactions at lower temperatures (Table 2.2, entries 4, 6-7, 11). However, 
these reactions also showed formation of the nitrosamine. Based on this unsuccessful reaction 
optimization and the fact that diazeniumdiolates do not typically form on amides, this strategy 
was abandoned in favor of a more successful approach. 
2.5 Conclusion  
The goal of this project was to synthesize a small molecule antibiotic prodrug that could 
detect and kill bacteria. To accomplish this, I envisioned a compound with a fluorescent sensor, a 
NO donor group, and an amino acid that would be cleaved by a bacterial protease to release NO. 
My approach was to synthesize 2-aminoacridone-tagged L-alanine, which would fluoresce 
yellow after the protease L-alanyl aminopeptidase in bacteria cleaved L-alanine from my 
compound, releasing NO from a diazeniumdiolate group. I successfully synthesized a fluorescent 
Fig. 2.19 UV-vis spectra of products of reactions to attempt to form diazeniumdiolate on model 
and non-fluorescent compounds showing potential nitrosamine formation. 
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sensor with a fluorescent molecule and an amino acid attachment that fluoresces in the presence 
of P. aeruginosa, based on our bacterial studies.  
In addition to the fluorescent sensor, I synthesized a model compound similar to the 
fluorescent sensor to use to perfect the conditions of the NO addition reaction. I also synthesized 
a non-fluorescent version of the sensor that would be able to detect bacteria by sensing NO 
release. I tried many variations on a basic Boc deprotection reaction, investigating different 
bases, additives, solvents, and temperatures, but found limited success, likely due to the 
difficulty of removing a Boc group under basic conditions. Future experiments could investigate 
further basic deprotection conditions, but my project moved in a different direction, making the 
need for basic deprotection conditions unnecessary.  
I also analyzed samples of my compounds that the Schoenfisch group at UNC Chapel 
Hill reacted with NO. Using UV-Vis spectroscopy, I found that the diazeniumdiolate group 
likely was successfully formed on the non-fluorescent compound. Unfortunately, despite several 
attempts and varied conditions, such as solvent, temperature, and NO pressure, I was unable to 
functionalize the model compound or non-fluorescent compound with a diazeniumdiolate group 
using my NO reactor set-up. This challenge is likely due to the rarity of forming 
diazeniumdiolates on amides rather than secondary amines. There is only one literature report of 
forming a diazeniumdiolate on an amide, in which Holland and coworkers formed a 
diazeniumdiolate on nicotinamide, highlighting the difficulty of this reaction. Basing my 
approach on functionalizing an amide with a diazeniumdiolate turned out to be infeasible.  
In answer to the research question posed at the beginning of this chapter, can a dual 
function small molecule be synthesized with a fluorescent tag that changes color in the presence 
of bacteria and leads to NO release to kill bacteria? At this point in the research project, I have 
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not achieved this goal. I ran into challenges in completing the third step in the goals laid out in 
the beginning of this chapter, functionalizing the fluorescently tagged amino acid with a 
diazeniumdiolate group. This chapter details several failures encountered while attempting to 
reach this goal, indicating that this is not a feasible approach. Despite these setbacks, based on 
this work, I was able to develop a new, more feasible approach to continue this project, which 
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To continue to progress toward the goal of addressing the problem of antibiotic resistance 
by synthesizing a small molecule to detect and kill bacteria, I searched for a new approach. The 
challenges with forming the diazeniumdiolate on the L-alanylaminopeptidase indicator discussed 
in chapter 2 lead me to decide to redesign the structure. The difficulties arose with forming a 
diazeniumdiolate on an amide functionality, which has only one report of being successful.1 
However, I wanted to keep the color-changing bacterial indicator function. To keep similar 
functionality with an aminopeptidase enzyme, I considered all of the other amino acids and 
chose proline, which has a secondary amine functionality that could be functionalized with a 
diazeniumdiolate group. This approach has precedence for being feasible, as proline is a starting 
material to make a common diazeniumdiolate, PROLI/NO. In addition, if PROLI/NO 
decomposes to form a nitrosamine, which are typically carcinogenic compounds, N-
nitrosoproline has been shown to be non-carcinogenic.2,3 Certain bacterial species also contain 
prolylaminopeptidases, which cleave proline from peptide bonds, so the compound could still act 
as a fluorescent enzyme-activated bacterial indicator. Based on these reasons, I decided to add 
proline to the aminoacridone fluorescent compound instead of alanine, then functionalize the 
secondary amine of proline with a diazeniumdiolate, a more viable pathway.  
I would like to thank Jesus B. Tapia for performing MS experiments for this project. I 
would also like to thank Dr. Joe Saavedra (National Institutes of Health) for helpful discussions 
and advice and Dr. Brad Borlee (Colorado State University) for providing the bacteria strain, 
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Pseudomonas aeruginosa PAO1. This work was supported by a grant from the Monfort 
Foundation. This project was originally published in Journal of Materials Chemistry B (Hibbard, 
H. A. J., Reynolds, M. M. Fluorescent nitric oxide donor for the detection and killing of 
Pseudomonas aeruginosa. J. Mater. Chem. B. 2019, 7, 2009-2018). 
3.2 Introduction 
The Review on Antimicrobial Resistance predicts that by 2050, one person will die every 
three seconds from a bacterial infection,4 surpassing both heart disease and cancer as the most 
common cause of death.5 This epidemic of antibiotic-resistant bacteria creates a critical need for 
researchers to develop better methods for detection and treatment of bacterial infections. A 
multifunctional material that could both detect and eradicate bacterial infections would be ideal. 
Multifunctional materials are a promising new area of research, offering improved 
efficiency and versatility, while reducing costs. Unfortunately, few examples exist of materials 
that can both detect and kill bacteria, and these examples are exclusively larger molecules, 
including polymers and nanoparticles.6–8 Small molecules, on the other hand, tend to release 
active drug compounds much faster.9 Additionally, the small molecule could be incorporated 
into a polymer support to make biomedical devices. 
In this work, a dual-function small molecule is specifically designed, synthesized, and 
tested to detect the presence of and kill bacteria, shown in Figure 3.1. Briefly, a derivative of a 
Fig. 3.1 Schematic showing nitric oxide release and color change of sensor. Nitric oxide is 
released from the diazeniumdiolate functional group spontaneously, killing Pseudomonas 
aeruginosa bacteria cells. A bacterial enzyme then cleaves proline from the fluorescent 
aminoacridone/proline compound, changing the fluorescent color from blue to yellow. 
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well-studied class of fluorescent molecules, aminoacridones, is attached to the amino acid 
proline to form an indicator for the bacterial enzyme prolyl aminopeptidase, which is known to 
cleave N-terminal proline from peptides.10 Next, a nitric oxide (NO) donor, a diazeniumdiolate 
similar to PROLI/NO, shown in Figure 3.2, is added to impart antibacterial activity.  
The fluorescent compound 2-aminoacridone is a commercially available, well-
characterized fluorescent reporter.11 It is commonly used to derivatize oligosaccharides for 
fluorescent analysis.12 Previous reports have also shown that attaching amino acids to derivatives 
of 2-aminoacridones allows for enzymatic detection of bacteria.13 For these reasons, a 2-
aminoacridone derivative is chosen as the fluorescent reporter to detect bacteria in this work. 
By attaching an amino acid to the fluorescent aminoacridone compound, the wavelength 
the emitted light changes, and a color change can be relied upon for bacterial detection. In this 
work, proline is attached to an aminoacridone, offering several advantages. Proline is cleaved by 
prolyl aminopeptidase, an enzyme found in Pseudomonas aeruginosa, a deadly bacteria species 
that is growing increasingly resistant to antibiotics and causes a significant amount of hospital-
acquired infections.10,14 In addition, a known NO donor, PROLI/NO (Figure 3.2), is formed from 
the secondary amine on proline, conveying antibacterial activity. There are a few recent reports 
of NO donors with fluorescent reporters, however, fluorescent changes in these compounds 
allow quantification of the amount of NO released, not detection of an external stimulus.15–18 
The compound in this work uses fluorescence to detect bacteria and NO release to kill bacteria. 
 
Fig. 3.2 Structure of proline-based diazeniumdiolate, PROLI/NO, a previously synthesized 
diazeniumdiolate formed by reacting nitric oxide with proline 
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Nitric oxide (NO) is an excellent small molecule candidate for incorporation into a new 
antibiotic. It plays many roles in the body, in addition to its broad-spectrum antimicrobial 
activity, killing both gram-positive and gram-negative strains of bacteria.19–22 Researchers have 
shown that NO uses multiple mechanisms of action to kill bacteria, meaning that bacterial 
resistance is much more difficult to develop, which is critical in stemming the spread of 
antibiotic-resistant bacterial infections.23,24 Studies by the Schoenfisch group show that bacteria 
are unable to develop resistance to exogenously applied NO, even after 20 days.23  
Nitric oxide is a potent antibacterial agent, but due to its high reactivity and gaseous nature, 
NO is difficult to deliver and dose as a stable drug compound.25 As a result, NO is almost always 
delivered as a prodrug, in the form of an NO donor that is metabolized into free radical NO via a 
chemical or enzymatic transformation. Some common NO donors include S-nitrosothiols, 
organic nitrites and nitrates, metal nitrosyls, and diazeniumdiolates.26–30 Diazeniumdiolates have 
the advantage of being very stable as solids and in basic media, releasing two equivalents of NO 
per equivalent of diazeniumdiolate, and having predictable half-lives for spontaneous NO 
release.31 One disadvantage of diazeniumdiolates is that they are known to decompose into 
nitrosamines, which are typically carcinogenic.32 However, the nitrosamine formed from proline, 
N-nitrosoproline, is one of the few non-carcinogenic nitrosamines.2,3 This could mean that if the 
nitrosamine forms from our synthesized proline aminoacridone compound, it would also be non-
carcinogenic, although future studies would be necessary to confirm its non-toxicity. Because of 
these advantages, a derivative of the diazeniumdiolate PROLI/NO (Figure 3.2) is chosen as the 
NO donor in this work. 
This report details the design and synthesis of a compound for its application as a dual-
function bacterial indicator and antibacterial agent. The research question posed in this chapter 
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is: can a dual function small molecule be synthesized with a fluorescent tag that changes color in 
the presence of bacteria and leads to NO release to kill bacteria? The proposed process is shown 
in Figure 3.1, where the proline-based diazeniumdiolate releases NO spontaneously to kill 
bacteria. The bacterial enzyme prolyl aminopeptidase found in P. aeruginosa then cleaves 
proline from the fluorescent aminoacridone compound, causing a fluorescent color change from 
blue to yellow that indicates the presence of bacteria. P. aeruginosa commonly causes infections 
in burn wounds33 and our compound could be useful in this case, releasing NO as site-specific 
broad-spectrum antibacterial agent to kill bacteria in the wound, and determining if the infection 
is caused by P. aeruginosa. To our knowledge, this is the first example of a multifunctional 
small molecule that can both detect and kill P. aeruginosa. 
3.3 Experimental Methods 
3.3.1 Materials and Methods. Acridone (98%) was purchased from Oxchem Corp (Wood Dale, 
IL, USA). Nitric acid (68-70%), iodomethane (98%), PBS tablets, and triethylamine (99.5%) 
were purchased from EMD Chemicals (Gibbstown, NJ, USA). Acetic acid (glacial) was 
purchased from BDH Chemicals (Radnor, PA, USA). Sodium hydride (57-63% oil dispersion), 
tin(II) chloride dihydrate, isobutyl chloroformate (98%), and anhydrous methanol (99.9%) were 
purchased from Alfa Aesar (Ward Hill, MA, USA). N,N-dimethylformamide (99.9%), 
hydrochloric acid (1 N), sodium hydroxide (98.8%), tetrahydrofuran, Oxoid nutrient broth 
(OXCM0001B), and Oxoid nutrient agar (OXCM0003B) were purchased from Fisher Scientific 
(Hampton, NH, USA). Boc anhydride (99.5%) was purchased from Chem Impex (Bensenville, 
IL, USA). Dichloromethane (99.5%) and trifluoroacetic acid (99%) were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Nitric oxide (99%) was purchased from Matheson Tri-gas 
(Montgomeryville, PA). Sodium methoxide (30% in methanol) was purchased from Acros 
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Organics (Geel, Belgium). CellTiter Blue was purchased from Promega (Madison, WI, USA). 
24-well and 96-well tissue culture nontreated plates were obtained from Corning (Corning, NY, 
USA). Argon (ultrahigh purity), nitrogen (ultrahigh purity), and oxygen were purchased from 
Airgas (Denver, CO, USA). Deionized water (18.2 MΩ·cm) was obtained from a Millipore 
Direct-Q water purification system (EMD Millipore, Billerica, MA, USA). Pseudomonas 
aeruginosa (PAO1) was provided by Dr. Brad Borlee at Colorado State University. 
Commercially available reagents were purchased and used without further purification unless 
otherwise indicated.  
All nuclear magnetic resonance (NMR) spectra were obtained on Varian Inova 400 (400 
MHz for 1H; 101 MHz for 13C) and/or Bruker US400 (400 MHz for 1H; 101 MHz for 13C) at 
room temperature unless noted otherwise. Chemicals shifts were reported in parts per million (δ 
scale), and referenced according the following standards: chloroform residual signal (δ 7.16), 
water residual signal (δ 4.79), or dimethyl sulfoxide residual signal (δ 2.50) for 1H signals; 
deuterated chloroform or deuterium dimethyl sulfoxide carbon resonances (middle peak is δ 
77.1, or δ 39.5, respectively) or tetramethylsilane for samples in deuterated water for 13C signals. 
Coupling constants were reported in Hertz (Hz) and multiplicities were reported as follows: 
singlet (s), doublet (d), doublet of doublets (dd), triplet (t), quartet (q), and multiplet (m). IR 
spectra were obtained on a Thermo Scientific Nicolet 6700 FT-IR spectrometer. Electrospray 
ionization mass spectrometry data were obtained on an Agilent 6224 TOF mass spectrometer 
equipped with a dual electrospray ion source operated in positive and negative mode. Excitation 
and emission spectra were obtained on a Horiba Jobin-Yvon FluoroLog-3 Spectrofluorometer. 
Melting points were obtained with an Electrothermal Mel-Temp apparatus. UV-Vis 
measurements were obtained with a Thermo Scientific Nicolet Evolution 300 spectrometer. Well 
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plate absorbance measurements were obtained with a Biotek Synergy 2 Multi-Mode Reader. 
Reactions were analyzed by thin layer chromatography (TLC) on aluminum sheets that were pre-
coated with silica gel 60 F254, and the reactions were purified by column chromatography using 
Alfa Aesar silica gel 60 (0.06-0.2 mm).  
3.3.2 Abbreviations. HNO3=nitric acid, AcOH= acetic acid, NaH= sodium hydride, DMF= 
N,N-dimethylformamide, MeI= methyl iodide, SnCl2∙2H2O= tin (II) chloride dihydrate, 
HCl= hydrochloric acid, iBuCF= isobutyl chloroformate, Et3N= triethylamine, TFA= 
trifluoroacetic acid, DCM= dichloromethane, Boc= tert-Butyloxycarbonyl), TFA= 
trifluoroacetic acid, DCM= dichloromethane, NO= nitric oxide, NaOMe= sodium 
methoxide, MeOH= methanol 
3.3.3 Synthetic Procedures and Characterization 
Compounds 2-5 were synthesized according to previously reported procedures; see Chapter 2, 
Section 2 for details. 
 
3.3.3.1 N-(10-methyl-9-oxo-9,10-dihydroacridin-2-yl)pyrrolidine-2-carboxamide (6, 
Pro/Fluoro). To a solution of 5 (430.5 mg, 2 mmol) in distilled DCM dried over 3 Å molecular 
sieves (20 mL, 0.1 M) at 0 °C, isobutyl chloroformate (285 µL, 2.2 mmol) and triethylamine 
(307 µL, 2.2 mmol) were added. After stirring for 30 min at 0 °C, 4 (493.4 mg, 2.2 mmol) was 
added and the reaction was warmed to rt and stirred for 18 h. The reaction was washed 
sequentially with aq. HCl (1 M, 20 mL), sat. aq. NaHCO3 (20 mL) and brine (20 mL). The 
organic layer was dried over Na2SO4 and concentrated in vacuo to afford an oily orange crude 
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solid. The crude product was dissolved in DCM (6.7 mL, 0.3 M) and trifluoroacetic acid (3.1 
mL, 40 mmol) was added. The reaction was stirred at rt for 3 h, and the solvent was then 
removed in vacuo. The concentrate was dissolved in 15 mL of DCM, then washed with sat. aq. 
NaHCO3 (10 mL) and extracted with DCM (3 × 10 mL). The organic layer was dried over 
Na2SO4 and concentrated in vacuo to afford an orange oily solid. The crude product was purified 
by flash column chromatography (SiO2, 100% EtOAc, 5% MeOH/DCM, 10% MeOH/DCM 
gradient), affording the title compound as an orange solid (188 mg, 29%). 1H NMR (400 MHz, 
CDCl3) δ 10.02 (s, 1H, H15), 8.64 (dd, J = 9.3, 2.7 Hz, 1H, H6), 8.56 (dd, J = 8.0, 1.5 Hz, 1H, 
H14), 8.20 (d, J = 2.6 Hz, 1H, H2), 7.73 (t, J = 8.7 Hz, 1H, H1), 7.54 (dd, J = 8.9, 6.8 Hz, 2H, 
H3, H11), 7.29 (t, J = 7.5 Hz, 1H, H12), 3.92 (s, 3H, H19), 3.91 – 3.81 (m, 1H, H20), 3.08 (dq, J 
= 16.4, 6.5 Hz, 2H, H22), 2.23 (m, 1H, H24), 2.08 (m, 1H, H24), 1.84 – 1.73 (m, 2H, H23).34 13C 
NMR (101 MHz, CDCl3) δ 177.68 (C10), 173.60 (C16), 142.34 (C4), 139.11 (C13), 133.76 
(C8), 132.35 (C2), 127.72 (C6), 126.30 (C9), 122.47 (C5), 121.88 (C1), 121.06 (C12), 116.31 
(C11), 115.66 (C14), 114.70 (C3), 60.95 (C20), 47.35 (C22), 33.68 (C19), 30.80 (C24), 26.29 
(C23). HRMS (+ESI) Found 322.1556 (Calcd. 322.1556 for C19H20N3O2; [M+H]+). m.p. 54-56 
oC. νmax/cm-1 3676br, 3255br, 2989w, 2972w, 2901w, 1675w, 1589s, 1504s, 1423s, 1275s, 
1179s, 1066s, 879w, 806s, 749s, 684s. λEX = 419 nm, λEM = 499 nm (EtOH).
 
3.3.3.2 2-((10-methyl-9-oxo-9,10-dihydroacridin-2-yl)carbamoyl)pyrrolidin-1-ium (7, 
Pro/Fluoro/H+). Crude 6 (200 mg, 0.47 mmol, post work-up, prior to column chromatography) 
was dissolved in DCM (2 mL, 0.235 M) and trifluoroacetic acid (1 mL, 13.1 mmol) was added to 
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the reaction. The reaction stirred at rt for 2 h, and the solvent was then removed in vacuo. The 
product was precipitated out in diethyl ether and filtered, affording the title compound as a 
yellow powder (145 mg, 96%). 1H NMR (400 MHz, d6-DMSO) δ 10.76 (s, 1H, H15), 9.33 (s, 
1H, H21), 8.73 (s, 1H, H21), 8.63 (d, J = 2.6 Hz, 1H, H6), 8.34 (d, J = 8.3 Hz, 1H, H14), 8.04 
(dd, J = 9.3, 2.6 Hz, 1H, H2), 7.96 – 7.77 (m, 3H, H1, H3, H11), 7.34 (t, J = 7.8 Hz, 1H, H12), 
4.37 (d, J = 7.9 Hz, 1H, H20), 3.96 (s, 3H, H19), 3.31 (m, 2H, H22), 2.40 (m, 1H, H24), 2.02 – 
1.93 (m, 2H, H23).13C NMR (101 MHz, d6-DMSO) δ 176.62 (C10), 167.22 (C16), 142.50 (C4), 
139.48 (C13), 134.43 (C8), 132.41 (C2), 126.92 (C6), 126.78 (C9), 122.08 (C5), 121.56 (C1), 
117.56 (C12), 116.53 (C11), 116.41 (C14), 116.39 (C5), 60.20 (C20), 46.28 (C22), 34.12 (C19), 
29.99 (C24), 24.05 (C23).  HRMS (+ESI) Found 322.1563 (Calcd. 322.1556 for C19H20N3O2; 
[M]+). m.p. 210.5-211.5 oC. νmax/cm-1 3084br, 1665s, 1637w, 1617w, 1586s, 1550w, 1507s, 
1466w, 1430w, 1351w, 1292w, 1280w, 1200s, 1181s, 1128s, 1051w, 1039w, 1002w. λEX = 421 
nm, λEM = 489 nm (H2O). 
 
3.3.3.3 Sodium 1-( N-(10-methyl-9-oxo-9,10-dihydroacridin-2-yl)pyrrolidine-2-
carboxamide)diazen-1-ium-1,2-diolate (8, Pro/Fluoro/NO). A solution of 7 (100 mg, 0.31 mmol) 
in anhydrous MeOH (3.1 mL, 0.1 M) was mixed with 30% sodium methoxide in methanol (133 
µL, 0.62 mmol) that had previously been dried over activated 3 Å molecular sieves for at least 24 
h. The resulting solution was flushed with argon, then charged with 5 atm of NO and stirred at rt. 
A thick yellow precipitate began to form within 3 h of exposure to NO. After 24 h, the pressure 
was released, and the product was collected by filtration, washed with ether, and dried under 
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vacuum to give the title compound as a yellow powder (110 mg, 88%). 1H NMR (400 MHz, 0.5 
mM NaOD in D2O) δ 7.64 (d, J = 7.7 Hz, 1H, H6), 7.57 (d, J = 2.3 Hz, 1H, H14), 7.32 (dd, J = 
9.2, 2.4 Hz, 1H, H2), 7.28 – 7.13 (m, 2H, H1, H3), 6.98 (d, J = 8.9 Hz, 1H, H11), 6.78 (t, J = 7.5 
Hz, 1H, H12), 3.71 (t, J = 7.2 Hz, 2H, H22), 3.22 (s, 3H, H19), 3.21 – 3.09 (m, 2H, H24), 2.81 – 
2.66 (m, 1H, H20), 2.07 (m, 1H, H23), 1.93 (m, 1H, H23). 13C NMR (101 MHz, 0.5 mM NaOD 
in D2O) δ 177.60 (C10), 165.99 (C16), 143.53 (C4), 140.28 (C13), 137.49 (C8), 133.44 (C2), 
132.13 (C6), 125.00 (C9), 120.78 (C5), 120.55 (C1), 119.07 (C12) , 117.63 (C11), 115.89 (C14), 
114.67 (C3), 93.98 (C20), 47.46 (C22), 34.36 (C24), 32.84(C19), 18.89 (C23). HRMS (+ESI) 
Found 381.1427 (Calcd. 381.1437 for C19H19N5O4; [M+H]+). m.p. 174 oC decomp. νmax/cm-1 
3678br, 2989s, 2901w, 1668s, 1581s, 1506s, 1466s, 1406s, 1279w, 1250w, 1241w, 1177s, 
1125s, 1066s. λEX = 397 nm, λEM = 462 nm (0.01 M NaOH).  
3.3.4 Nitric Oxide Release Measurements. Nitric oxide generation was recorded in real time 
using a chemiluminescence-based GE Nitric Oxide Analyzer (NOA). Before each use, the NOA 
was calibrated using a 39.6 ppm NO calibration gas cylinder. Pro/Fluoro/NO 8 powder was 
added into the NOA sample cell in the dark at rt. The powder was purged continuously with 
ultrapure nitrogen gas for 5-10 min to collect a baseline release. An aliquot of deoxygenated 
nutrient broth (2.6 g in 200 mL of Millipore water, pH 7.4) was added through the side injection 
port of the NOA vessel to give the specified initial concentration. The lights were turned on and 
the vessel was placed in a 37 °C water bath. The nutrient broth solution was purged continuously 
with ultrapure nitrogen gas for the duration of the experiment. NO release was recorded in 1 s 
intervals as parts per billion with a gas sampling rate of 200 mL/min. The solution was 
maintained in a nitrogen atmosphere with bubbling rate of 48-54 mL/min N2 directly into the 
solution and flow gas introduced into the remaining headspace. 
78 
 
3.3.5 Bacteria Studies 
3.3.5.1 Pseudomonas aeruginosa Bacteria Culture. Initial stock culture of Pseudomonas 
aeruginosa (PAO1) was made by streaking with a sterile inoculating loop onto agar plates and 
incubating overnight at 37 °C. A colony was inoculated in sterilized nutrient broth media (NBM, 
13 g nutrient broth/1 L Millipore water) and grown overnight at 37 °C until an optical density at 
600 nm (OD600nm) ≈0.7 was reached. This bacterial solution was combined with glycerol (30% 
v/v) in a 1:1 fashion to obtain a final glycerol concentration of 15% (v/v). These solutions were 
stored at −80 °C until use. Prior to each bacterial experiment, a frozen culture was thawed at rt 
and then centrifuged at 4700 rpm for 10 min. The supernatant was discarded, and the pellet was 
resuspended using 5 mL NBM. This was transferred to an additional NBM (15 mL) and allowed 
to grow overnight with shaking at 120 rpm until the OD600nm ≈1.0. The culture was diluted to an 
OD600nm ≈0.35 using warmed NBM prior to beginning experiments. 
3.3.5.2 Bacterial Detection Study. Pro/Fluoro/H+ 7 (5 mg) was dissolved in dimethyl sulfoxide 
(DSMO, 200 μL) and added to sterilized nutrient agar [powder base (2.8 g) in Millipore water 
(100 mL)] at 50 °C to a final concentration of 50 mg/L. The mixture was divided among five 
sterile Petri dishes and allowed to set overnight before inoculating each plate with 20 µL of a 
Pseudomonas aeruginosa suspension (OD600=0.033-0.038) using a sterile plastic spreader. The 
positive control was made using the same procedure by mixing DMSO (200 μL) with sterile 
nutrient agar [powder base (2.8 g) in Millipore water (100 mL)] before inoculation. The plates 
were incubated at 37 °C for 24 h before analysis. The plates were illuminated by an Aldrich 
Spectroline F-series hand-held UV lamp at a wavelength of 365 nm. 
3.3.5.3 Cell Viability Assay Solutions. Solutions of Pro/Fluoro/NO (0.1 mM, 40 mg/L; 1 mM, 
400 mg/L; and 10 mM, 4,000 mg/L) were made in Pseudomonas aeruginosa culture solution in 
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NBM. To a 24 well plate was added the Pro/Fluoro/NO solutions (1 mL; 0.1 mM, 1 mM, or 10 
mM) in triplicate.  The positive control, Pseudomonas aeruginosa culture only, and the negative 
control, Pro/Fluoro/NO in sterile nutrient broth, were plated in the same manner. The plates were 
incubated at 37 °C for 24 h before analysis. The plates were illuminated by an Aldrich 
Spectroline F-series hand-held UV lamp at a wavelength of 365 nm. A standard Cell Titer Blue 
cell viability assay was performed to determine antibacterial efficacy of Pro/Fluoro/NO. Three 
aliquots (100 µL) of each solution in the 24 well plate were transferred to a 96 well plate. To 
each well containing solution, 20 µL of Cell Titer Blue stock solution (1:5 Cell Titer Blue 
reagent:nutrient broth), warmed to 37 °C, was added. The plate was incubated at 37 °C for 2 h, 
then the absorbance was measured at 570 and 600 nm using a plate reader. 
3.3.5.4 Statistical Analysis. All biological assays were performed using at least three samples and 
assayed in replicate form. Viability assays are reported as the mean and 95% confidence interval. 
All data were evaluated for potential outliers using the Grubbs Test. The statistical differences in 
data were evaluated using the Student’s t test (p < 0.05) at the 95% confidence level. 
3.4 Development of Synthetic Route to Pro/Fluoro/NO 
The steps I developed to synthesize the enzyme-activated bacterial indicator Pro/Fluoro 
(6) are shown in Figure 3.3. I used the steps developed and discussed in depth in Chapter 2, 
Section 2.3 to make the fluorescent aminoacridone, then attached proline instead of alanine to 
form the indicator Pro/Fluoro. In the first step of the synthesis, I nitrated acridone (1) with nitric 
acid in the presence of acetic acid to form 2, 2-nitroacridone. This procedure gives a yield of 
64% of a mixture of the 2-nitro and 4-nitro isomers, which are separated in a later step. In next 
step of the synthesis, I methylated 2 to form 3 in Figure 3.3. I modified a previously reported 




yield.35 I reduced the nitro group, 3 to 4 in Figure 3.3, using tin(II) chloride dihydrate and 
hydrochloric acid, following a previously published procedure.36 The crude product showed 
evidence of the undesirable 4-isomer as well as the desired 2-isomer. Fortunately, I developed 
column chromatography conditions on silica gel to separate the isomers, giving an isolated yield 
of 4 of 60%. When dissolved in ethanol, I observe that compound 4 appears yellow under a UV 
light (365 nm). 
In the next step to make the indicator, I coupled Boc-protected proline (5) to the 
aminoacridone, 4, using isobutyl chloroformate and triethylamine. After an aqueous work-up, I 
removed the Boc protecting group using trifluoroacetic acid to give compound 6, Pro/Fluoro. I 
purified the deprotected product by column chromatography, giving a 29% yield. We used mass 
spectrometry and 1H- and 13C-NMR spectra to confirm the synthesis of Pro/Fluoro 6 (Figures 
3.17-3.18). I observe that Pro/Fluoro 6 appears blue under a UV light (365 nm) when dissolved 
in ethanol. The synthetic route to Pro/Fluoro 6 I developed gives an overall yield of 8% over five 
steps. This is the first synthesis of an indicator designed to detect prolyl aminopeptidase in 
bacteria. 
Fig. 3.3 Overall reaction scheme developed for the synthesis of fluorescent indicator Pro/Fluoro 




3.5 Pro/Fluoro/NO as a Bacterial Indicator 
With the synthesis of Pro/Fluoro 6 complete, I wanted to test the bacterial detection 
ability of Pro/Fluoro 6 as a proof of concept, to ensure that a color change would be possible 
once NO is released (Figure 3.1). I selected P. aeruginosa for the bacterial studies because it 
produces a prolyl aminopeptidase enzyme, which I hypothesized would cleave N-terminal 
proline from Pro/Fluoro 6, causing a color change.37 P. aeruginosa is also a deadly gram-
negative bacteria strain, resistant to many common antibiotics and is the cause of death in many 
immunocompromised hospital patients.14  
I attempted bacterial detection experiments with Pro/Fluoro 6, but it is not soluble enough 
in aqueous-based agar and precipitated out before the agar set, preventing sensing. To overcome 
this problem, Pro/Fluoro 6 was protonated using trifluoroacetic acid to form 7 (Pro/Fluoro/H+), 
shown in Figure 3.4. Protonation solubilized Pro/Fluoro/H+ 7 in the agar, forming a homogenous 
solution.  
 
To perform the bacterial sensing experiments, I dissolved Pro/Fluoro/H+ 7 in dimethyl 
sulfoxide (DMSO) and mix it with cooled sterilized nutrient agar. I inoculated the agar plates 
with P. aeruginosa and incubated them at 37°C for 18 hours. The positive control plates consist 
of agar mixed with DMSO but without Pro/Fluoro/H+ 7, which I inoculated with P. aeruginosa. 
For the negative control plates, I mixed agar with Pro/Fluoro/H+ 7 in DMSO but did not 
inoculate the plates with P. aeruginosa. After incubation, I illuminated the plates with a 365 nm 
Fig. 3.4 Synthesis of fluorescent indicator Pro/Fluoro/H+ 7, used for Pseudomonas aeruginosa 




UV light to determine if a color change occurred. Yellow fluorescence indicates that enzymatic 
cleavage occurred, releasing proline and compound 4 to fluoresce yellow (Figure 3.1). Blue 
fluorescence indicates that no enzymatic cleavage occurred; it is the color of fluorescence of 
intact Pro/Fluoro/H+ 7. Each experiment had five samples and was repeated three times.  
The results of these experiments can be seen in Figure 3.5, showing that there is a clear 
color change due to the presence of P. aeruginosa. The positive control shows no fluorescence 
under UV light (Figure 3.6), indicating that fluorescence is due entirely to the synthesized 
Pro/Fluoro/H+ 7 compound. The negative control, left in Figure 3.5, clearly fluoresces blue, 
indicating that no cleavage of Pro/Fluoro/H+ 7 occurs when P. aeruginosa is not present. The 
experimental plate, right in Figure 3.5, fluoresces yellow under UV light, indicating that proline 
is cleaved from Pro/Fluoro/H+ 7 by P. aeruginosa, leaving compound 4 to fluoresce yellow.  
Based on the above experimental observations, I conclude that Pro/Fluoro/H+ 7 can be 
used as an indicator to detect if P. aeruginosa is present using UV light. I observe a clear and 
obvious color change from blue to yellow indicating the presence of P. aeruginosa. My 
Fig. 3.5 Representative agar plates showing color change from blue to yellow under a 365 nm UV 
lamp in the presence of Pseudomonas aeruginosa, as expected. Left: negative control- not 
inoculated with Pseudomonas aeruginosa, Pro/Fluoro/H+ 7, appears blue; right- inoculated with 
Pseudomonas aeruginosa, Pro/Fluoro/H+ 7, appears yellow 
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hypothesis is that the enzyme prolyl aminopeptidase, produced by P. aeruginosa,10 cleaves 
proline, causing the color change. If my hypothesis is correct, this is the first example of a prolyl 
aminopeptidase-specific indicator. Based on my hypothesis, any bacteria species containing this 
enzyme would be detectable via this sensing mechanism, such as Clostridium difficile, which can 
cause life-threatening gastrointestinal infections.38 
3.6 Synthesis and Characterization of Properties of Pro/Fluoro/NO 
3.6.1 Synthesis of Pro/Fluoro/NO 
Once I demonstrated the functionality of the bacterial indicator, the last step in the 
synthesis is to attach a diazeniumdiolate group to Pro/Fluoro 6. Adding the diazeniumdiolate 
group to the compound imparts the ability to release NO, giving it antibacterial activity and 
creating a dual-function material. Diazeniumdiolates are typically formed by reacting secondary 
amines with gaseous NO at elevated pressures,32 which in my case is at the proline amine 
Fig. 3.6 A-C are photos of repeated experiments for bacterial detection, colonies of 
Pseudomonas aeruginosa after incubation in the presence of Pro/Fluoro/H+ 7 illuminated 
under a 365 nm UV light. The positive control (left column of plates in images A-C) is 
inoculated with P. aeruginosa with no Pro/Fluoro/H+ 7 present and shows no fluorescence or 
color. The negative control (middle column of plates) is not inoculated with P. aeruginosa 
but contains Pro/Fluoro/H+ 7 and shows a blue color, indicating that Pro/Fluoro/H+ 7 is not 
cleaved. The experiment plates are in the right column and are inoculated with P. aeruginosa 
and contain Pro/Fluoro/H+ 7, and show a yellow color, indicating that Pro/Fluoro/H+ 7 is 
cleaved apart and changes color. 
A B C 
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location, seen in Figure 3.7. The diazeniumdiolate reaction is based on the previously reported 
procedure to synthesize the proline-based diazeniumdiolate, PROLI/NO (Figure 3.2).39 As can 
be seen in Figure 3.7, I reacted Pro/Fluoro 6 with NO at high pressure, 5 atm, in the presence of 
sodium methoxide in methanol. I discovered that it is important to use anhydrous methanol and 
to dry the methanolic sodium methoxide over activated 3 Å molecular sieves before running the 
reaction, as water decomposes diazeniumdiolates.32 During the reaction, I observed the 
formation of a yellow precipitate product 8, Pro/Fluoro/NO, and upon filtration and drying, a 
yield of 88% is achieved. Diazeniumdiolates are typically white powders, but in my case, the 
yellow color of the product is due to the fluorescent acridone compound, and is not indicative of 
diazeniumdiolate decomposition.31   
 
 
The formation of diazeniumdiolates is typically confirmed by UV-Vis spectroscopy due 
to their distinctive peak at 250 nm.31 However, an absorbance peak due to the fluorescent 
acridone component occurs at 260 nm (Figure 3.8), interfering with the diazeniumdiolate 
absorbance peak. To confirm the formation of the diazeniumdiolate Pro/Fluoro/NO 8, we used 
several techniques. I observe the formation of a precipitate in the course of the reaction shown in 
Figure 3.7, which is typical of diazeniumdiolate-forming reactions.39 The physical properties of 
the product of the reaction are different than the starting material; the product is no longer 
soluble in organic solvents as Pro/Fluoro 6 is. It is, however, soluble in water and basic solutions, 
Fig. 3.7 Reaction of Pro/Fluoro 6 under high pressure NO in the presence of NaOMe in methanol 
developed to form the fluorescent diazeniumdiolate Pro/Fluoro/NO 8.  
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which is indicative of the formation of a diazeniumdiolate salt.40 The 1H-NMR spectrum of 
Pro/Fluoro/NO 8 (Figure 3.9) shows the disappearance of the proline N-H peak and a shift in the 
other peaks compared to the 1H-NMR spectrum of Pro/Fluoro 6 (Figure 3.9), which provides 
indirect evidence that the desired reaction took place. Electrospray ionization time-of-flight mass 
spectrometry (ESI-TOF MS) was performed in a basic solvent mixture, and the accurate mass of 
the diazeniumdiolate was found at 381 m/z (Figure 3.10), further leading us to conclude that the 
reaction was successful.  
 Taken together, this evidence shows that we successfully synthesized the 
diazeniumdiolate, Pro/Fluoro/NO 8. The overall yield of the synthesis of Pro/Fluoro/NO 8 over 
six steps is 7%. Compared to total syntheses of other common antibiotics and their analogs, our 
synthetic procedure requires significantly fewer steps, as well as giving a much higher overall 
yield.41 This is the first time that this diazeniumdiolate is synthesized in the literature. It also one 
of very few diazeniumdiolates with a fluorescent component, which use fluorescence to quantify 
Fig. 3.8 UV-Vis spectra of aminoacridone compound 4 (1 mM in EtOH), Pro/Fluoro 6 (1 mM 
in EtOH) Pro/Fluoro/NO 8 (1 mM in 0.01 M NaOH) 
86 
 
 the amount of NO release.15,18 Our synthesized compound Pro/Fluoro/NO 8 is the first example 
of a diazeniumdiolate with a fluorescent marker to detect bacteria. 
Fig. 3.9 Left: showing disappearance of peak at 10.03 ppm of proline H on Pro/Fluoro 6 (top) 
after formation of Pro/Fluoro/NO 8 (bottom). Right: showing peak shifts from Pro/Fluoro 6 
(top) to formation of Pro/Fluoro/NO 8 (bottom). 
* 
* 
Fig. 3.10 Electrospray ionization time-of-flight mass spectrometry (ESI-TOF MS) spectrum 
showing correct mass of 8. The experiment was run in a solvent system of 80 v/v% methanol, 
19.5 v/v% water, and 0.5 v/v% ammonia, with a pH ≈ 12 to stabilize the diazeniumdiolate. 
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3.6.2 NO Release Measurements 
Once we synthesized Pro/Fluoro/NO 8, I measured the amount of NO released at 
different concentrations using a nitric oxide analyzer (NOA). An NOA uses chemiluminescence 
to directly quantify the amount of NO released by oxidizing NO with ozone, forming nitrogen 
dioxide in an excited state. Upon relaxation, it emits a certain amount of light, which is measured 
and related to the moles of NO released via a previously determined calibration constant. I 
performed NOA experiments to determine the NO release profile of Pro/Fluoro/NO 8 and to 
quantify the amount of NO release. During the NOA experiments, I observed that NO release 
from Pro/Fluoro/NO 8 is light sensitive. I saw a visible decrease in NO release when the 
overhead lights were turned off, and a return to previous NO release levels when the lights were 
turned on again, although there is still above-baseline NO release when the lights are off. This 
light sensitivity could be due to the photosensitivity of acridone compounds, which has been 
previously reported.42 Light could be exciting the acridone piece of Pro/Fluoro/NO 8, leading to 
an increase in the release of NO. 
First, I determined the total amount of possible NO release from Pro/Fluoro/NO 8. 
Previous reports show that NO release from diazeniumdiolates displays first order kinetics, and 
occurs when the amine on which the diazeniumdiolate is protonated, causing up to two 
molecules of NO to be released from the compound.32 I chose experimental conditions to release 
all the NO in Pro/Fluoro/NO 8. Most diazeniumdiolates are stable as solids when stored at -20 ˚C 
or below, or in solutions at pH 12 or above.43 Diazeniumdiolates are unstable in acidic and 
neutral conditions, so exposure to these conditions forces the release of NO. To determine the 
total amount of NO released, I forced NO off the diazeniumdiolate by injecting a basic solution 
containing the diazeniumdiolate into an acidic buffer (pH = 3), as well as shining a UV light on 
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the solution to address the light sensitivity of the diazeniumdiolate. By comparing the observed 
total moles of NO release from Pro/Fluoro/NO 8 in these experiments to the theoretical amount 
of NO release possible, the amount of NO released from the diazeniumdiolate can be calculated. 
In these calculations, we assume two moles of NO per mole of Pro/Fluoro/NO 8, as is typical in 
a diazeniumdiolate.32 Based on our calculations, Pro/Fluoro/NO 8 releases 75 ± 15% of the 
theoretical 200% of NO possible. Previous literature reports have shown that based on their 
structure, some diazeniumdiolates do not release the entirety of the theoretical 200% of NO, due 
to decomposition or other factors.44–48 For example, Bushan, et. al. reported that the stability of 
the diazeniumdiolate protecting group is important, as photochemical instability can lead to 
decomposition into the nitrosamine, decreasing diazeniumdiolate yield.44,45 Maragos and 
coworkers found that some diazeniumdiolates decompose in solution, resulting in less than 200% 
of the theoretical release of NO, and that increasing the pH of the solution decreases NO release 
from diazeniumdiolates.46,47  
Next, I measured the amount of NO release at initial concentrations of 0.1, 1, and 10 mM 
Pro/Fluoro/NO 8. I chose the conditions of the NO release measurements to most closely mimic 
the future cell viability assay conditions. The experiments are run in nutrient broth media (NBM, 
pH 7.4) at 37 °C for 24 hours with overhead lights on, and all experiments were run at least three 
times. A representative NO release profile can be seen in Figure 3.11, showing an initial spike of 
high NO release, then dropping off to a steady release after about one hour, as can be seen in the 
inset. This release profile matches the release profile of other diazeniumdiolates.49 The triplicate 
experimental plots for each concentration can be seen in Figures 3.12-3.14. The results of these 
experiments can be found in Table 3.1. In column 2 of Table 3.1, entries 1-3, the amount of NO 
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experiments can be found in Table 3.1. In column 2 of Table 3.1, entries 1-3, the amount of NO 
Fig. 3.12 Three trials of real-time NO release plots of 0.1 mM Pro/Fluoro/NO 8 in NBM 
Fig. 3.11 Representative real-time NO release profile of Pro/Fluoro/NO 8 at an initial 
concentration of 1 mM in nutrient broth at 37 °C, showing steady release of NO from 1–24 
hours. Inset shows an initial spike of NO release in the first hour. 




release is normalized to the mass of Pro/Fluoro/NO 8 used in each experiment. At 10 mM, 853 
µmol of NO/g of Pro/Fluoro/NO 8 is released (Table 3.1, Entry 3), compared to only 322 µmol 
of NO/g of Pro/Fluoro/NO 8 at a concentration of 0.1 mM (Table 3.1, Entry 1). As can be seen in 
column 3 of Table 3.1, this corresponds to 46% of the total possible NO released at 10 mM 
(Table 3.1, Entry 3) and 17% at 0.1 mM (Table 3.1, Entry 1), assuming 75% of the theoretical 
NO is released based on previous experiments. The data in Table 3.1 show that less NO is 
released at the 0.1 mM concentration. This could be due to less availability of NO to be released 
at lower concentrations or because the level of NO release approaches the limit of detection 
of the NOA instrument. An increased amount of NO release observed at concentrations of 10 
mM should lead to increased antibacterial activity, which I observe in the cell viability studies.  
3.7 Antibacterial Activity of Pro/Fluoro/NO with Pseudomonas aeruginosa 
 With the amount of NO release measured, I determined the antibacterial efficacy of 
Pro/Fluoro/NO 8. To study this, I exposed P. aeruginosa to Pro/Fluoro/NO 8, and then I 
performed a spectroscopic assay, CellTiter Blue (CTB), to determine the percent of viable 







Percentage of total possible 
NO released (%)a 
 
 1 0.1 322 ± 45 17 ± 2  
 2 1 731 ± 87 40 ± 5  
 3 10 853 ± 35 46 ± 2  
 aData is presented as mean ± standard deviation, n=3  
Fig. 3.14 Three trials of real-time NO release plots of 10 mM Pro/Fluoro/NO 8 in NBM 
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bacteria cells after exposure to the therapeutic. The CTB assay relies on the transformation of 
blue resazurin (λmax = 600 nm) to pink resorufin (λmax = 570 nm) accomplished by healthy 
bacteria, where the absorbance is measured to determine an increase or decrease in the metabolic 
activity of viable bacteria cells compared to a positive control (PC).50 The positive control in 
these experiments is P. aeruginosa culture with no therapeutic. For these experiments, I mixed P. 
aeruginosa culture in NBM with Pro/Fluoro/NO 8 to initial concentrations of 0.1, 1, and 10 mM, 
and then incubated for 24 hours at 37 °C.   
The results of the CTB assay of P. aeruginosa after exposure to Pro/Fluoro/NO 8 (Figure 
3.15) indicate that it has antibacterial activity at certain doses. At concentrations of 0.1 mM 
Pro/Fluoro/NO 8, I observed a 93 ± 7% viability, a 7% reduction in bacteria which is not 
significant compared to the positive control (100 ± 2% viability). The 1 mM dose causes a 
decrease in bacteria viability, as I observed 77 ± 9% cell viability, corresponding to a 23% 
reduction, a statistically significant reduction in bacteria compared to the positive control. The 10 
mM dose is the most effective, with 35 ± 10% cell viability after exposure, a 65% reduction after 
exposure to the therapeutic. This reduction is statistically significant compared to the positive 
control, as well as compared to the reduction from the 1 mM dose. While typically a more 
significant reduction in the number of bacteria remaining is necessary for antibacterial 
materials,51 I demonstrate that this compound has antibacterial effects as a proof of concept. I 
show that Pro/Fluoro/NO 8 has antibacterial effects statistically significant compared to the 
positive control at concentrations of 1 and 10 mM. 
Wink and Mitchell, as well as Schairer and co-workers, show that concentrations of NO 
in the low micromolar range have antibacterial effects.24,52 At an initial concentration of 0.1 mM 
Pro/Fluoro/NO 8, at the peak of the instantaneous NO release measurements represented by the 
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spike of NO release in Figure 3.11, the concentration of NO in the solution ranges from 0.6-4.1 
nM. Because the concentration of NO does not reach micromolar ranges, this could explain why 
at an initial concentration of 0.1 mM Pro/Fluoro/NO 8, there is not a significant reduction in the 
number of bacteria cells. The NO concentration does not reach levels high enough to have 
antibacterial activity, based on literature values (>1 µM).24,52 The experiments at an initial 
concentration of 1 mM Pro/Fluoro/NO 8 reach concentrations of NO ranging from 167-196 nM. 
The experiments at an initial concentration of 10 mM Pro/Fluoro/NO 8 reach concentrations of 
NO ranging from 149-576 nM. At concentrations of 1 and 10 mM, the concentration of NO is 
one to two orders of magnitude higher than at 0.1 mM. This could explain why bacteria cell 
viability is significantly lower at 1 and 10 mM concentrations, as NO concentrations are closer to 
the micromolar range.  
After exposure, I observed a color change from blue to yellow in the presence of P. 
aeruginosa (Figure 3.16), similar to the previous detection experiments. The solutions of P. 
Fig. 3.15 Cell viability after 24-hour exposure of Pseudomonas aeruginosa to Pro/Fluoro/NO 8 
at initial concentrations of 0.1, 1, and 10 mM as determined by CellTiter Blue assay. Average 
and 95% confidence interval displayed, n = 9. Statistically significant differences between 
cellular viabilities are indicated (*) as determined by a student’s t test. PC=positive control 
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aeruginosa in NBM that are exposed to Pro/Fluoro/NO 8 at all concentrations appear yellow 
under a UV light at 365 nm. Solutions of Pro/Fluoro/NO 8 at varying concentrations in nutrient 
broth media without P. aeruginosa are blue under UV light as expected. This demonstrates that 
the detection function also works post-NO release. Together, the results of these experiments 
demonstrate the dual-function of Pro/Fluoro/NO 8 to both detect and kill Pseudomonas 
aeruginosa.  
3.8 Conclusion 
The research question posed at the beginning of this chapter was: can a dual function 
small molecule be synthesized with a fluorescent tag that changes color in the presence of 
bacteria and leads to NO release to kill bacteria? This work shows that yes, it is possible. To the 
best of our knowledge, work described in this chapter is the first example of a small molecule 
multifunctional material that can both detect and kill bacteria. A synthetic procedure is 
developed to attach proline to a fluorescent aminoacridone compound, Pro/Fluoro 6. Upon 
Fig. 3.16 24 well plate under UV light after 24-hour incubation. A2-A4: P. aeruginosa, 
positive control (PC); B2-B4: 1 mM Pro/Fluoro/NO, P. aeruginosa, yellow fluorescent color; 
B5-B6: 1 mM Pro/Fluoro/NO, blue fluorescent color; C2-C4: 100 µM Pro/Fluoro/NO, P. 
aeruginosa, yellow fluorescent color; C5-C6: 100 µM Pro/Fluoro/NO, blue fluorescent color 
A1 





no P. aeruginosa 
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protonation, bacterial studies show a clear and distinct color change from blue to yellow under 
UV light in the presence of Pseudomonas aeruginosa, the first example of a prolyl 
aminopeptidase-specific indicator. A reaction is developed to react Pro/Fluoro 6 with NO to form 
the novel diazeniumdiolate Pro/Fluoro/NO 8. NO release measurements show that 
Pro/Fluoro/NO 8 releases 853 µmol of NO/g at an initial concentration of 10 mM. P. aeruginosa 
is exposed to Pro/Fluoro/NO 8, and bacteria cell viability is reduced by 65 ± 10% at a 
concentration of 10 mM Pro/Fluoro/NO 8 after 24 hours of exposure. After exposure, a color 
change from blue to yellow is observed under UV light in the presence of P. aeruginosa. These 
results demonstrate the dual function of Pro/Fluoro/NO 8 to detect and kill P. aeruginosa, 
creating a very versatile material.  
In the future, the amount of NO release from Pro/Fluoro/NO 8 could be increased by 
increasing the amount of nitrosation, potentially improving antibacterial efficacy. This could 
allow a lower dose of the diazeniumdiolate to be applied with the same or better results. More 
controlled release of NO could be achieved with a protecting group on O2 of the 
diazeniumdiolate.32 Incorporation into a polymer could also help to control NO release. 
Pro/Fluoro/NO 8 could also be tested with other bacteria species that produce the prolyl 
aminopeptidase enzyme, such as Clostridium difficile, a gram-positive bacteria strain that causes 
severe gastrointestinal infections. In the long term, Pro/Fluoro/NO 8 could be incorporated into a 
polymer support,53 which could be made into a bandage that would have antibacterial properties, 
as well as visualizing when a bacterial infection is present. While there are complications to 
overcome in the practical application of the synthesized compound, this is an exciting proof of 
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4.2 Introduction 
The alarming trend of increasing antibiotic resistance in bacteria illustrates the dire need 
for new antibiotics. One major cause of the rise in antibiotic-resistant strains of bacteria is the 
overuse of antibiotics.1 Antibiotic prodrugs that only release the active antibiotic when bacteria 
are present, such as enzyme-activated antibacterial compounds, can help overcome this 
problem.2,3 In this work, we show that the bacterial enzyme nitroreductase activates the release 
of nitric oxide, a known antimicrobial agent, from a novel prodrug to kill bacteria. 
Nitroreductases are a class of enzymes that reduce nitro groups to hydroxylamine or 
amine moieties.4,5 These enzymes have been used in biocatalysis applications to reduce 
nitroaromatic compounds.6–8 Nitroreductase enzymes have also been studied in prodrug 
applications to trigger the release of anti-cancer therapeutics at the specific location of a tumor in 
directed enzyme prodrug therapy (DEPT) to treat cancer.9–14 Nitroreductases are found in 
bacteria and very few eukaryotes, but are not found in humans.15 For this reason, nitroreductases 
could be used to catalyze the release of an antibiotic site-specifically in humans, concentrating 
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the active drug where an infection is located. The compound would only release the therapeutic 
in large amounts if an infection develops, preventing the overuse of antibiotics. This would help 
address the issue of bacteria developing antibiotic resistance, and potentially reduce or eliminate 
side effects from antibiotics. Antibacterial prodrugs could also prevent recurring, chronic 
infections by accumulating in dormant persister cells, and be metabolized by an enzyme inside 
the cell, releasing the active drug and killing the cell.2 Nitroreductase enzymes have previously 
been used to reduce nitro-containing antibiotics, such as nitrofurazone and nitrofurantoin,16 
demonstrating the viability of this study. In this paper, we use the Escherichia coli-derived 
nitroreductase NfsB, an oxygen-insensitive enzyme, to reduce the nitro group of a prodrug to an 
amine, initiating the release of an antibacterial therapeutic, nitric oxide (NO). 
Nitric oxide has been shown to have potent antibacterial effects. It kills bacteria via 
multiple mechanisms by reacting with oxygen and superoxide species in the body, forming 
reactive nitrogen and oxygen species, which can alkylate DNA and inhibit enzyme function in 
bacteria, among other detrimental effects.17,18 Studies have shown that bacteria are unable to 
develop resistance to exogenously-applied NO, even after 21 days.19 In addition, NO has a very 
short half-life, which could minimize side effects from the antibiotic.20 For these reasons, NO is 
of interest to be used in new antibiotics.  
In addition to its antibacterial activity, NO plays many roles in the body as a cell-
signaling molecule, as part of the immune response, and as a vasodilator to lower blood 
pressure.21–23 Because of the multitude of effects it can have on the body, it is critical to deliver 
NO site-specifically as a therapeutic to avoid major side effects. Enzyme-activated nitric oxide-
releasing prodrugs have previously been synthesized, typically employing diazeniumdiolates as 
the NO donor.24 A diazeniumdiolate is a type of nitric oxide-releasing functional group (Figure 
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4.1), releasing two equivalents of NO per one equivalent of diazeniumdiolate spontaneously in 
biological medium with a predictable half-life.25 A few antimicrobial diazeniumdiolates have 
been published which release NO spontaneously, but these compounds could lead to serious side 
effects due to non-specific release of NO. By attaching a group to the O2 position of a 
diazeniumdiolate (Figure 4.1), spontaneous NO release can be slowed or even prevented 
entirely.24 Examples include protecting groups cleaved by cytochrome p450 enzymes, 
glycosidases, or esterases to activate the release of NO from O2-protected diazeniumdiolates.26–28 
To the best of my knowledge, there are no examples of small molecule antibiotic 
diazeniumdiolate prodrugs. There are a limited number of related examples of antimicrobial 
diazeniumdiolate prodrugs, in which Collins, Allan, and coworkers use transpeptidases or β-
lactamases to activate NO release for anti-biofilm applications.29,30  
Precedence for nitroreductase-activated diazeniumdiolates is demonstrated by the 
Chakrapani group, where they used nitroaromatic-protected diazeniumdiolates for applications in 
cancer therapeutics.31 Based on this precedence, I applied the idea of nitroaromatic-protected 
diazeniumdiolate to antibacterial applications. The hypothesis posed at the beginning of this 
work is: can a small molecule antibacterial prodrug be developed to be activated to release NO 
only in the presence of bacterial enzymes? In this work, I investigated a variety of 
diazeniumdiolates to protect with a nitroaromatic group. Eventually, I optimized the synthetic 
conditions with nitroaromatic-protected piperazine-based diazeniumdiolates. I demonstrated in 
this work that a nitroreductase enzyme derived from Escherichia coli catalyzes the release of 




NO. In the absence of the enzyme, NO is not released, demonstrating that NO release is specific 
to the presence of the nitroreductase enzyme. Excitingly, when E. coli is exposed to my 
synthesized diazeniumdiolates, significant reductions in bacteria are observed. This is the first 
report of antibacterial nitroreductase-activated diazeniumdiolates, demonstrating the potential 
use of antibiotic prodrugs for site-specific delivery of therapeutics to treat bacterial infections. 
4.3 Experimental Methods 
4.3.1 Chemicals: Ethyl 1-piperazinecarboxylate (99%), 4-nitrobenzyl bromide (99%), 15-crown-
5 (98%), nitroreductase from Escherichia coli (90%), and β-Nicotinamide adenine dinucleotide 
2′-phosphate reduced tetrasodium salt hydrate (NADPH, 97%) were purchased from Sigma-
Aldrich (St. Louis, MO, USA). 1-(tert-Butoxycarbonyl)piperazine (98%) and 1-
Carbobenzoxypiperazine (95%) were purchased from TCI (Cambridge, MA, USA). Nitric oxide 
(99%) was purchased from Matheson Tri-gas (Montgomeryville, PA, USA). Sodium methoxide 
(30% in methanol) was purchased from Acros Organics (Geel, Belgium). Oxoid nutrient broth 
(OXCM0001B) and Oxoid nutrient agar (OXCM0003B) were purchased from Fisher Scientific 
(Hampton, NH, USA). Escherichia coli (ATCC 25922) was obtained from American Type 
Culture Collection (ATCC, USA). Argon (ultrahigh purity), nitrogen (ultrahigh purity), and 
oxygen were purchased from Airgas (Denver, CO, USA). Deionized water (18.2 MΩ·cm) was 
obtained from a Millipore Direct-Q water purification system (EMD Millipore, Billerica, MA, 
USA). 
4.3.2 Abbreviations: The following abbreviations are used throughout: rt= room temperature, h= 
hour, min= minute, THF= tetrahydrofuran, 15-crown-5= 1,4,7,10,13-Pentaoxacyclopentadecane, 
NaOH= sodium hydroxide, DCM= dichloromethane, Na2SO4= sodium sulfate, EtOAc= ethyl 
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acetate, SiO2= silica, PBS= phosphate-buffered saline, DMSO= dimethyl sulfoxide, Boc= tert-
Butyloxycarbonyl, Cbz= carboxybenzyl. 
4.3.3 Instruments: All nuclear magnetic resonance (NMR) spectra were obtained on Varian 
Inova 400 (400 MHz for 1H; 101 MHz for 13C) and/or Bruker US400 (400 MHz for 1H; 101 
MHz for 13C) at room temperature unless noted otherwise. Chemicals shifts were reported in 
parts per million (δ scale) and referenced according the following standards: chloroform residual 
signal (δ 7.16) for 1H signals; deuterated chloroform carbon resonances (middle peak is δ 77.1) 
for 13C signals. Coupling constants were reported in Hertz (Hz) and multiplicities were reported 
as follows: singlet (s), doublet (d), doublet of doublets (dd), triplet (t), quartet (q), and multiplet 
(m). IR spectra were obtained on a Thermo Scientific Nicolet 6700 FT-IR spectrometer. 
Electrospray ionization mass spectrometry data were obtained on an Agilent 6224 TOF mass 
spectrometer equipped with a dual electrospray ion source operated in positive and negative 
mode. Melting points were obtained with an Electrothermal Mel-Temp apparatus. UV-Vis 
measurements were obtained with a Thermo Scientific Nicolet Evolution 300 spectrometer. 
Reactions were analyzed by thin layer chromatography (TLC) on aluminum sheets that were pre-
coated with silica gel 60 F254, and the reactions were purified by column chromatography using 
Alfa Aesar silica gel 60 (0.06-0.2 mm).  
4.3.4 Experimental Procedures 
Diazeniumdiolates were synthesized according to previously reported procedures.32 In brief, the 
piperazine starting material (1 equiv.) was stirred to dissolve in anhydrous methanol (2.1 M) in a 
high pressure reaction vessel. Sodium methoxide (30% in methanol, 1 equiv.) was added. The 
reaction vessel was attached to a high-pressure stainless-steel nitric oxide reactor system, purged 
with high purity argon, then charged with nitric oxide gas (80 psi, 99%). After stirring under 
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pressure for 24 h, the white precipitate that formed was washed with methanol, then diethyl ether 
and dried under vacuum for 1 h. The products were stored at -20 ˚C until further use. Spectra 
matched the previously reported values. 
4.3.4.1 General procedure for synthesis of O2-(4-nitrobenzyl) diazeniumdiolates 
To a 0 ˚C solution of diazeniumdiolate (0.75 mmol, 1.5 eq.) in anhydrous THF (0.1 M), 15-
crown-5 (1 mmol, 2 eq.) was added. After 30 minutes stirring at 0 ˚C, 4-nitrobenzyl bromide (0.5 
mmol, 1 eq.) was added and the reaction was allowed to warm to rt. After stirring for 2-4 h, the 
reaction mixture was concentrated in vacuo to remove THF. The crude product was purified by 
flash column chromatography, affording the title compound.  
 
4.3.4.2 O2-(4-Nitrobenzyl) 1-(4-ethoxycarbonylpiperazin-1-yl)diazen-1-ium-1,2-diolate, 3a. 
Following the general procedure, stirring for 4 h, prior to column chromatography purification, 
the crude mixture was dissolved in DCM (10 mL) and NaOH (1 M, 10 mL) was added. The 
aqueous layer was extracted with DCM (3 × 10 mL), then the combined organic layers were 
washed sequentially with deionized water (10 mL) and brine (15 mL), then dried over Na2SO4 
and concentrated in vacuo to afford a yellow oil. After purification by column chromatography 
(SiO2, 10%, 30% EtOAc in hexanes gradient), 3a is collected as a pure pale yellow crystalline 
solid (128-154 mg, 79 ± 7%, n=4). 1H NMR (400 MHz, CDCl3) δ 8.15 (d, J = 8.5 Hz, 2H, H9), 
7.46 (d, J = 9.5 Hz, 2H, H8), 5.24 (s, 2H, H6), 4.07 (q, J = 7.1 Hz, 2H, H2), 3.56 (t, J = 5.2 Hz, 
4H, H4), 3.30 (t, J = 5.1 Hz, 4H, H5), 1.19 (t, J = 7.1 Hz, 3H, H1). 13C NMR (101 MHz, CDCl3) 
δ 155.04 (C3), 147.98 (C10), 142.81 (C7), 128.66 (C8), 123.87 (C9), 73.94 (C6), 61.87 (C2), 
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51.01 (C5), 42.33 (C4), 14.59 (C1). HRMS (+ESI) Found 354.1408 (Calcd. 354.1414 for 
C14H19N5O6; [M+H]+). UV (DCM) λmax (ε) 241 nm (30.4 mM-1cm-1); 263 nm (15.8 mM-1cm-1). 
m.p. 105.5-108 oC. νmax/cm-1 3110 w, 3081 w, 2876 br, 1683 s, 1602 m, 1519 s, 1423 m, 1343 s, 
1221 s, 1121 s, 1031 s, 956 s, 848 s, 739 s. 
 
4.3.4.3 O2-(4-Nitrobenzyl) 1-(4-tert-butyoxycarbonylpiperazin-1-yl)diazen-1-ium-1,2-diolate, 3b. 
Following the general procedure stirring for 2 h, after purification by column chromatography 
(SiO2, 5%, 15%, 40% EtOAc in hexanes gradient), 3b is collected as a pure pale yellow 
crystalline solid (46-123 mg, 42 ± 21%, n=3). 1H NMR (400 MHz, CDCl3) δ 8.24 (d, J = 8.7 Hz, 
2H, H9), 7.55 (d, J = 8.7 Hz, 2H, H8), 5.31 (s, 2H, H6), 3.58 (t, J = 6 Hz, 4H, H4), 3.35 (t, J = 6 
Hz, 4H, H5), 1.46 (s, 9H, H1). 13C NMR (101 MHz, CDCl3) δ 154.17 (C3), 147.98 (C10), 
142.85 (C7), 128.65 (C8), 123.85 (C9), 80.57 (C2), 73.91 (C6), 51.07 (C5), 42.32 (C4), 28.31 
(C1). HRMS (+ESI) Found 382.1721 (Calcd. 382.1727 for C16H23N5O6; [M+H]+). UV (DCM) 
λmax (ε) 240 nm (32.8 mM-1cm-1); 264 nm (12.6 mM-1cm-1). m.p. 132-135 oC. νmax/cm-1 2980 br, 
2932 br, 1677 s, 1604 w, 1521 s, 1406 s, 1343 s, 1224 m, 1124 s, 1033 s, 845 s, 738 s.
 
4.3.4.4 O2-(4-Nitrobenzyl) 1-(4-benzyloxycarbonylpiperazin-1-yl)diazen-1-ium-1,2-diolate, 3c. 
Following the general procedure stirring for 2 h, after purification by column chromatography 
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(SiO2, 15%, 40% EtOAc in hexanes gradient), 3c is collected as a pure pale yellow crystalline 
solid (159-184 mg, 81 ± 7%, n=3). 1H NMR (400 MHz, CDCl3) δ 8.16 (d, J = 8.7 Hz, 2H, H9), 
7.47 (d, J = 8.8 Hz, 2H, H8), 7.28 (m, 5H, H11, H12, H13), 5.24 (s, 2H, H6), 5.06 (s, 2H, H2), 
3.60 (m, 4H, H4), 3.30 (m, 4H, H5). 13C NMR (101 MHz, CDCl3) δ 154.80 (C3), 147.98 (C10), 
142.80 (C7), 136.17 (C1), 128.67 (C8), 128.58 (C12), 128.29 (C13), 128.07 (C11), 123.86 (C9), 
73.95 (C6), 67.62 (C2), 50.97 (C5), 42.45 (C4). HRMS (+ESI) Found 416.1564 (Calcd. 
416.1570 for C19H21N5O6; [M+H]+). UV (DCM) λmax (ε) 240 nm (32.8 mM-1cm-1); 264 nm (13.0 
mM-1cm-1). m.p. 74-77 oC. νmax/cm-1 2935 w, 2850 br, 1704 s, 1605 w, 1513 s, 1439 s, 1348 s, 
1215 s, 1126 s, 1013 s, 848 m, 744 s, 698 s. 
4.3.5 Nitric Oxide Release Measurements: Nitric oxide generation was recorded in real time 
using a chemiluminescence-based GE Nitric Oxide Analyzer (NOA). Before each use, the NOA 
was calibrated using a 43.83 ppm NO calibration gas cylinder (Airgas). For the experiments to 
determine NO release at different concentrations, solutions of 3a-c in DMSO were made (1, 10 
and 100 mM). PBS (1480 µL,10 mM in Millipore water), NADPH (400 µL, 10 mM in PBS), and 
the corresponding 3a-c solution (20 µL, 1, 10, or 100 mM in DMSO) to a final concentration of 
0.01, 0.1, and 1 mM are added to NOA cell in a 37 °C water bath. The solution is purged 
continuously with ultrapure nitrogen gas for 5-10 min to collect a baseline release. 
Nitroreductase enzyme (50 µL, 1 mg/mL in PBS) is then added through the side injection port of 
the NOA vessel. The solution is purged continuously with ultrapure nitrogen gas with bubbling 
rate of 55 mL/min directly into the solution and flow gas introduced into the remaining 
headspace for the duration of the experiment. NO release is recorded in 15 s intervals as parts per 
billion. NO release data is presented as the average of at least 3 trials ± standard deviation. 
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4.3.6 NADPH Consumption Studies: A baseline spectrum is collected of a solution of 100 µM 3a 
(10 µL, 10 mM solution in DMSO) in PBS (970 µL, 10 mM in Millipore water). NADPH (10 
µL, 20 mM in PBS) is added to a concentration of 200 µM, and a time zero spectrum from 200-
400 nm was collected, as well as a spectrum after 5 minutes as a control to ensure that NADPH 
absorbance does not decrease over time without enzyme present. Nitroreductase enzyme (10 µL, 
1 mg/mL in PBS) is added and data is collected in cycles in intervals (approximately every 5 
seconds for 60 cycles) from 335-345 nm at rt. Absorbances are collected at 340 nm and plotted 
over time. The data is presented as the average of 3 trials ± standard deviation. 
4.3.7 Bacteria Studies 
4.3.7.1 Escherichia coli Bacteria Culture: Initial stock culture of Escherichia coli was made by 
reconstituting lyophilized bacteria in warm nutrient broth media (NBM, 13 g nutrient broth/1 L 
Millipore water) and grown overnight at 37 °C and 150 rpm until an optical density at 600 nm 
(OD600nm) ≈1.0 was reached. This bacterial solution was combined with glycerol (30% v/v) in a 
1:1 fashion to obtain a final glycerol concentration of 15% (v/v). These solutions were stored at 
−80 °C until use. Prior to each bacterial experiment, a frozen culture was thawed at rt and then 
centrifuged at 4700 rpm for 10 min. The supernatant was discarded, and the pellet was 
resuspended in NBM. This was transferred to additional NBM and allowed to grow overnight 
with shaking at 120 rpm until the OD600nm ≈1.0. The culture was diluted to an OD600nm ≈0.3-0.35 
using warmed NBM prior to beginning experiments. 
4.3.7.2 Bacterial Viability The previously made 3a-c solutions in DMSO (10 µL; 1, 10 or 100 
mM) were added to E. coli culture (107 CFU/mL) in NBM (990 µL, OD600nm ≈0.3-0.35) in 1.5 
mL Eppendorf microcentrifuge tubes to final concentrations of 0.01, 0.1, and 1 mM. The positive 
control was E. coli culture in NBM (1 mL, OD600nm ≈0.3-0.35). The solutions were placed in a 
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static 37 ˚C incubator for 24 h. Agar plates were made by adding 15 mL of sterilized nutrient 
agar [powder base (14 g) in Millipore water (500 mL)] to sterile Petri dishes and allowed to set 
for at least 2 h. After 24 h exposure, the E. coli solutions underwent serial tenfold dilution with 
sterile NBM to reach 104 or 105 dilution factors, and the agar plates were inoculated with 20 µL 
of the diluted E. coli solutions using a sterile plastic or glass spreader. The agar plates were 
placed in a static 37 ˚C incubator overnight and colony-forming units (CFUs) were counted after 
24 h (n = 9). The number of CFUs were calculated using the equation: 
𝐶𝐹𝑈𝑚𝐿 = (# 𝐶𝐹𝑈 𝑐𝑜𝑢𝑛𝑡𝑒𝑑)(𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟)𝑉𝑜𝑙𝑢𝑚𝑒 𝑝𝑙𝑎𝑡𝑒𝑑 (𝑚𝐿)  
The percent reduction in the number of viable bacteria was calculated as follows: 
% 𝑟𝑒𝑑𝑢𝑐𝑡𝑖𝑜𝑛 = 𝐶𝐹𝑈 𝑎𝑓𝑡𝑒𝑟 𝑒𝑥𝑝𝑜𝑠𝑢𝑟𝑒 𝑡𝑜 𝑡ℎ𝑒𝑟𝑎𝑝𝑒𝑢𝑡𝑖𝑐 𝑚𝐿⁄𝐶𝐹𝑈 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑚𝐿⁄  
4.3.7.3 Statistical Analysis All biological experiments were performed using at least nine 
samples. Viability assays are reported as the mean and 95% confidence interval. All data were 
evaluated for potential outliers using the Grubbs Test. The statistical differences in data were 
evaluated using the Student’s t test (p < 0.05) at the 95% confidence level. 
4.4 Synthesis of Nitroaromatic-Protected Diazeniumdiolates 
I designed the antibacterial diazeniumdiolate prodrugs with specific function and 
requirements in mind, beginning with known diazeniumdiolates that would be stable under the 
nitroaromatic protection conditions. These molecules would display nitroreductase-activated NO 
release. I was first interested in looking at a variety of diazeniumdiolates with different half-
lives, as this could potentially affect NO release and the therapeutic effects of the compounds. 
Diazeniumdiolate half-lives can range from seconds to hours, so I investigated diazeniumdiolates 
representing this range of half-lives, from PROLI/NO and PYRRO/NO with half-lives of a few 
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seconds, to piperazine-based diazeniumdiolates with half-lives of a few minutes, to DPTA/NO 
with a half-life of 30 minutes to a few hours (Figure 4.2).32,33 Unfortunately, I found that the 
protection conditions led to formation of large amounts of side products for PROLI/NO, 
PYRRO/NO, and DPTA/NO. A basic workup step to try to remove starting material and other 
side products did not help with purification, and attempting different column chromatography 
conditions also did not afford the pure product. Ultimately, I decided to move ahead with the 
piperazine-based diazeniumdiolates, as the purification of these compounds was more straight 
forward. 
 
Fig. 4.2 Diazeniumdiolates with varied half-lives and attempted to protect with nitroaromatic 
group 
Piperazine diazeniumdiolates are known to have half-lives ranging from two to five 
minutes, a mid-range half-life for diazeniumdiolates, and this range was deemed to be ideal for 
initial testing for the intended antibacterial applications.20,32 Some piperazines have antibacterial 
activity, depending on substituents, which could further enhance the antibacterial activity of our 
compounds.34,35 Piperazines are similar to the piperidine derivative previously published, 
providing precedence that protection conditions would not decompose the diazeniumdiolate.31 
To synthesize these novel nitroaromatic-protected diazeniumdiolates, several piperazine 
diazeniumdiolates were synthesized. Based on a known synthetic procedure,32 the piperazine 
118 
 
starting material was reacted under high pressure NO gas in the presence of sodium methoxide, 







After the successful synthesis of the piperazine diazeniumdiolates, I developed a 
procedure to O2-protect the diazeniumdiolates with a nitroaromatic group, based on a previous 
literature report.31 Figure 4.3 shows these protecting conditions, in which the diazeniumdiolate 
was mixed with 15-crown-5 to trap the sodium counterion, then 4-nitrobenzyl bromide was 
added to form the nitroaromatic-protected diazeniumdiolates 3a-c in an SN2-style reaction. I 
developed a basic work-up procedure to purify the ethyl carboxylate derivative 3a, followed by 
column chromatography, significantly improving the yield of 3a to 79 ± 7% (mean ± standard 
deviation, n ≥ 3). Boc- (3b, 42 ± 21%) and Cbz- (3c, 81 ± 7%) protected piperazine derivatives 
were also synthesized to evaluate if the group on the piperazine leads to significant differences in 
the functionality of the compound.  
The different piperazine protecting groups also allow for varied deprotecting conditions if 
the piperazine functional handle is desired. The nitroaromatic protecting group on the 
diazeniumdiolate should improve the stability to various deprotection conditions of the 
piperazine. With the piperazine functional handle, the compound could be incorporated into a 
Fig. 4.3 Reaction scheme showing protection of various piperazine diazeniumdiolates with a 
nitroaromatic group.  
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polymer, such as PVC or polyurethane, and used to make antibacterial medical devices or 
coatings.36–38 
4.5 Nitric Oxide Release Properties of Nitroreductase-Activated Diazeniumdiolates  
Once the nitroaromatic-protected diazeniumdiolates were synthesized, I evaluated them 
for their ability to release NO in the presence of a nitroreductase (NTR) enzyme using a nitric 
oxide analyzer (NOA). An NOA uses chemiluminescence to directly quantify the amount of NO 
released by oxidizing NO with ozone, forming nitrogen dioxide in an excited state. Upon 
relaxation, excited state NO2 emits a photon, which is measured and related to the moles of NO 
released via a previously determined calibration constant. This instrument provides direct 
measurement of NO release as a function of time.  
For the NO release quantification experiments, the diazeniumdiolate compounds were 
added to a solution of PBS and warmed to 37 °C to mimic physiological conditions and future 
bacterial viability studies. NADPH was added to the solution, as it necessary as a reducing agent 
for the NTR enzyme to function. A baseline release was collected to determine if the protected 
diazeniumdiolates release NO spontaneously under these conditions. The NTR enzyme was then 
added to the solution to induce NO release, which was quantified until the baseline returned to 0 
ppb. The NTR enzyme used in these experiments was the commercially available nitroreductase 
NfsB, isolated from Escherichia coli, a well-studied enzyme that has previously been shown to 
reduce various nitroaromatic compounds.16 The NO release experiments were repeated three 
times for each compound at each concentration to demonstrate reproducible results. 
The diazeniumdiolate compounds 3a-c do not release NO when the NTR enzyme is not 
present (Figure 4.4). When the diazeniumdiolate compounds 3a-c are in solution, the baseline 
release of NO is below the limit of detection, indicating that there is no observable spontaneous 
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release of NO. Excitingly, upon injection of a solution of the NTR enzyme in PBS, there was an 
immediate response shown by a steep release of NO (Figure 4.4). NO release quickly reaches a 
maximum, then more slowly releases NO until all of the diazeniumdiolate groups decompose. 
One reported hypothesis for how NO release occurs in the presence of nitroreductase is that the 
enzyme reduces the nitro group first to a hydroxylamine, then to a primary amine.31 The amine 
then tautomerizes to the imine, resulting in the loss of the group from the diazeniumdiolate. The 
amine component of the diazeniumdiolate is then protonated, causing two molecules of NO to be 
released from the compound, which displays first order kinetics.39 Alternatively, the NTR 
enzyme could reduce the nitroaromatic group to the hydroxylamine, which then tautomerizes to 
an oxime species, then the protecting group is released from the diazeniumdiolate. The amine of 
the diazeniumdiolate is protonated, causing the release of NO. Either of these mechanisms are 
plausible, but as nitroreductase enzymes reduce nitro groups to amines via a hydroxylamine  
Fig. 4.4 A representative NO release plot of COOEt 3a showing that NO release is dependent 






Fig. 4.5 NO release plots for 3 trials of COOEt 3a (0.01 mM in PBS). 
Fig. 4.6 NO release plots for 3 trials of COOEt 3a (0.1 mM in PBS). 
Fig. 4.7 NO release plots for 3 trials of COOEt 3a (1 mM in PBS). 
Fig. 4.8 NO release plots for 3 trials of Boc 3b (0.1 mM in PBS). 
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intermediate, the latter mechanism is potentially more likely. The NO release data shown in 
Figure 4.4 provides strong support that the prodrug is activated by the NTR enzyme. 
Experiments were performed with at least 3 trials at varying concentrations and the three 
different piperazine substituents (Figures 4.5-4.9).  
To provide further evidence that the prodrug is enzyme activated, the consumption of 
NADPH by the nitroreductase enzyme is measured, as NADPH is a necessary cofactor for 
enzyme function. In this experiment, UV-vis absorbance is measured at 340 nm, where NADPH 
is known to have a peak, but disappears as it is converted to NADP+ by the enzyme.40 By 
Fig. 4.10 Absorbance at 340 nm of NADPH and COOEt 3a in the presence of NTR enzyme 
showing decreasing NADPH concentration over time as it is consumed by NTR enzyme. 
Fig. 4.9 NO release plots for 3 trials of Cbz 3c (0.1 mM in PBS). 
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tracking the absorbance at 340 nm, it is assumed that NADPH is being consumed by the enzyme, 
indicating that the enzyme is activated. The NTR enzyme is added to a solution of 3a and 
NADPH in PBS, then absorbance is measured over time. The data (Figure 4.10) shows that 
NADPH concentration decreases in the presence of the substrate 3a after the NTR enzyme is 
added, as expected based on literature reports.41 Previous literature data shows that NADPH 
should be consumed over time (absorbance at 340 nm decreases) as enzymes consume the 
cofactor as they function, which is exactly what I observe in this experiment. The structure of the 
cofactor NADPH is changed in the presence of the NTR enzyme, showing that the enzyme is 
converting the structure of the cofactor in solution. This experiment demonstrates that the 
enzyme is activated during the experimental conditions and corroborates the results observed in 
the NO release experiments. 
Total NO release is measured for 3a at concentrations of 0.01, 0.1, and 1 mM (Table 4.1, 
entries 1-3), and for 3b-c at a concentration of 0.1 mM (Table 4.1, entries 4-5). Table 4.1 shows 
that the total amount of NO release does not match the theoretical yield, but several literature 
reports indicate that diazeniumdiolates do not always release 100% of the theoretical NO 
available, based on their structure or due to decomposition.42–44 Reports have demonstrated that 
diazeniumdiolates can decompose in solutions of low pH,43 or that photochemically activated 
Table 4.1 NO release data showing the normalized amount and the percent 
of total NO released at different concentrations for 3a-c 
Entry R group 
Conc. 
(mM) 








1 COOEt (3a) 0.01 9.7 ± 1.2 × 10-9 24 ± 3 0.2 
2 COOEt (3a) 0.1 2.1 ± 0.1 × 10-7 52 ± 3 2.7 
3 COOEt (3a) 1 5.3 ± 0.5 × 10-7 13 ± 1 4.8 
4 Boc (3b) 0.1 4.4 ± 0.4 × 10-8 11 ± 1 1.1 
5 Cbz (3c) 0.1 6.7 ± 0.6 × 10-8 17 ± 2 0.7 
aData is presented as mean ± standard deviation, n=3  
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diazeniumdiolates can decompose to the nitrosamine.42,45 Our hypothesis for the observed less 
than 100% recovery of NO is based on the aqueous experimental conditions. Based on our 
observations, the synthesized compounds 3a-c have limited solubility in aqueous solutions at 
higher concentrations. The NTR enzyme is soluble in water and is unable to access the prodrugs 
3a-c when they are not dissolved in solution, resulting in lower NO recovery. These solubility 
observations are supported in Table 4.1, as the COOEt derivative 3a releases the highest 
percentage of NO (entry 2) and is the least hydrophobic protecting group. At the highest 
concentration of the COOEt derivative 3a (entry 3), less of the theoretical NO is released, as less 
of it dissolves in the aqueous solution. The Boc- 3b and Cbz-protected derivatives 3c are even 
more hydrophobic, and less of the theoretical NO is released at the same concentration as the 
ethyl carboxylate derivative 3a (entries 2, 4-5), further demonstrating that solubility plays a role 
in NO release. 
4.6 Antibacterial Activity of Piperazine Diazeniumdiolates  
To investigate the antibacterial activity of the synthesized prodrugs, E. coli was chosen as 
the initial species of interest. E. coli is well-known to contain a nitroreductase enzyme, which is 
commercially available and was used for the NO release experiments (section 3.2). E. coli is a 
very common infection-forming species and worryingly, is growing increasingly resistant to 
common antibiotics, indicating a pressing need for new antibacterial agents to treat E. coli 
infections.46,47 To determine the antibacterial activity of the synthesized nitroreductase-activated 
diazeniumdiolates 3a-c, E. coli was exposed to varying concentrations of the compounds. The 
positive control in these experiments was E. coli with no synthesized compound present. The 
initial hypothesis was that E. coli would metabolize the synthesized compounds via the 
nitroreductase enzyme it produces, inducing NO release and killing the bacteria.  
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The results of the cell viability experiments with E. coli are shown in Figure 4.11. Figure 
4.11a shows a decrease in viability of E. coli cells when exposed to higher concentrations of the 
COOEt derivative 3a, indicating that the compound effectively kills E. coli. There is no 
statistically significant difference between the positive control and the COOEt derivative at a 
0.01 mM concentration (Figure 4.11a). Excitingly, however, there is a 56% reduction in the 
number of viable bacteria at concentrations of 0.1 mM 3a, from 4.6 ± 0.7 × 108 CFU/mL to 2.0 ± 
0.7 × 108 CFU/mL. At a dose of 1 mM 3a, a 94% reduction in bacterial viability was observed, 
from 4.6 ± 0.7 × 108 CFU/mL to 3.1 ± 0.6 × 107 CFU/mL. Likely, the correlation between 
improved antibacterial activity and 3a concentration is due to the observed higher amount of NO 
release (Table 4.1, entries 1-3). This observation is supported by Wink and Mitchell, as well as 
Schairer and co-workers, who show that concentrations of NO in the low micromolar range (>1 
µM) have antibacterial effects.17,48 At the time of the highest peak of NO release, instantaneous 
concentrations of NO reach micromolar levels for COOEt 3a, 2.7 µM (0.1 mM, Table 4.1, entry 
2) and 4.8 µM (1 mM, Table 4.1, entry 3), which could explain the significant antibacterial 
Fig. 4.11 a) Percent viability of E. coli after exposure to 3a at concentrations of 0.01 mM, 0.1 
mM, and 1 mM. b) Percent viability of E. coli after exposure to 3a, 3b, or 3c at a concentration 
of 0.1 mM. Average and 95% confidence interval displayed, n ≥ 9. Statistically significant 




activity at these concentrations. Figure 4.11b shows that the Boc and Cbz-protected derivatives, 
3b and 3c, also provoke a reduction in the amount of viable E. coli. While this result is exciting, 
the amount of reduction does not match the antibacterial activity of the COOEt derivative 3a. 
Instead at a concentration of 0.1 mM, 3b induces a 26% decrease in the number of viable 
bacteria, from 3.7 ± 0.8 × 108 CFU/mL to 2.8 ± 0.3 × 108 CFU/mL. The Cbz derivative 3c 
induces a more significant decrease in the amount of viable E. coli by 41%, to 2.2 ± 0.3 × 108 
CFU/mL. At the same concentration (0.1 mM), the COOEt derivative 3a causes a higher 
reduction in the number of bacteria (56%). These experimental results are consistent with Wink 
and Mitchell’s report that greater than micromolar concentrations of NO have antibacterial 
effects;48 the Boc-protected derivative 3b peaks at an instantaneous concentration of 1.1 µM of 
NO, and the Cbz derivative 3c peaks at an instantaneous concentration 0.7 µM, which is close to 
the antibacterial range of ≥1 µM (Table 4.1, entries 4-5). Because these values are less than the 
instantaneous release concentration (2.7 µM) for 0.1 mM COOEt 3a, however, I observe a lower 
reduction in the number of bacteria. In contrast to the experiments performed with 3a, 
preliminary experiments exposing E. coli to increased concentrations of the Boc 3b and Cbz 
derivatives 3c does not lead to a further reduction in the number of bacteria. This could be due to 
the solubility issues observed the NO release experiments discussed in section 3.2. Due to the 
more hydrophobic nature of the Boc and Cbz protecting groups compared to the COOEt group, 
3b and 3c do not dissolve as well in aqueous solutions at higher concentrations, and therefore do 
not kill more bacteria at higher concentrations. 
 As piperazines have been shown to have antibacterial activity in some cases, it is 
important to determine the extent to which the observed antibacterial effects are due to NO 
release. To support the claim that NO is responsible for the observed antibacterial effects, E. coli 
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are exposed to the non-NO releasing structural parts of the compound in a control experiment. 
These structures are shown in Figure 4.12, 4-nitrotoluene and the corresponding piperazine 
derivative to the diazeniumdiolate (1a-c). For these control experiments, E. coli was exposed to 
both 4-nitrotoluene and the corresponding piperazine, either COOEt 1a, Boc 1b, or Cbz 
piperazine 1c at the relevant concentrations (0.01, 0.1, or 1 mM, Figure 4.13). Based on these 
experiments, the COOEt piperazine 1a and 4-nitrotoluene combination shows no significant 
reduction compared to the positive control at concentrations of 0.01, 0.1 and 1 mM. At 0.01 mM 
COOEt 1a and 4-nitrotoluene, there is an increase in bacterial growth, 120% of the positive 
control. At a concentration of 0.1 mM, the Boc 1b and Cbz 1c piperazine and 4-nitrotoluene  
combination does not cause a significant reduction in E. coli. This experiment also showed a 
small increase in bacterial viability, to 124% (3b) and 126% (3c). These control experiments 
demonstrate that the antibacterial activity of compounds 3a-c is due to the NO- releasing 
diazeniumdiolate functional group in the compound, not due to the possible antibacterial activity 
of the parent structure.   
After testing the antibacterial activity of our compounds against E. coli, I was interested 
in exploring possible antibacterial activity with other nitroreductase-producing bacteria species. 
Pseudomonas aeruginosa contains a nitroreductase enzyme of the same nitroreductase subgroup 
as E. coli NfsB, indicating that similar antibacterial activity would be observed with P. 
Fig. 4.12 Control compounds exposed to bacteria, 4-nitrotoluene on the left and piperazine 
starting materials 1a-c on the right. 
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aeruginosa upon exposure to our compounds.49 P. aeruginosa is a deadly bacterial species, 
growing increasingly resistant to most common antibiotics, illustrating a critical need to develop 
new antibacterial agents to kill this particular bacterial strain.50 Using the previously stated 
plating and CFU counting method, during preliminary testing we observed a decrease in the 
number of viable bacteria after exposure to 3a. However, the same controls previously discussed 
in which the bacteria are exposed to the compounds in Figure 4.13 showed the same or greater 
reduction in the number of viable bacteria. Unfortunately, I am not able to conclude that NO 
release from 3a-3c induces the same antibacterial activity against P. aeruginosa as with E. coli. 
This could be due to possible lower catalytic activity of the P. aeruginosa nitroreductase 
enzyme, or lack of access to the enzyme in P. aeruginosa. In the future, this issue could be 
addressed by simultaneous application of the compounds and isolated NfsB nitroreductase 
enzyme to kill P. aeruginosa infections.  
4.7 Conclusion 










Fig. 4.13 Control experiments with E. coli exposed to COOEt 3a at concentrations of 0.01, 0.1, 
and 1 mM and Boc 3b and Cbz 3c at a concentration of 0.1 mM. Data is reported as mean and 
standard deviation bars with n ≥ 9 
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The research question posed at the beginning of this chapter is: can a small molecule 
antibacterial prodrug be developed to be activated to release NO only in the presence of bacterial 
enzymes? This work shows that yes, antibacterial enzyme-activated diazeniumdiolate prodrugs 
are synthesized and activated in the presence of a bacterial nitroreductase enzyme. Novel 
nitroaromatic-protected piperazine diazeniumdiolates were synthesized, COOEt, Boc, and Cbz 
piperazine derivatives. Analysis of NO release from the compounds demonstrates that NO 
release occurs only in the presence of a nitroreductase enzyme, releasing up to 5.3 ± 0.5 × 10-7 
moles of NO. The antibacterial activity of the compounds against E. coli was analyzed, causing 
up to a 94% reduction in the number of bacteria. This study demonstrates the possibility of 
antibiotic nitric oxide prodrugs, which could allow targeted delivery of NO to infections. In the 
future, the compounds could be derivatized and tested against other bacterial species containing 
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After the success of synthesizing an enzyme-activated diazeniumdiolate specific to 
bacterial enzymes (discussed in Chapter 4), I wanted to incorporate the compound into a 
polymeric matrix. Through this process, new antibacterial materials could be developed. These 
materials could be used to coat or make new medical devices that have long-term antibacterial 
activity, preventing infection complications with medical implants. This work was supported by 
grants from the Monfort Foundation and the National Institutes of Health (5R21EB016838-02). 
The research described in this chapter will be submitted to the journal ACS Applied Biomaterials. 
5.2 Introduction 
The growing trend of antibiotic resistant bacterial infections calls for new ways to treat 
bacterial infections. Antibiotic prodrugs, which only release the active therapeutic in the 
presence of bacteria, can help reduce the opportunity for bacteria to develop resistance.1 Medical 
devices are a site where bacterial infections can develop, and these infections are often incredibly 
difficult to treat and can require removal of the device to treat the infection. The Centers for 
Disease Control and Prevention (CDC) estimates that 1 out of every 31 hospital patients acquire 
a healthcare-associated infection (HAI), 25.6% of which are device-associated infections, costing 
billions of dollars per year.2,3 To help address this problem, antibacterial coatings can be added 
to devices and implants to prevent infections.4 Bacteria can attach to the surface of a medical 
device and multiply to form an infection. A coating on the device that releases an antibiotic 
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could prevent bacterial attachment and eventual infection. An antibacterial prodrug coating that 
only releases the active drug in the presence of bacteria could prevent medical device infections, 
battle resistance development, and have long-term antibacterial activity.  
Nitric oxide (NO) is a gaseous small molecule that plays several roles in the body, such 
as cell signaling, immune response, and vasodilation, as well as being a potent therapeutic when 
applied exogenously, promoting would healing, killing cancer cells, and killing bacteria. Its 
antibacterial activity is of particular interest, as it is potent, and a report from Privett, et. al., 
showed that bacterial resistance to NO does not develop even after 21 days of exposure.5 NO 
donors are found in many forms, including S-nitrosothiols (RSNOs), metal nitrosyls, organic 
nitrates and nitrites, and diazeniumdiolates.6–11  
To increase the usability of NO donors for medical device applications, they must be 
incorporated into a polymer, either non-covalently or covalently. There are many examples of 
NO releasing polymers12–15, used for many applications.16,17 Many types of NO donors 
incorporated into polymeric matrices have been used for varied applications, most commonly 
RSNOs18–20 and diazeniumdiolates21–23.  
Diazeniumdiolates are a functional group made up of two NO groups attached to a 
secondary amine that release two moles of NO per mole of substrate. They typically release NO 
spontaneously with a well-defined half-life ranging from seconds to hours. NO release can be 
prevented by protecting the O2 position of the diazeniumdiolate functional group, stopping NO 
release until the removal of the protecting group. If this group is metabolized by an enzyme, then 
NO release from the compound is enzyme-activated. Diazeniumdiolate-containing polymers can 
increase the stability of the functional group and lengthen the time-release profile of the 
compound, allowing for more controllable NO release.24 To the best of our knowledge, there is 
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only one report of an enzyme-activated diazeniumdiolate polymer, in which Zhao and coworkers 
synthesize a chitosan polymer containing a glycosylated diazeniumdiolate activated by a 
glycosidase enzyme and show its application in increasing cell proliferation for improved wound 
healing.25 A similar idea is employed in this work, applying the concept of enzyme-activated 
diazeniumdiolate polymers to antibacterial treatments.  
In a previous report from our lab, we described the synthesis, characterization, and 
analysis of some of the first bacterial enzyme-activated diazeniumdiolates.26 Piperazine-based 
diazeniumdiolates were synthesized, then protected with a nitroaromatic group (Figure 5.1). 
Upon exposure to a nitroreductase (NTR) enzyme, a family of enzymes found almost exclusively 
in bacteria and known to reduce nitro groups, the protecting group is removed, leading to NO 
release. These novel compounds release NO only in the presence of the enzyme, indicating that 
these compounds could be used as bacterial prodrugs. The research question posed in this 
chapter is: will incorporating a nitroaromatic-protected diazeniumdiolate into a polymer 
composite maintain the NO release properties of the compound and create a material with 
enzyme-activated antibacterial properties? To investigate the possible use of these compounds as 
enzyme-activated antibacterial medical device coatings, I describe the preparation of polymer 
films containing Et-PIPER/NO-NO2 (1a, Figure 5.1), the compound with the highest 
antibacterial performance based on previous experimental results.26 I fully characterized the 
 




properties of the films using scanning electron microscopy (SEM), energy-dispersive x-ray 
analysis (EDX), and nitric oxide analyzers to quantify NO release, and I analyzed the 
antibacterial activity of the films by counting colony-forming units (CFUs) after exposure to the 
films. This is the first report of an antibacterial enzyme-activated NO releasing polymer material.  
5.3 Experimental Methods 
5.3.1 Materials. Ethyl 1-piperazinecarboxylate (99%), 4-nitrobenzyl bromide (99%), 15-crown-5 
(98%), high molecular weight poly(vinyl chloride), nitroreductase from Escherichia coli (90%), 
and β-Nicotinamide adenine dinucleotide 2′-phosphate reduced tetrasodium salt hydrate 
(NADPH, 97%) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Anhydrous (Dri-
Solv, 99.8%) tetrahydrofuran was purchased from EMD Millipore (Billerica, MA, USA). Nitric 
oxide (99%) was purchased from Matheson Tri-gas (Montgomeryville, PA, USA). Sodium 
methoxide (30% in methanol) and dioctyl sebacate (97%) were purchased from Acros Organics 
(Geel, Belgium). Medical grade polyurethane (Tecophilic SP 80A-150) was obtained from 
Lubrizol (Wickcliffe, OH, USA). Oxoid nutrient broth (OXCM0001B), Oxoid nutrient agar 
(OXCM0003B), and tetrahydrofuran were purchased from Fisher Scientific (Hampton, NH, 
USA). Escherichia coli (ATCC 25922) was obtained from American Type Culture Collection 
(ATCC, USA). Argon (ultrahigh purity), nitrogen (ultrahigh purity), and oxygen were purchased 
from Airgas (Denver, CO, USA). Deionized water (18.2 MΩ·cm) was obtained from a Millipore 
Direct-Q water purification system (EMD Millipore, Billerica, MA, USA). 
5.3.2 Abbreviations. The following abbreviations are used throughout: rt= room temperature, h= 
hour, min= minute, THF= tetrahydrofuran, 15-crown-5= 1,4,7,10,13-Pentaoxacyclopentadecane, 
NaOH= sodium hydroxide, DCM= dichloromethane, Na2SO4= sodium sulfate, EtOAc= ethyl 
acetate, SiO2= silica, NADPH= β-Nicotinamide adenine dinucleotide 2′-phosphate reduced 
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tetrasodium salt hydrate, NBM= nutrient broth media, PBS= phosphate-buffered saline, PVC= 
poly(vinyl chloride), DOS= dioctyl sebacate, PU= polyurethane, NO= nitric oxide, SEM= 
scanning electron microscope, EDX= energy dispersive X-ray spectrometer 
5.3.3 Instruments. NO release measurements were obtained using a Sievers 280i Nitric Oxide 
Analyzer (NOA, GE Analytical Instruments, Boulder, CO, USA). Reactions were analyzed by 
thin layer chromatography (TLC) on aluminum sheets that were pre-coated with silica gel 60 
F254, and the reactions were purified by column chromatography using Alfa Aesar silica gel 60 
(0.06-0.2 mm). SEM imaging was performed using a JEOL JSM-6500F scanning electron 
microscope. Gold coating was performed using a Denton Vacuum Desk II Gold Sputter Coater. 
SEM/EDX analysis was performed using the SEM equipped with a Thermo Electron energy 
dispersive X-ray spectrometer (EDX) for qualitative and quantitative elemental analysis. 
5.3.4 Experimental Procedures 
5.3.4.1 Synthesis of sodium 1-(4-Ethoxycarbonylpiperazin-1-yl)diazen-1-ium-1,2-diolate. The 
diazeniumdiolate was synthesized according to a previously reported procedure.26 In brief, ethyl 
1-piperazinecarboxylate (1 equiv.) was stirred to dissolve in anhydrous methanol (2.1 M) in a 
high pressure reaction vessel. Sodium methoxide (30% in methanol, 1 equiv.) was added. The 
reaction vessel was attached to a high-pressure stainless-steel nitric oxide reactor system, purged 
with high purity argon, then charged with nitric oxide gas (80 psi, 99%). After stirring under 
pressure for 24 h, the white precipitate that formed was washed with methanol, then diethyl ether 
and dried under vacuum for 1 h. The products were stored at -20 ˚C until further use. Spectra 
matched the previously reported values.26 
5.3.4.2 Synthesis of O2-(4-Nitrobenzyl) 1-(4-ethoxycarbonylpiperazin-1-yl)diazen-1-ium-1,2-
diolate. The diazeniumdiolate was protected according to a previously reported procedure.25 In 
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brief, to a 0 ˚C solution of diazeniumdiolate (0.75 mmol, 1.5 eq.) in anhydrous THF (0.1 M), 15-
crown-5 (1 mmol, 2 eq.) was added. After 30 minutes stirring at 0 ˚C, 4-nitrobenzyl bromide (0.5 
mmol, 1 eq.) was added and the reaction was allowed to warm to rt. After stirring for 4 h, the 
reaction mixture was concentrated in vacuo. The crude mixture was dissolved in DCM (10 mL) 
and NaOH (1 M, 10 mL) was added. The aqueous layer was extracted with DCM (3 × 10 mL), 
then the organic layers were washed sequentially with deionized water (10 mL) and brine (15 
mL), dried over Na2SO4 and concentrated in vacuo to afford a yellow oil. After purification by 
column chromatography (SiO2, 10%, 30% EtOAc in hexanes gradient), the pure product is 
collected as a pale yellow crystalline solid. Spectra matched the previously reported values.25 
5.3.4.3 Preparation of polyvinyl chloride/polyurethane films. High molecular weight polyvinyl 
chloride (PVC, 2 g) was mixed with plasticizer dioctyl sebacate (DOS, 1.1 mL) in a 2:1 
PVC:DOS ratio in THF (20 mL, 10% w/v), stirring at 1200 rpm for at least 1 h to dissolve. 500 
µL aliquots of PVC were cast in 10 mL Pyrex beakers, three times, allowing for layers to dry 1 h 
in between additions, for a total of three layers of PVC per film. Medical grade SG 80A-150 
polyurethane (PU, 100 mg) was dissolved in THF (2 mL, 5 w/v%), stirring at 1200 rpm for at 
least 3 h to dissolve. The NO2-protected diazeniumdiolate was then added in the appropriate 
w/v% (control= 0%, 0.25%= 5 mg/2 mL PU/THF mixture, 1%= 20 mg/2 mL PU/THF mixture, 
2.5%= 50 mg/2 mL PU/THF mixture), stirring to dissolve in the PU mixture. One 400 µL aliquot 
of the appropriate PU mixture was cast on top of the PVC layered films. The films were allowed 
to cure in a fume hood overnight, then removed from the beaker and cut to 15 x 15 mm squares 
for NO release experiments, and 7.5 x 15 mm rectangles for bacteria experiments. 
5.3.4.4 SEM and SEM/EDX Analysis. SEM images were obtained using an accelerating voltage 
of 10.0 kV and a working distance of 10.0 mm. For SEM images, all films were sputtered with a 
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20 nm layer of gold. SEM/EDX analysis was performed with uncoated films with an accelerating 
voltage of 2 kV. Quantitative elemental analysis data was obtained for carbon, oxygen, and 
nitrogen. 
5.3.4.5 Nitric oxide release measurements under physiological conditions. The amount of NO 
release from each w/v% film (0%, 0.25%, 1%, and 2.5%) was assessed over a 24 h period using 
a nitric oxide analyzer (NOA, Sievers 280i, GE Analytical Instruments, Boulder, CO, USA). 
Before each experiment, the NOA was calibrated using ultra-high purity nitrogen as zero gas and 
a 45 ppm NO calibration gas cylinder (Airgas), according to the manufacturer's standard 
operating procedures. The NOA sample holder was under nitrogen, contained 1500 µL degassed 
PBS, 400 µL NADPH (10 mM in PBS), and 1 film (15 x 15 mm), and was maintained at 37 °C, 
to mimic both experimental and physiological conditions. Sufficient baseline of the PBS, 
NADPH, and film solution was obtained before injection of the nitroreductase enzyme. 
Nitroreductase enzyme (50 µL, 1 mg/mL in PBS) was then added through the side injection port 
of the NOA vessel. The solution was purged continuously with ultra-high purity nitrogen gas 
with bubbling rate of 55 mL/min directly into the solution and flow gas introduced into the 
remaining headspace for the duration of the experiment. NO release was recorded in 5 s intervals 
as parts per billion. Each experiment was allowed to run for 24 h before analyzing total moles 
released over that time period. NO release data is presented as the average of at least 3 trials ± 
standard deviation. NO flux from the polymer films were calculated using the equation below. 
𝑁𝑂 𝑓𝑙𝑢𝑥 = 𝑡𝑜𝑡𝑎𝑙 𝑚𝑜𝑙𝑒𝑠 𝑁𝑂 𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑(𝑠𝑢𝑟𝑓𝑎𝑐𝑒 𝑎𝑟𝑒𝑎 𝑜𝑓 𝑓𝑖𝑙𝑚)(𝑡𝑖𝑚𝑒) 
5.3.4.6 Nitric oxide release during thermal decomposition of films. A similar procedure was used 
as the experiments measuring NO release under physiological conditions. A used 2.5% film from 
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the physiological conditions experiment was placed in an empty NOA cell and a baseline release 
was established. The cell was heated to 120 °C in a sand bath and NO release was measured for 
four hours until the film began to turn black and melt. 
5.3.4.7 Preparation of and nitric oxide release from KTpClPB-containing films. The potassium 
tetrakis(4-chlorophenylborate (KTpClPB) films were made in a similar manner to the previously 
described procedure. The plasticized PVC layers were made and cast in the same way. The PU 
layer was made by dissolving medical grade SG 80A-150 polyurethane (PU, 50 mg) in THF (1 
mL, 5 w/v%), stirring at 1200 rpm for at least 3 h to dissolve. The NO2-protected 
diazeniumdiolate (2.5 mg) and KTpClPB (0.125% w/v, 1.125 mg/1 mL PU/THF mixture) were 
then added, stirring to dissolve in the PU mixture. One 400 µL aliquot of the appropriate PU 
mixture was cast on top of the PVC layered films. The films were allowed to cure in a fume hood 
overnight, then removed from the beaker and cut to 15 x 15 mm squares for NO release 
experiments. The NO release experiments were run exactly as previously described under 
physiological conditions with the KTpClPB-containing 0.25% films. 
5.3.5 Bacterial Studies 
5.3.5.1 Escherichia coli Bacteria Culture. Initial stock culture of Escherichia coli was made by 
reconstituting lyophilized bacteria in warm nutrient broth media (NBM, 13 g nutrient broth/1 L 
Millipore water) and grown overnight at 37 °C and 150 rpm until an optical density at 600 nm 
(OD600nm) ≈1.0 was reached. This bacterial solution was combined with glycerol (30% v/v) in a 
1:1 fashion to obtain a final glycerol concentration of 15% (v/v). These solutions were stored at 
−80 °C until use. Prior to each bacterial experiment, a frozen culture was thawed at rt and then 
centrifuged at 4700 rpm for 10 min. The supernatant was discarded, and the pellet was 
resuspended in NBM. This was transferred to additional NBM and allowed to grow overnight in 
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a 37 °C incubator with shaking at 120 rpm until the OD600nm ≈1.0. The culture was diluted to an 
OD600nm ≈0.3-0.35 using warmed NBM prior to beginning experiments. 
5.3.5.2 Bacterial Viability. The PVC/PU/diazeniumdiolate films (0.25%, 1%, and 2.5%; 7.5 x 15 
mm) were added to E. coli culture (107 CFU/mL) in NBM (1 mL, OD600nm ≈0.3-0.35) in 1.5 mL 
Eppendorf microcentrifuge tubes. The positive control was E. coli culture in NBM (1 mL, 
OD600nm ≈0.3-0.35) with a PVC/PU control film (0% diazeniumdiolate). The negative control 
was E. coli culture in NBM (1 mL, OD600nm ≈0.3-0.35). The solutions were placed in a static 37 
˚C incubator for 24 h. Agar plates were made by adding 15 mL of sterilized nutrient agar 
[powder base (14 g) in Millipore water (500 mL)] to sterile Petri dishes and allowed to set for at 
least 2 h. After 24 h exposure, the E. coli solutions underwent serial tenfold dilution with sterile 
NBM to reach a 105 dilution factor, and the agar plates were inoculated with 20 µL of the diluted 
E. coli solutions using a sterile plastic or glass spreader. The agar plates were placed in a static 
37 °C incubator overnight and colony-forming units (CFUs) were counted after 24 h (n = 9). The 
number of CFUs were calculated using the equation: 
𝐶𝐹𝑈𝑚𝐿 = (# 𝐶𝐹𝑈 𝑐𝑜𝑢𝑛𝑡𝑒𝑑)(𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟)𝑉𝑜𝑙𝑢𝑚𝑒 𝑝𝑙𝑎𝑡𝑒𝑑 (𝑚𝐿)  
The percent reduction in the number of viable bacteria was calculated as follows: 
% 𝑟𝑒𝑑𝑢𝑐𝑡𝑖𝑜𝑛 = 𝐶𝐹𝑈 𝑎𝑓𝑡𝑒𝑟 𝑒𝑥𝑝𝑜𝑠𝑢𝑟𝑒 𝑡𝑜 𝑓𝑖𝑙𝑚 𝑚𝐿⁄𝐶𝐹𝑈 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑚𝐿⁄  
5.3.5.3 Statistical Analysis. All biological experiments were performed using at least three 
replicates with at least three samples per replicate. Viability assays are reported as the mean and 
95% confidence interval. All data were evaluated for potential outliers using the Grubbs Test. 
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The statistical differences in data were evaluated using the Student’s t test (p < 0.05) at the 95% 
confidence level. 
5.4 Synthesis of PVC/PU Blends with Piperazine Diazeniumdiolates  
Toward the goal of using enzyme-activated diazeniumdiolates in an antibacterial medical 
device coating, I prepared polymer composite films containing varying amounts of the protected 
diazeniumdiolate 1a (Figure 5.1). To prepare the films, I cast plasticized PVC in three layers, 
allowing the layers to dry in between additions. The plasticizer dioctyl sebacate (DOS) was used 
to improve the flexibility and decrease the brittleness of the PVC. PU was mixed with 0.25, 1, or 
2.5% w/v Et-PIPER/NO-NO2 (1a), then one layer of the PU mixture was cast on top of the PVC 
layers, and the films were cured overnight. The resulting films can be seen in Figure 5.2. The 
films are referred to throughout this chapter in terms of the percent w/v of Et-PIPER/NO-NO2 
diazeniumdiolate 1a in the film (0.25, 1, or 2.5% w/v).  
The choice of materials used to make the films was intentional based on experience, 
experimentation, and intended application. Both PVC and PU are commonly used to make 
medical devices such as catheters and tubing, indicating the relative safety and applicability of 
these polymers.27,28 I chose to layer plasticized polyvinyl chloride (PVC) and medical grade 
polyurethane (PU) to balance mechanical properties and usability. PVC adds sturdiness to the 
films, as hydrophilic PU alone in water can have a lower viscosity, making it impracticable for 
many applications. The layered PVC gave the films a visibly smoother surface texture, as well as 
adding durability to the films. Less than three layers of PVC caused the films to curl up in 
solution, potentially preventing complete aqueous saturation of the PU/diazeniumdiolate layer 
and limiting NO release. I chose a hydrophilic PU to mix with the diazeniumdiolate 1a, 
hypothesizing that PU uptake of water in solution would better allow the NTR enzyme to diffuse 
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into the PU layer of the films, initiating enzyme-activated NO release. In addition, 
diazeniumdiolate-containing PU materials have previously been reported, demonstrating the  
feasibility of this approach.29 Adding more than 2.5% w/v of diazeniumdiolate to the films led to 
significant opacity of the films, which could limit the applications of the material. 
5.5 Characterization of PVC/PU Blends with Piperazine Diazeniumdiolates 
5.5.1 SEM and SEM/EDX Analysis 
To investigate the surface composition of the prepared diazeniumdiolate polymer films, 
the films were characterized by scanning electron microscopy (SEM) and energy-dispersive x-
ray analysis (EDX). SEM images of films show that the higher the content of the 
diazeniumdiolate (higher percent w/v), the more diazeniumdiolate crystals are observed (Figure 
5.3). The 2.5% w/v films appear to be entirely coated in diazeniumdiolate (Figure 5.4a). The 
SEM images of the control films (containing 0% diazeniumdiolate) appear different than the 
diazeniumdiolate-containing films. At low magnification (200x, Figure 5.3), the films appear 
uniform, and upon higher magnification, there appear to be polymer contaminants or undissolved 
pieces of PVC or PU (Figures 5.6-5.7). For the diazeniumdiolate containing films, the higher the 
a b 
c d 
Fig. 5.2 Images of varying percent w/v Et-PIPER/NO-NO2 polymer films a) control (0%) b) 0.25% 
c) 1% d) 2.5% 
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percent w/v, the higher the amount of diazeniumdiolate observed on the surface (Figure 5.3). For 
the 0.25% films, the distribution of the diazeniumdiolate crystals appears to be visibly uniform, 
although there are some larger aggregates of diazeniumdiolate (Figures 5.8-5.10). Images of the 
the 1% films show more diazeniumdiolate across the surface of the films, and they appear similar 
a b 
c d 
Fig. 5.3 Representative SEM images of a) control (0%) b) 0.25% c) 1% d) 2.5% films at 
200x magnification showing increasing amounts of diazeniumdiolate on the surface with 
increasing % w/v 
Fig. 5.4 Characterization data for polymer films. (a) Representative SEM image of 2.5% w/v 
film at 1000x magnification. (b) Representative EDX layered elemental surface map of 2.5% 
w/v film. Blue pixels represent nitrogen, green pixels represent oxygen, and red pixels represent 
carbon. (c) Representative NO release plot for 2.5% w/v film 
10 µm 100 µm 
a b c 
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to the 0.25% films, with diazeniumdiolate crystals spread across the polymer matrix (Figure 
5.11-5.13). The 2.5% films appear to be entirely coated in diazeniumdiolate, with no visibly 
apparent polymer observable (Figures 5.4, 5.14-5.16). The 2.5% w/v films became charged very 
easily when acquiring SEM images, potentially due to the higher amount of charged 
diazeniumdiolate groups present on the surface. These SEM images show that the higher the 
percent w/v of diazeniumdiolate in the polymer films, the more diazeniumdiolate is observable 
on the surface of the films, as expected. 
 SEM/EDX analysis was performed to determine the elemental surface composition of the 
films. EDX analysis involves focusing a high energy beam of electrons on the surface of a 
sample and analyzing the characteristic X-ray pattern emitted by the excited atoms to determine 
the elemental composition of the sample. The SEM/EDX surface map analysis shows that the 
films are made up of mostly of carbon, followed by oxygen, and then nitrogen in the 
diazeniumdiolate-containing films (Table 5.1). The control films (0% w/v Et-PIPER/NO-NO2, 
PU/PVC only) showed 0% nitrogen as no diazeniumdiolate is present and the surface is 91.7% 
carbon and 8.3% oxygen (Table 5.1, entry 1), likely from the composition of the polymers. The 
0.25% films contain 0.2% nitrogen, demonstrating that the presence of diazeniumdiolate in the 
films increases the amount of nitrogen on the surface of the films (Table 5.1, entry 2). The 1% 
films contain more nitrogen, 2.4%, indicating a trend of increasing amounts of nitrogen on the 
surface with increasing amounts of diazeniumdiolate present in the film, as would be expected 
(Table 5.1, entry 3). This trend continues with the 2.5% films, made up of 13.2% nitrogen (Table 
5.1, entry 4; Figure 5.3b). The SEM/EDX analysis provides quantitative evidence 
complementing the qualitative SEM observations that the higher percent w/v diazeniumdiolate-
containing films contain more diazeniumdiolate on the surface. 
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Table 5.1 Surface composition of diazeniumdiolate polymer films determined by SEM/EDX 
Entry 
% w/v of Et-PIPER/NO-NO2 
in film 
Carbon (wt.%)a Oxygen (wt.%)a Nitrogen (wt.%)a 
1 Control (0%) 91.7 ± 0.1% 8.3 ± 0.1% 0.0 ± 0.1% 
2 0.25% 76.4 ± 0.1% 23.5 ± 0.1% 0.2 ± 0.1% 
3 1% 75.2 ± 0.1% 22.5 ± 0.1% 2.4 ± 0.1% 
4 2.5% 72.3 ± 0.1% 14.5 ± 0.1% 13.2 ± 0.1% 
aData is reported as the mean ± standard deviation, n=3 
 
5.5.2 Quantification of NO Release from Polymer Films 
NO release properties of the films were investigated in the absence and presence of the 
NTR enzyme (NfsB isolated from E. coli). NO release is characterized using a nitric oxide 
analyzer (NOA), which uses chemiluminescence to directly quantify the amount of NO released. 
NO released from a substrate is oxidized by ozone generated in situ in the instrument, forming 
excited state nitrogen dioxide (NO2). Excited state NO2, upon relaxation, emits a photon which is 
measured and related to the moles of NO released with a previously determined calibration 
constant, providing direct measurement of NO release as a function of time.  
To quantify the amount of NO released from the polymer films, the films were placed in 
a solution of phosphate-buffered saline (PBS) and β-Nicotinamide adenine dinucleotide 2′-
phosphate reduced tetrasodium salt hydrate (NADPH), an essential cofactor to the NTR enzyme 
acting as a reducing agent. A baseline measurement was collected without the NTR enzyme 
present. No NO release was observed from the films when the NTR enzyme is not present. This 
observation is expected based on previously reported results in which the diazeniumdiolate 
powder did not release appreciable NO when the enzyme was not present, providing strong 
evidence that the diazeniumdiolate is enzyme-activated.25 The NTR enzyme is injected into the 
solution, and NO release is measured for 24 hours. Experiments with each percent w/v film were 
repeated three times to demonstrate reproducible results (Figures 5.17-5.19). 
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All the percent w/v films containing diazeniumdiolate (0.25, 1, and 2.5%) release similar 
amounts of NO (Figure 5.4c, Table 5.2, entries 1-3), ranging from 2.8-4.3 × 10-6 moles of NO. 
Control films containing 0% diazeniumdiolate were tested for NO release under identical 
conditions to the diazeniumdiolate-containing films and released a negligible amount of NO 
(data not shown). The concentration of NO release is in the micromolar range, which is the 
concentration level (>1 µM) known to have antibacterial effects.30,31 The amount of NO release 
from each of the percent w/v films showed no discernible pattern correlating to the amount of 
NO donor loading (Table 5.2, entries 1-3). This could be attributed to a localized basic 
environment in the films, which can happen as NO is released and the amount of secondary 
amine byproducts increases, increasing the basicity of the local environment.32 This would 
stabilize the diazeniumdiolate, as diazeniumdiolates are more stable in higher pH environments, 
and prevent further NO release. To test this, I made films with a PU layer containing 0.12% 
potassium tetrakis(4-chlorophenylborate (KTpClPB) and 0.25% diazeniumdiolate. KTpClPB is a 
salt with a large organic anion that can buffer the environment within the polymer film and 
prevent a high pH environment from forming as the concentration of secondary amines 
increases.32 After making these KTpClPB-containing 0.25% diazeniumdiolate films, I ran NO 
release experiments to determine if additional NO would be released as compared to the amounts 
of NO released under physiological conditions. However, I found that these films released 4.0 × 
10-6 moles of NO, which is very similar to the amount of NO (3.6 ± 0.7 × 10-6 moles) released 
Table 5.2 NO release from Et-PIPER/NO-NO2 polymer films 
Entry 
% w/v of Et-PIPER/NO-NO2 
in film 
Total moles of NO 
(moles)a 
NO flux (moles NO cm-2 min-1)a 
1 0.25% 3.6 ± 0.7 × 10-6 2.7 ± 0.5 × 10-9 
2 1% 4.3 ± 0.7 × 10-6 2.7 ± 0.8 × 10-9 
3 2.5% 2.8 ± 0.1 × 10-6 2.4 ± 0.8 × 10-9 
aData is reported as the mean ± standard deviation, n=3 
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from the films containing no KTpClPB. This experiment shows that it is unlikely that a local 
basic environment forming in the films is preventing complete NO release.  
Other hypotheses as to the similar amounts of release from each percent w/v film could 
be limited diffusion of the enzyme into the polymer to catalyze NO release or to limited 
solubility of the NO donor in aqueous conditions, which can affect NO release, as I previously 
observed.25 This would lead to incomplete release of NO from the films. To determine if the 
films still contain NO after measuring NO release under physiological conditions, heat could be 
used to force any remaining NO in the films out. To determine this, I ran an experiment with a 
2.5% w/v film that the amount of NO release had previously been determined by exposure to 
NADPH and NTR enzyme. I placed the used film in an NOA cell with no solution, heated the 
film to 120 °C in a sand bath, and measured the amount of NO release. I observed an additional 
amount of NO released from the film of up to 20% more NO (5.8 × 10-7 moles of NO) before the 
polymer started to melt and decompose and I ended the experiment. This shows that there is 
additional NO in the films, which could explain why the different percent w/v films show similar 
amounts of total NO release. A certain amount of NO is accessible in the films and is able to be 
released, while some additional NO is trapped in the films. 
I also calculated the NO flux from the polymer films (Table 5.2). The flux from each of 
the percent w/v films is remarkably similar. The flux measurement is much higher than the 
natural endothelial flux of NO in the body, 1 × 10-10 mol cm-2 min-1.33 The amount of NO release 
observed and the NO flux levels indicate that the films will have antibacterial activity.30 
5.6 Antibacterial Activity of Polymer Blends with Escherichia coli  
E. coli is a common infection-forming species that is troublingly growing increasingly 
resistant to many antibiotics.34,35 Because of this, E. coli was chosen as the bacterial species of 
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interest in the antibacterial efficacy studies. In addition, it is known to contain an NTR enzyme, 
one of which was the isolated NTR enzyme used in the NO release experiments, and activates 
NO release from Et-PIPER/NO-NO2.25  
 To determine the antibacterial efficacy of the diazeniumdiolate films, E. coli was exposed 
to the films (0.25%, 1%, and 2.5%) for 24 hours. The bacterial solution was diluted and plated on 
agar, then colony forming units (CFUs) were counted. The negative control in these experiments 
was E. coli solution with no film present. The positive control was E. coli exposed to a PVC/PU 
film containing 0% diazeniumdiolate. Based on our previous work, E. coli should metabolize the 
diazeniumdiolate, catalyzing NO release with the NTR enzymes it produces.25  
As can be seen in Figure 5.5, all percent w/v films containing the therapeutic cause a 
decrease in the number of viable bacteria, in similar amounts. The 0.25% film reduces cell 
viability by 64% and the 1% and 2.5% films both cause a 66% reduction. The negative control, 
on the other hand, does not significantly reduce the number of viable bacteria, with a 0% 
reduction. The positive control with E. coli exposed to the 0% polymer film causes an 
insignificant 3% reduction, showing that polymer films alone do not have antibacterial activity. 
This data shows that the diazeniumdiolate Et-PIPER/NO-NO2 films have significant antibacterial 
effects. All of the percent w/v films cause similar amounts of reduction in bacteria, which fits 
with the NO release data. This could be due to potential difficulties of the bacteria with accessing 
the diazeniumdiolate to activate NO release within the films if bacteria are only able to access 
NO on the surface of the films. These results are an exciting proof of concept of the first example 





 The research question posed at the beginning of this chapter is: will incorporating a 
nitroaromatic-protected diazeniumdiolate into a polymer composite maintain the NO release 
properties of the compound and create a material with enzyme-activated antibacterial properties? 
The research described in this chapter describes the first antibacterial enzyme-activated NO-
releasing polymer composite. Through extensive characterization, NO release from the polymers 
is shown to be enzyme activated, and NO is released at concentrations known to have 
antibacterial effects. The NO release properties are similar to the powder form of the 
diazeniumdiolate. NO release from the polymer composite remains nitroreductase enzyme 
activated. Investigation of the antibacterial activity of the polymer composites against E. coli 
excitingly showed that the films have significant antibacterial effects, reducing bacterial cell 
Fig. 5.5 Cell viability of E. coli after exposure to Et-PIPER/NO-NO2 % w/v films. 
NC=negative control, E. coli with no polymer film; PC=positive control, E. coli with 0% w/v 
polymer film. Average and standard error bars displayed, n ≥ 9. Statistically significant 
differences between cellular viabilities are indicated (*) as determined by a student’s t test.  
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viability by up to 66%. The diazeniumdiolate composite films continue to have antibacterial 
effects as the powder form does, albeit with lower reductions, possibly due to lower solubility 
and aqueous saturation of the polymer composites. 
Future work will focus on increasing the amount of NO release from the polymer films in 
the presence of bacteria, leading to more potent antibacterial activity. This could potentially be 
achieved by increasing the surface area of the therapeutic to allow greater access and increase 
antibacterial activity. These polymer composite films could be used to make or coat medical 
devices to add long-term antibacterial properties, helping to address the problem of implant 
infection and improving patient outcomes. 




Fig. 5.6 Representative SEM images of control (0%) films at 1000x magnification. 





Fig. 5.9 Representative SEM images of 0.25% films at 1000x magnification. 
Fig. 5.8 Representative SEM images of 0.25% films at 500x magnification. 





Fig. 5.11 Representative SEM images of 1% films at 500x magnification. 
Fig. 5.13 Representative SEM images of 1% films at 3000x magnification. 




Fig. 5.16 Representative SEM images of 2.5% films at 3000x magnification. 
Fig. 5.15 Representative SEM images of 2.5% films at 1000x magnification. 
Fig. 5.14 Representative SEM images of 2.5% films at 500x magnification. 
164 
 




Fig. 5.17 Triplicate experiments of NO release for 0.25% w/v Et-PIPER/NO-NO2 films 
Fig. 5.18 Triplicate experiments of NO release for 1% w/v Et-PIPER/NO-NO2 films 
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 The contributions made to the advancement of novel antibacterial materials research 
described in this dissertation are significant. The research began in this dissertation can be 
continued to develop practical NO-releasing antibiotics and antimicrobial materials. The project 
described in Chapters 2 and 3 represents the first example of a small molecule capable of both 
detecting and killing bacteria.1 The synthesized molecule combines the idea of an enzyme-
activated colorimetric bacterial indicator with a NO donor to impart antibacterial properties. 
Limited examples of dual function macromolecules have been previously described,2–4 but a 
small molecule with multiple functions offers the advantages of being more versatile and can be 
incorporated into a polymeric matrix if desired. Through this work, I demonstrated the synthesis 
of a fluorescent indicator small molecule and its ability to change color in the presence of P. 
aeruginosa. I also showed that it releases NO in amounts known to have antibacterial activity, 
and that it causes up to a 65% reduction in P. aeruginosa. This research represents one of the 
first forays into developing multifunctional small molecule antibiotics, which is extremely 
important to address the complex problem of antibiotic resistance. As the current antibiotic 
resistance problem highlights, bacteria quickly evolve new pathways to develop resistance, and 
research aiming to combat this problem must focus on new areas of potential. 
 The work described in Chapters 4 and 5 represents some of the first examples of a 
bacterial enzyme-activated diazeniumdiolate prodrug materials.5 NO has been known to be a 
potent antimicrobial agent for many years, but challenges have arisen in creating a stable 
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delivery system. Diazeniumdiolates hold great potential for controlled release of NO and 
incorporating them into a molecule activated by a bacterial enzyme could be a useful way to 
prevent bacterial resistance from developing. An enzyme-activated NO donor prodrug allows 
localized release of NO, avoiding indiscriminate exposure of bacteria to the therapeutic and the 
potential for resistance to develop. As discussed in Chapter 4, I successfully synthesized a 
nitroaromatic-protected diazeniumdiolate and demonstrated that NO release from the compound 
is nitroreductase enzyme activated. Antibacterial efficacy experiments demonstrated that the 
compounds lead to up to a 94% reduction in E. coli.  
After synthesizing a novel nitroreductase-activated diazeniumdiolate, I wanted to 
incorporate the small molecule into a polymer material to demonstrate its potential biomedical 
application preventing infections on medical devices, as described in Chapter 5. Thorough 
characterization of the material by SEM, EDX, and NOA analysis ensured that the properties of 
the small molecule are maintained in the polymer composite. Incorporated into a polymer, the 
material demonstrated similar enzyme-activated NO-release and antibacterial activity against E. 
coli. This is one of the first examples of an enzyme-activated NO-releasing material with 
antibacterial activity, with the potential to prevent bacterial adhesion and biofilm formation by 
releasing NO when bacteria encounter the medical implant. This material could be used as a 
coating for medical devices to impart long-term antibacterial activity, preventing infections on 
in-dwelling devices and significantly improving patient outcomes.  
6.2 Future Directions 
6.2.1 Dual function fluorescent indicator 
Based on the work described in this dissertation, there are several directions future work 
could take. For the dual function color changing small molecule project, it would be of interest to 
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determine the limit of detection (LOD) of the indicator. This would be useful to determine the 
smallest number of bacteria that need to be present to observe a visible color change and 
determine the limits of usability of the indicator.  
Increasing the amount of nitrosation of the compound would potentially increase the 
antibacterial efficacy of the compound. Based on calculations from the NO release studies, the 
compound is only 37% nitrosated, releasing only 75% of the theoretical 200% NO release that is 
possible. Increasing the amount of NO release could potentially increase the antibacterial activity 
of the compound, as higher amounts of NO release should lead to higher antimicrobial activity. 
Increasing amounts of NO release could be accomplished by optimizing the diazeniumdiolate 
reaction conditions, through investigation of the effects of solvent, temperature, and reaction 
time, to favor higher amounts of product formation (diazeniumdiolate-functionalized material). 
This could also potentially be accomplished by first forming the PROLI/NO diazeniumdiolate 
and protecting it, then coupling the diazeniumdiolate to the fluorescent compound. This method 
would ensure that each molecule has a diazeniumdiolate functional group. A protecting group on 
the diazeniumdiolate would also prevent spontaneous release of NO, which could prevent 
detrimental side effects.  
When considering diazeniumdiolates as therapeutics, it is important to consider that they 
can decompose into carcinogenic nitrosamines.6 Cytotoxicity studies would be necessary before 
the synthesized fluorescent diazeniumdiolate compound is used in any in vitro study. The 
diazeniumdiolate formed is a derivative of PROLI/NO, which can form N-nitrosoproline, one of 
a few nitrosamines that has been shown to be non-carcinogenic.7 This is a promising sign that the 
diazeniumdiolate would not decompose into a carcinogenic nitrosamine, but further toxicity 
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testing would be needed to ensure its safety. It would also be important to determine the 
cytotoxicity of the fluorescent aminoacridone, as this has not been previously investigated. 
6.2.2 Nitroreductase-Activated Diazeniumdiolate and Polymer Composite 
As previously stated, it is important to detect bacterial infections to help prevent the 
unnecessary prescription of antibiotics. Toward this goal, a method could be developed to 
determine if bacteria are present and to quantify the number of bacteria by relating the number of 
bacteria to the amount of nitroreductase with the nitroreductase activated diazeniumdiolates. This 
could be accomplished by quantifying the decrease in absorbance due to the nitro group of the 
nitroaromatic protecting group on the diazeniumdiolate, using UV-vis or another technique. As 
the nitro group is metabolized by the nitroreductase enzyme, its absorbance peak at around 375 
nm will disappear in proportion.8 The disappearance of the nitro group of the diazeniumdiolate 
protecting group is correlated to the presence of bacterial nitroreductase enzyme and the release 
of NO from the compound, so the disappearance of this peak can be used to indicate the presence 
of bacteria. Once this correlation is determined, the compound can be used to quantify the 
number of bacteria present, helping to diagnose a patient with a bacterial infection. 
 Another direction to improve the function and applicability of these compounds would be 
to try to increase the activity of the nitroreductase enzyme to the substrate. By using a different 
nitro-protecting group that bacteria have a higher affinity for, higher potency could potentially be 
achieved. There are several substrates that have been tested with nitroreductase enzymes and a 
few nitroreductase-activated antibiotics. For example, the cancer prodrugs CB1954 and PR-104A 
both are activated by nitroreductases found in E. coli.9,10 Introducing substrates with similar 
substituents as these compounds could potentially increase the activity of the nitroreductase 
enzyme to the diazeniumdiolate, leading to higher amounts of NO release and higher 
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antibacterial efficacy. Antibiotics such as metronidazole and nitrofurantoin can be activated by 
nitroreductases and are other potential models for enzyme-activated diazeniumdiolate protecting 
groups that would allow for higher activity of the nitroreductases toward the substrate.11,12 
 Another direction would be to investigate bacteria species beyond E. coli and P. 
aeruginosa as I investigated in this dissertation. Most bacteria contain a nitroreductase enzyme, 
so other bacteria could potentially be killed by the nitroreductase-activated prodrugs I 
synthesized. For example, nitroreductases found in Mycobacterium smegmatis, Bacillus 
amyloliquefaciens, Gluconobacter oxydans have been characterized, among others.13–15 These 
bacteria species could potentially activate the nitroaromatic-protected prodrugs similarly to the 
E. coli-derived nitroreductase NfsB. 
 In addition, as with the dual function compound, it will be important to determine the 
cytotoxicity of the compounds before their use in any in vitro experiments. It would be important 
to determine any degradation byproducts under physiological conditions, especially if the 
polymer composites were to be used for long term implants. The polymer composites would 
need to be tested to determine if there are any leachates from the material. 
 If cytotoxicity from byproducts or leachates from the polymer composite materials 
proved to be a challenge after testing, one direction to address this would be to covalently attach 
the NO donor molecule to the surface of the polyurethane substrate. Previous work has shown 
that this is a viable strategy, as polyurethanes can be functionalized with diazeniumdiolates16 and 
piperazines can be used as linkers for diazeniumdiolate groups.17 Polymers have also been 
functionalized with piperazine groups, which would be necessary for attachment of the Et-
PIPER/NO-NO2 diazeniumdiolate group.18–20 By functionalizing polyurethane with piperazine, 
the piperazine could then be reacted with NO to form the diazeniumdiolate group, which would 
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then be covalently attached to the polymer, then the diazeniumdiolate could be protected with the 
nitroaromatic group to prevent spontaneous release. Covalent attachment of the diazeniumdiolate 
group to the polymer material would prevent release of byproducts from the material, which 
could help avoid potential cytotoxicity problems. As the application of this material is for 
medical device coatings, covalent attachment of the diazeniumdiolate to the surface of the 
polymer would allow optimal access of bacteria to the enzyme-activated therapeutic. 
It would also be of interest to investigate amount of bacterial adhesion to the surface of 
the polymer films. In the experiments that I described in Chapter 5 of this dissertation, I counted 
the CFUs in the bacterial solution after removing the polymer composite materials. These 
experiments show that the polymer materials are able to reduce the number of bacteria in the 
surrounding solution, but to further probe how these materials would interact in a medical device 
coating, it would ideal to test bacterial adhesion to the surface of the materials. This would be 
interesting because the bacteria must interact with the polymer composite in order for NO to be 
released, but it would be interesting to see if the subsequent NO release is sufficient to prevent 
bacterial adhesion to the surface. This is especially important, as bacterial adhesion is the first 
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